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 Mice with mutations in the genes Attractin (Atrn) and Mahogunin ring finger-1 
(Mgrn1) have remarkably similar phenotypes: null mutations at either locus cause both 
a hyperpigmented coat-color phenotype and a progressive spongiform 
neurodegeneration. This noteworthy phenotypic overlap suggests that ATRN and 
MGRN1 gene products work together to accomplish a conserved cellular process that 
is important for both pigmentation and the prevention of neurodegeneration.  In the 
pigment cell, the function of ATRN and MGRN1 is known to be important for the 
downregulation of signaling by the master regulator of pigment production, the 
melanocortin 1 receptor (MC1R).  Using the convenient model system of the pigment 
cell, I have determined that ATRN physically interacts with both MGRN1 and MC1R, 
and that ATRN displays a constitutive endolysosomal trafficking behavior that is 
MGRN1-dependent.  I propose a model wherein the interaction between ATRN and 
MGRN1 localizes the ATRN/MC1R complex to the site of protein sorting by the 
Endosomal Sorting Complex Required for Transport (ESCRT) protein TSG101, which 
is a known MGRN1 interactor and a target of MGRN1’s E3 ubiquitin ligase activity. 
This coordinated behavior of ATRN and MGRN1 may direct the sorting of ATRN-
associated MC1R into the intracisternal vesicles of multivesicular bodies (MVBs) by 
ESCRT proteins, providing a novel mechanism for attenuation of MC1R signaling.   
  If the pigment-type switching defects of Atrn and Mgrn1 mutants are caused 
by a defect in ESCRT activity, a similar failure of ESCRT sorting could underlie the 
spongiform neurodegeneration seen in these mutants, and perhaps in human 
spongiform encephalopathies such as prion disease and HIV-associated dementia. As a 
proof-of-concept experiment to test this hypothesis, I knocked out the ESCRT protein 
TSG101 in neurons of adult mice to determine whether ESCRT dysfunction can cause 
spongiform neurodegeneration. Here I present preliminary results suggesting a 
profound neurodegenerative consequence of ECSRT dysfunction.  
 
Keywords: attractin, mahogunin ring finger 1, melanocortin 1 receptor, ATRN, 
MGRN1, MC1R, pigment-type switching, spongiform neurodegeneration, spongiform 
change, spongiform encephalopathy, lysosomal targeting, lysosomal trafficking, 
multivesicular body sorting, TSG101, ESCRT, endogenous retrovirus, prion. 
  iii
BIOGRAPHICAL SKETCH 
Will Pope Walker is a native of Pensacola, FL.  Home-educated through primary and 
secondary school, his first exposure to formal education was as a dual-enrollment 
student at Pensacola Junior College, where an introductory lab course in zoology 
deeply impressed him with the incredible diversity of ways there are of being alive.  
He transferred to the University of West Florida planning to study “critters” as a 
marine biology major, but became enchanted by the exquisite processes by which 
biological function emerges from genomic information and received his B.S. in 
molecular biology summa cum laude 1999.  After spending a few years at a variety of 
jobs including lab technician, adjunct lecturer, anatomy lab instructor, and 
professional bushwhacker leading a survey crew through the snake-infested wetlands 
of his home county, he began graduate studies at Cornell University in 2004 and 
joined the lab of Teresa M. Gunn in 2005.  While there he was fortunate to see a bit 
more of the world than some graduate students do, working on experiments both on 
campus in Ithaca and at the McLaughlin Research Institute for Biomedical Sciences in 
Great Falls, MT.  Will is a skeptical but still rather easily excitable fellow who smiles 
when he talks about biology, unless the subject turns to the over-credulous use of ill-
characterized antibodies.
  iv
 
 
 
 
 
 
 
 
 
 
 
 
For my grandparents.
  v 
ACKNOWLEDGEMENTS 
 A dissertation project becomes a curious thing, the outcome of a deeply 
individual obsession and struggle, and at the same time a monument to countless 
gestures of goodwill generously given.  I have been greatly helped in this journey by 
many, many kind people.  My greatest debt is to my advisor, Dr. Teresa M. Gunn, 
who has provided me with my lab home these last five years and has ceaselessly 
modeled the primary scientific virtues of curiosity, openness, enthusiasm, and 
indomitability.  I think the transformation involved in becoming a scientist comes 
gradually; it’s partly forged in intense moments of frustration or excitement, but it’s 
mostly absorbed imperceptibly from immersion in the life of the lab.  Teresa’s wide 
interests and confident approach to science make her lab a truly exciting place to 
work, and for the many lessons I’ve absorbed in it I owe a debt that I can only pay 
forward.   
 One of the greatest unexpected revelations I encountered when I entered the 
scientific community was the collegial generosity prevailing among so many in the 
discipline.  Many fellow scientists have given graciously of their time, consideration, 
and expertise to help me overcome experimental obstacles or learn new techniques, 
and have freely shared reagents, constructs, and mouse lines that cost them much labor 
to produce.  I especially appreciate the generosity of Melissa Burmeister, who spent 
hours in a bare concrete room huddled over a stereotactic injection apparatus with me 
until I got a new technique into my hands.  Elodie Le Pape, whom I have not yet met 
but for whom I hope to be able to do a good turn one day, demonstrated extraordinary 
generosity by sending me one of the only Eppendorf tubes of purified recombinant 
agouti protein in the whole world, saving me months of work at the cost of at least a 
few weeks of her own. The ready willingness of many other scientists at Cornell and 
around the world to help out with gifts of plasmids, cell lines, antibodies, and mice has 
  vi
been instrumental in the completion of this project.  I have learned to greatly value the 
attitude of these generous colleagues, for whom to offer help is second nature.  
Despite our individual scientific preoccupations, the general enterprise of scientific 
progress is something that we are all in together.    
 My committee members, Drs. Dave Lin, William Brown, and Eric Alani, I 
sincerely thank for investing their time, critical consideration, and scientific acumen in 
helping a young scientist fumble his way into the ancient and honorable company of 
scholars.  
 I thank all members of the Gunn Lab, past and present, for the countless small 
considerations and big favors accumulated over the years.  Not all labs get along as 
well as Teresa’s always seems to, so I feel lucky to have been surrounded all this time 
by so many good eggs. Christina, I’m sure I’d still be useless in the lab if I hadn’t had 
the good fortune to share a lab bay with you.  Thanks for your encouraging presence 
and your ready advice.   
  For more than two years in Teresa’s lab I had the good fortune to work with a 
very dedicated and thoughtful undergraduate scholar, Caroline Wee.  Caroline, thanks 
for hanging in there with me back when I had no idea how to design and delegate a 
workable project.  “Helping” you with your honors thesis was a great lesson for me in 
the tactics of experimental strategy.  I’m just glad the experience didn’t chase you off 
to medical school! 
 My family has provided unconditional love and countless gestures of support 
during my time Upstate and out West.  All I can do is love them back. 
 To my friends in Ithaca who have so often provided companionship for good 
times or a sympathetic ear during the frustrating periods, you know who you are.  I’m 
glad our lives crossed paths.  Let’s stay friends for a long time. 
  vii
 I feel very blessed to have been welcomed by a special community. We 
scientists are fortunate that we are enabled by society to do what we do, to follow our 
curiosity and engage in that uniquely human calling, the difficult but rewarding 
journey of learning how to come to understand.  I’m very blessed.  When I think of the 
many kindnesses I’ve encountered on the way to this dissertation, sometimes I’m 
surprised to find tears come to my eyes. 
  viii
TABLE OF CONTENTS 
Biographical Sketch         iii 
Dedication          iv 
Acknowledgements         v 
List of Figures          ix 
List of Tables          xi 
List of Abbreviations         xii 
Chapter One: Spongiform Neurodegeneration and Pigment-type Switching 1 
Chapter Two: Bioinformatic and Genetic Studies of Attractin Family Proteins 30 
Chapter Three: Cell Biology and Interactions of ATRN, MGRN1, and MC1R 63 
Chapter Four: ATRN, MGRN1, and MC1R in Melanocytes    91 
Chapter Five: Neurodegeneration as a Consequence of ESCRT Dysfunction 114 
References          143 
  ix
LIST OF FIGURES 
Figure 1.1. Phenotypes of ATRN and MGRN mutant mice.   2 
Figure 1.2. Spongiform neurodegeneration in prion disorders.  8 
Figure 1.3. Coat color phenotypes of pigment-type switching mutants. 18 
Figure 1.4. The pigment-type switching pathway    19 
Figure 2.1. Protein and exon structure of murine ATRN   32 
Figure 2.2. The murine ATRN family of proteins    38 
Figure 2.3.  ATRN family proteins across eukaryotic phyla   43 
Figure 2.4. Innovations in the ATRN family on the Tree of Life  44 
Figure 2.5 Conservation of ATRN and ATRNL1 across vertebrates 47 
Figure 2.6. Multiple alignment of ATRN family cytoplasmic tail sequence 48 
Figure 2.7. Rescue of Atrn mutant phenotypes by Atrnl1 overexpression 50 
Figure 2.8. Phenotypic overlap of Mgrn1 and Atrn family mutants  57 
Figure 2.9. Highly conserved sequences in ATRN family cyto tails  58 
Figure 3.1. GPCR trafficking in the endolysosomal pathway  64 
Figure 3.2. Colocalization of tagged ATRN and MC1R   75 
Figure 3.3. ATRN and MC1R in the endolysosomal pathway  77 
Figure 3.4. ATRN-GFP is degraded in lysosomes    79 
Figure 3.5. Coimmunoprecipitation of ATRN with MGRN1 and MC1R 81 
Figure 3.6. MGRN-sensitive punctate localization of ATRN-CYTO-GFP 84 
Figure 3.7. Model of interaction of ATRN, MGRN1, and MC1R  86 
Figure 4.1. MGRN1-dependent lysosomal trafficking of ATRN-GFP 96 
Figure 4.2. Appearance of endogenous ATRN by Western blot  97 
Figure 4.3. Response of Endogenous ATRN to MC1R ligands and CQ 99 
Figure 4.4. ATRN is abnormally glycosylated in Mgrn1 mutants cells 102 
Figure 4.5. MC1R-GFP traffics to lysosomes in melanocytes  104 
  x 
Figure 4.6. Unified model of ATRN/MGRN1/MC1R in melanocytes 108 
Figure 5.1. The class E vps compartment in ESCRT-depleted cells  117 
Figure 5.2. Accumulation of autophagosomes upon ESCRT dysfunction 119 
Figure 5.3. PI(3,5)P2 regulatory mutants cause spongiform change  120 
Figure 5.4 Inducible CamKCreER-T2 activity in mouse brain  127 
Figure 5.5 Generation of Tsg101 null allele in adult mouse brain  128 
Figure 5.6 Weight loss phenotype resulting from Tsg101 deletion  129 
Figure 5.7. Weight loss is transient after neuronal Tsg101 deletion  130 
Figure 5.8. Cerebral and hippocampal atrophy after Tsg101 deletion 132 
Figure 5.9. Appearance of spongiform change after Tsg101 deletion 133 
 
  xi
LIST OF TABLES 
Table 1.1. Phenotypes of ATRN alleles     34 
Table 2.1. Protein sequences used in this study    40 
Table 2.2. Rescue of Atrn mutant phenotypes by Atrnl1 transgene  52 
Table 5.1. Effects of Tsg101 gene deletion in adult mouse brain  130 
 
  xii
LIST OF ABBREVIATIONS 
Agouti Signaling Protein       ASP/ASIP 
Adenylate Cyclase     AC 
Amyloid Beta peptide     A 
Attractin     ATRN 
Attractin-like protein 1     ATRNL1 
Base pair     bp 
Bovine Spongiform Encephalopathy    BSE 
Central Nervous System     CNS 
Chronic Wasting Disease     CWS 
Coding Sequence     CDS 
Creutzfeldt-Jakob Disease     CJD 
Delta Opioid Receptor     DOR 
Endogenous Retrovirus     ERV 
Endoplasmic Reticulum     ER 
Endosomal Complex Required for Sorting    ESCRT 
Endosomal Recycling Complex    ERC 
Epidermal Growth Factor     EGF 
Epidermal Growth Factor Receptor    EGFR 
Factor Induced Gene 4     FIG4 
Fetal Bovine Serum     FBS 
Formation of Aploid and Binucleates 1    FAB1 
Frontotemporal Dementia     FTD 
G protein alpha     G 
G protein-coupled Receptor    GPCR 
G protein-coupled Receptor Kinase    GRK 
  xiii
Gerstmann-Straussler-Scheinker disease    GSS 
Glycophosphatidylinositol     GPI 
Hematoxylin and Eosin     H&E 
HEPES-Buffered Saline     HBS 
Human Immunodeficiency Virus    HIV 
Intracisternal A Particle     IAP 
Lateral Plate Mesoderm     LPM 
Left-Right Patterning     L-R Patterning 
Lysosome-associated Membrane Protein     LAMP 
Mahogunin Ring-finger 1     MGRN1 
Mannose-6-Phosphate Receptor    M6PR 
Melanocortin 1 Receptor     MC1R 
Melanocortin 2 Receptor     MC2R 
Melanocortin 4 Receptor     MC4R 
Melanocortin Receptor Accessory Protein    MRAP 
Molecular Weight     mw 
1-methyl-4-phenylpyridinium    MPP+ 
Multiple EGF domains 8     MEGF8 
Multivesicular Body     MVB 
Open Reading Frame     ORF 
Peptide N-glycosidase F     PNGase F 
Phosphatidylinositol (3,5) biphosphate    PI(3,5)P2 
Polyacrylamide Gel Electrophoresis    PAGE 
Prion Protein     PrP 
Prion Protein (gene)     Prnp 
Reactive Oxygen Species     ROS 
  xiv 
Really Interesting New Gene    RING 
Receptor Associated Membrane Protein    RAMP 
RING finger protein 157     RNF157 
Sodium Dodecyl Sulfate     SDS 
Superoxide Dismutase 1     SOD1 
12-O-tetradecanoylphorbol-13-acetate     TPA 
Trans-Golgi network     TGN 
Transmissible Spongiform Encephalopathy   TSE 
Tris-buffered Saline     TBS 
Tris-buffered Saline with Tween-20    TBS/T 
Tumor Susceptibility Gene 101    TSG101 
Vacuole partitioning 14     VAC14 
Variant Creutzfeldt-Jakob Disease                                         vCJD 
5-bromo-4-chloro-3-indolyl--D-galactopyranoside             X-gal 
  1 
CHAPTER ONE 
SPONGIFORM  NEURODEGENERATION & THE PIGMENT-TYPE SWITCHING 
SYSTEM
1 
Introduction 
 Spongiform neurodegeneration is a histopathologically striking form of brain 
disease: under the light microscope, sections of affected brain tissue appear to be 
riddled with thousands of tiny holes.  The appearance, enlargement, and spread of 
these vacuoles herald dementia and, eventually, death for the unfortunate victims of 
several different human diseases, but little is known about how these spongiform 
vacuoles form.  To explore this problem, I have made use of a fascinating pair of 
mouse mutants, each of which develops spongiform neurodegeneration.  Mice with 
null mutations in the genes attractin (Atrn) and mahogunin ring finger-1 (Mgrn1)  
exhibit a remarkable degree of phenotypic overlap, sharing both a progressive 
spongiform neuroencephalopathy and a particular defect in the control of pigment 
production (Figure 1.1).  This peculiar genetic situation indicates that the protein 
products ATRN and MGRN1 are likely to be cooperating partners in a conserved 
molecular pathway that functions in the brain to prevent spongiform 
neurodegeneration, and also in the pigment cell to regulate pigment-type switching.  
Therefore, I have used the pigment cell as a model system in which to explore this 
functional relationship of ATRN and MGRN1, with the expectation that the insights 
gained will translate into a new understanding of the mysterious and destructive 
phenomenon of spongiform neurodegeneration. To provide the necessary background 
for this study, this chapter reviews the problem of spongiform change, and then 
introduces the model system of pigment-type switching. After exploring the functions 
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 Portions of this chapter are modified with the permission of the publisher from Walker and Gunn, 
2010a and Walker and Gunn, 2010b. 
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Figure 1.1. Spongiform neurodegeneration and hyperpigmentation in Atrn and Mgrn1 
mutant mice. A: Low-magnification view of widespread spongiform 
neurodegeneration in Atrn
mg/mg 
brain.  B: Mgrn1
-/- 
mice (right) are hyperpigmented. C: 
Atrn
-/- 
mice (right) are hyperpigmented phenotypes. D: Spongiform neurodegeneration 
in hippocampus of 13-month-old Mgrn1
-/- 
mouse. E: Spongiform neurodegeneration in 
thalamus of 4-month-old Atrn
-/-
 mouse. Scale bars in D&E represent 50 μm. Images 
are modified with permission from (A) Bronson et al., 2001; (B) Jiao et al., 2009b; 
(C) Walker et al., 2007; (D) He et al., 2003; and (E) Gunn et al., 2001. (Note: the 
unlabeled mouse in C is an animal from a transgenic rescue experiment with a 
complex genotype; it displays an agouti coat coloration similar to a wild-type mouse.) 
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of ATRN and MGRN1 from the perspective of pigment-type switching in Chapters 2 
through 4, this study will return to the subject of spongiform neurodegeneration in 
Chapter 5, in which insights from studies in the pigment model system will be applied 
to build and test a hypothesis regarding the underlying mechanism of spongiform 
change. 
 
Characteristics of spongiform neurodegeneration in human disease 
 Spongiform neurodegeneration (also referred to as spongiform encephalopathy 
or spongiform change) is defined as the appearance of membrane-bound vacuoles 
within the neuropil; that is, within the dense meshwork of axonal and dendritic 
processes (and embedded cell bodies) of the cells of the nervous system (Masters and 
Richardson, 1978). These vacuoles typically become larger and more numerous as 
disease progresses, displacing normal cell contents and presumably disrupting normal 
cellular processes.  Human spongiform neuroencephalopathies are uniformly fatal.  
Among these, the canonical examples of spongiform neuropathology are the various 
transmissible spongiform encephalopathies (TSEs), which are understood to result 
from the spread of an infectious conformational form of the prion protein; however, 
histopathologically similar spongiform change occurs in other diseases and it can be 
induced in several experimental mouse model systems by genetic means, as discussed 
below.  From the perspective of public health, understanding the mechanism of this 
peculiar neuropathology is of considerable interest because of the devastating 
consequences of the various spongiform pathologies on their human (and animal) 
victims.  As a scientific puzzle, spongiform change offers one paramount challenge: to 
understand the disease, one must explain how the abnormal vacuolar membranous 
compartments arise.  This gives the investigation of spongiform change a tractably 
delimited focus, unlike many other neuropathologies for which the phenomenon to be 
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explained is, broadly, “cell death.”   While a great deal has been learned about the 
characteristics of dying neurons in other pathologies, it is often difficult to know 
whether the common mechanisms so frequently uncovered (such as apoptotic and/or 
autophagic cell death, oxidative stress, and synaptic dysfunction) represent specific 
disease pathways or are merely common end-stage characteristics of distressed 
neurons.   Obviously, if an ultimate goal of neurodegeneration research is to identify 
etiologically important points for intervention in specific disease pathways, then the 
earlier disease-specific events are especially important to understand.  In the case of 
the spongiform encephalopathies, the defining disease-specific event is the formation 
of the spongiform vacuole itself; therefore, the major question to be asked is, what is 
the origin of the abnormal membrane that accumulates to become a vacuole?  Some 
light can be shed on this question by considering the best-characterized examples of 
spongiform encephalopathies, the prion-related TSEs. 
  
Spongiform degeneration in transmissible spongiform encephalopathies 
 Prion-related disorders provide classic examples of human spongiform 
encephalopathy. The first of these disorders to be described was Creutzfeldt-Jakob 
disease (CJD)(Creutzfeldt 1920; Jakob 1921), which occurs sporadically in the 
population at a frequency of about 1:1,000,000 persons, and also in a rare, dominantly 
inherited fashion in a few identified families (Masters et al., 1978, Brown et al., 1987, 
Will, 1993).  Progressive spongiform neurodegeneration, astrogliosis and microglial 
activation with neuronal loss, and the extracellular accumulation of proteinacious 
amyloid plaques are the classical pathological hallmarks of CJD (Masters and 
Richardson, 1978). The clinical manifestation of the disease typically begins with a 
prodromal constellation of mood and sleep disturbances, leading within a year to 
dementia, loss of motor control, torpor, and finally death (Roos et al., 1973).  The 
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disorder arises from a remarkable property of the prion protein (PrP), which is the 
major component of the CJD amyloid plaques (McKinley, Bolton, and Prusiner, 
1983). As is now understood, the underlying cause of the disease is the spread of an 
abnormal conformational state of PrP within the nervous system (reviewed in Prusiner 
et al., 2004a).  This disease-related conformational state (referred to as PrP
D 
or PrP
Sc 
) 
is capable of inducing the conversion of normally folded cellular PrP
C  
molecules into 
its own toxic conformational state.  A single founder inoculum of PrP
D 
can therefore 
seed a chain reaction of prion conversion into the PrP
D
 form, which resists 
degradation, undergoes oligomerization, and accumulates in the brain.  The initial 
conversion of PrP from PrP
C 
 to the pathological conformation can occur 
spontaneously (as is likely to be the case in victims of sporadic CJD) or as a result of 
mutations in the prion (Prnp) gene sequence in familial CJD and in the related 
disorders Gerstmann-Straussler-Scheinker disease (GSS) (Hsiao et al., 1989) and fatal 
familial insomnia (FFI) (Goldfarb et al., 1992).  Remarkably, the ability of PrP
D
 to 
initiate disease is not necessarily limited to the body of its original host; PrP
D 
can act 
as an infectious agent, spreading from one individual to another via ingestion or other 
exposure.  The realization of this fact grew out of investigations of an obscure disease, 
kuru, which once afflicted the Fore people of the highlands of Papua New Guinea 
(Liberski and Brown, 2004).  This spongiform encephalopathy (recognized to bear 
close histopathological resemblance to CJD) was transmitted through the population 
by the cannibalistic funerary rites of the Fore people, who became infected with PrP
D 
by consuming the brains of their dead (kuru-infected) kinsmen.  While the kuru 
epidemic among the Fore has ceased along with their traditional funerary cannibalism, 
prion infection has become a matter of significant public health concern ever since the 
British bovine spongiform encephalopathy (BSE) outbreak of the 1990s.  This 
epidemic of prion disease spread widely among the British cattle population as a result 
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of the industrial use of bovine slaughterhouse remnants in cattle feed (reviewed in 
Wells and Wilesmith, 2004).  Subsequent ingestion of “mad cow disease-” infected 
meat products spread prion disease to human consumers, causing a variant form of 
CJD (vCJD). Infectious prion disease is also endemic in domestic sheep, where it is 
known as scrapie, and in several North American populations of deer and elk, in 
which it causes a syndrome known as chronic wasting disease (CWD) (reviewed by 
Prusiner et al., 2004b).   
 Work by many labs has elucidated many aspects of the PrP conversion process, 
including structural features of cellular and disease-related PrP, the kinetics and 
characteristics of PrP
D 
conversion, the intracellular trafficking and post-translational 
modifications of PrP, and the contributions of various regions of the protein to PrP
D 
formation.  However, how the spread of PrP
D
 leads to the characteristic syndrome of 
neurodegeneration of prion disease is still poorly understood.  It is clear that 
spongiform neurodegeneration is essentially a “gain-of-function” phenotype of the 
PrP
D 
conformer itself, and not a result of the loss of PrP
C 
functionality, as Prnp 
knockout mice do not develop neurodegeneration (reviewed by Flechsig et al., 2004).  
Prnp
-/-
 mice lack any overt neurodegenerative phenotype (although subtle behavioral 
effects can be demonstrated), a fact which has significantly hindered progress toward 
identifying the physiological function(s) of PrP
C
 and thus determining the likely 
pathogenic mechanism of PrP
D
.  In the absence of strong genetic data to guide 
investigators, interaction studies have provided a default starting point for exploration 
of the functions of PrP
C
, and the result has been a steady proliferation of studies 
reporting interactions between PrP and myriad putative interaction partners as 
dissimilar as (for example) tubulin, heat shock proteins, complement proteins, 
metalloproteases, RNA, and the Alzheimer-related peptide A (Petrakis and 
Sklaviadis, 2006; Costa et al., 2009; Osiecka et al., 2009; Satoh et al., 2009; Chen, 
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Yadov, and Surewicz 2010; Erlich et al., 2010, Silva et al., 2010).  The diversity of 
identified interactors has fueled a similarly wide range of hypotheses about the 
physiological function of PrP, with various groups suggesting roles for PrP in metal 
binding, cell survival signaling, synaptic transmission, immune functions, defense 
against oxidative stress, and other pathways (for recent reviews see Hu et al., 2008; 
Westergard, Christensen, and Harris, 2007; Hu, Rosenberg, and Stuve, 2007;Aguzzi, 
Baumann, and Bremer, 2008). 
 Whatever the physiological function of PrP
C
, it has become clear that trafficking 
and membrane localization of the protein are important both for the conversion of 
PrP
C
 to PrP
D
 and for the subsequent induction of pathological changes by the 
abnormal conformer. Trafficking studies have demonstrated that nascent PrP travels 
through the secretory pathway, acquiring N-linked glycosylation modifications and a 
glycophosphatidylinositol (GPI) anchor as post-translational modifications on the way 
(Campana, Sarnataro, and Zurzolo, 2005).  Once PrP arrives at the cell surface (to 
which it is held by the GPI anchor) it undergoes repeated rounds of endocytosis and 
recycling to the plasma membrane before traveling along the endosomal/lysosomal 
pathway for degradation (Reviewed by Harris et al., 2004).  Secretion of PrP to the 
cell surface is necessary for conversion to PrP
D
, suggesting that conversion may take 
place on the plasma membrane or within endosomal compartments.  Whereas normal 
trafficking of PrP is necessary for its conformational conversion, the topological 
localization of PrP to membrane appears to be important for disease progression as 
mutant PrP without its GPI anchor can convert to the PrP
D 
conformational state and 
propagate in mice but does not cause classical neuropathology (Campana et al, 2007).  
Conversely, a mutant PrP that adopts an abnormal transmembrane localization has 
been shown to underlie a particular form of GSS, perhaps as a result of its altered 
membrane association (Hegde et al., 1998). 
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 Histopathological and ultrastructural studies of prion-infected brains reveal a 
characteristic suite of membranous abnormalities within the affected cells (reviewed 
by DeArmond et al., 2004; Liberski, 2004; Peden and Ironside, 2004). The vacuoles 
themselves are membrane-bound structures of approximately 5-25 μm in diameter, 
sometimes containing cellular debris and membrane fragments (Figure 1.2).  Like 
other neurodegenerative diseases, prion diseases exhibit characteristic patterns of 
neuronal subpopulation vulnerability, with the distribution and severity of vacuolation 
in the brain dependent on both the “strain” of the initiating PrP
D
 prion (which is 
considered to reflect the protein’s particular conformational form) and by the host PrP 
genotype.  Some vacuoles are apparently bounded by the plasma membrane and are 
typically interpreted as swollen dendritic processes, which appear to be largely cleared 
of cytoplasmic contents.  Other vacuoles are membrane-bound structures occurring 
within cytoplasm, and are of uncertain origin.  Because these vacuoles can contain 
  
Figure 1.2. Histopathology of prion disease.  A: Spongiform vacuoles from brain of a 
goat with scrapie. B: Ultrastructural appearance of spongiform vacuole of CJD.  
Images used with permission from Liberski, 2004. 
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large inclusions (such as damaged mitochondria) and may appear to have a double-
layered peripheral membrane, some have suggested that autophagosomes may 
contribute to the formation of spongiform vacuoles.  In addition to vacuoles, other 
membranous abnormalities are typically observed in prion diseases.  Abnormally long 
invaginations of the plasma membrane, resembling extended caveolar cisternae and 
labeled with caveolin protein, have been reported by several groups and may reflect an 
abnormality in caveolar endocytosis.  Another feature reported to accompany many 
different types of prion disease is the appearance of minute “tubulovesicular bodies” 
in the prion disease-affected brain tissue (Liberski et al., 2008) and in prion-infected 
cultured cells (Manuelidis et al., 2007).  These enigmatic spherical or ovoid structures 
are 25-35 nm in size, and are not labeled by anti-PrP antibodies. 
 
Retrovirus-induced spongiform neurodegeneration 
 Infection with certain retroviruses causes spongiform neurodegeneration.  In 
humans, spongiform change appearing very similar to that seen in prion disease occurs 
in patients with HIV-associated dementia (Artigas et al., 1989), but PrP
D 
is not 
detectable in the brains of these patients (Goldwater and Paton, 1989). In mice, 
spongiform change histopathologically indistinguishable from prion encephalopathy is 
caused by several members of the murine leukemia virus (MuLV) family (e.g., see 
Brooks et al., 1979; Gravel, Kay, and Jolicoeur, 1993; Takase-Yoden and Watanabe, 
1997; Choe et al., 1998; reviewed by Gomez-Lucia, 2005), again without detectable 
involvement of PrP
D
 (Jolicoeur, Masse, and Kay, 1996). 
  
Spongiform degeneration in PI(3,5)P2 mutants 
 Phosphatidylinositol (3,5) diphosphate (PI[3,5]P2) is a low-abundance signaling 
lipid that is important for a variety of endosomal trafficking processes in yeast and 
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metazoa.  According to the current understanding of this molecule, PI(3,5)P2 is 
produced on the surface of endosomal compartments, where it mediates interactions 
between membrane proteins and trafficking effectors (Dove et al., 2009). In yeast, a 
trio of interacting proteins named Fab1p, Fig4p, and Vac14p are required to produce 
PI(3,5)P2 and deletion of any of them results in a distended vacuole phenotype 
(Odorizzi, Babst, and Emr, 1998; Bonangelino et al., 2002; Duex et al., 2006). (The 
yeast vacuole is a large membrane-bound organelle which has no exact counterpart in 
mammals but which shares features of mammalian late endosomes and lysosomes.)  In 
mammals, Fab1 has been shown to occupy the surface of early and/or late endosomes 
(Ikonomov, Sbrissa, and Shisheva, 2001; Rutherford et al., 2006) and colocalize with 
Vac14, suggesting that the entire complex is active on endosomes in a similar manner 
to that in yeast.  Spontaneous mutations in Fig4 or Vac14 (the pale tremor and 
infantile gliosis mutants, respectively) cause spongiform neurodegeneration in mice 
(Chow et al., 2007; Jin et al., 2008), implicating disruption of a PI(3,5)P2-dependent 
endosomal trafficking process in the formation of spongiform vacuoles.  Cytoplasmic 
vacuoles marked with the late endosome and lysosome marker, LAMP2, arise in 
cultured cells from Vac14 and Fig4 mutant mice, suggesting that late endosomal or 
lysosomal compartments contribute to the spongiform vacuoles in these mutants 
(Chow et al., 2007; Zhang et al., 2007).  More than one endosomal trafficking 
pathway is disrupted by impairment of PI(3,5)P2 production as cells isolated from 
Vac14 null mutant mice show defects in the endosome-to-Golgi retrograde trafficking 
of M6PR, as well as an apparent impairment of endo-lysosomal trafficking of 
cathepsin D (Zhang et al., 2007). Further evidence of a defect in the endo-lysosomal 
axis comes from the dilute pigmentation phenotype shared by the pale tremor and 
infantile gliosis mutants, the former of which has been shown to show a “clumped 
melanosome” abnormality suggestive of a lysosomal/melanosomal biogenesis defect 
  11 
(Chow et al., 2007).  Other trafficking deficiencies may be downstream of these 
defects in endo-lysosomal maturation or processing. Both Fig4 and Vac14 null 
mutants show impaired autophagy (Ferguson, Lenk, and Meisler, 2009), which is a 
lysosome-dependent process.  In humans, FIG4 mutations cause spongiform 
pathology in a form of Charcot-Marie-Tooth disease. In cells cultured from these 
patients, organelle trafficking is disrupted as a consequence of physical obstruction by 
vacuoles (Zhang et al., 2008). 
 PI(3,5)P2 mutants illustrate that defects in endosomal membrane trafficking can 
be associated with spongiform neurodegeneration.  Identifying the precise source of 
the abnormal membrane that accumulates to form the spongiform vacuole, however, is 
not necessarily easy.  The multiple trafficking defects seen in these mutants 
underscore the extreme degree of interconnection of intracellular trafficking pathways 
as well as the potential difficulty of pinning down a singular “identity” of an abnormal 
membrane such as that seen in spongiform neurodegeneration.  In contrast to vacuolar 
defects such as lysosomal storage disorders that are caused by a defect at the end of a 
trafficking pathway, spongiform neurodegeneration causes apparently “empty” 
vacuoles that cannot be identified as any particular cellular compartment on the basis 
of their lumenal contents.  The observation that a “compartment specific marker” such 
as LAMP2 labels the vacuoles in Fig4 and Vac14 mutants can be interpreted in 
multiple ways.  One interpretation would take the presence of the marker at face value 
and conclude that the LAMP2-labeled vacuoles represent abnormally swollen late 
endosomes or lysosomes.  Assuming this interpretation is correct, swelling could be 
the result of a general block at some point in endo/lysosomal maturation, meaning that 
the affected compartments could continue to receive, but not to process, new cargo, 
resulting in hypertrophy of their limiting membranes.  Alternatively, specific 
populations of cargo molecules may be accumulating in otherwise normal late 
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endosomes or lysosomes, not as the result of a general block in endolysosomal 
maturation or processing but because they specifically require PIP(3,5)P2 either to 
progress toward the lysosome or to be reclaimed by a recycling or retrograde 
trafficking pathway.  If one or the other of these mechanisms is correct and 
spongiform vacuoles are in fact abnormal late endosomes or lysosomes, these 
structures could act as sinks for any number of trafficking factors, the sequestration of 
which could have an effect on diverse trafficking pathways.  It is important to note, 
however, that transmembrane proteins such as LAMP2 are themselves dependent on 
membrane protein trafficking pathways for their normal localization.  The LAMP2 
labeling the vacuoles of Fig4 and Vac14 mutant cells could therefore signify not an 
endolysosomal identity of the abnormal compartment, but rather an aberration in the 
trafficking of LAMP2 itself.  If this is the case, one would look for an “identity” of the 
abnormal membrane by considering the biosynthetic pathway of LAMP2 and 
determining the point at which its normal progression is halted, or the compartment to 
which it is rerouted.  Finally, it may be that, from the point of view of the cellular 
trafficking machinery, abnormal membrane and its cargo may be, in a biologically 
meaningful sense, without an identity.  PI(3,5)P2  is thought to be one of the signals 
that, in combination with membrane cargo proteins and trafficking regulators, provide 
the combination of inputs to allow “coincidence detectors” to recognize compartment 
identity (Dove et al., 2009).  One may imagine the system-wide loss of such a signal 
could result in the general accumulation of all manner of membranes (and associated 
cargo) that cannot generate the signals to fall within the purview of any particular 
processing system.  These caveats aside, the discovery of spongiform encephalopathy 
in PI(3,5)P2 regulatory mutants is an exciting advance and it focuses attention on the 
late endosome/lysosome axis as an area of interest in explaining spongiform 
neurodegeneration.  
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Spongiform neurodegeneration in ATRN mutant rodents 
 Mouse and rat mutants bearing mutations in Atrn are well-characterized models 
of spongiform encephalopathy.  Spongiform change morphologically indistinguishable 
from that found in prion disease was first described in the zitter mutant rat by Rehm 
and colleagues (1982) and subsequently characterized at the ultrastructural level in a 
series of papers by Kondo and colleagues (Kondo et al., 1991; Kondo et al., 1992; 
Kondo et al., 1995; Kondo, Sato, and Nagara, 1991).  As zitter mapped to rat 
chromosome 3(which bears a region of homology to the prion locus in mice), it was 
suspected that zitter might be a mutation in Prnp. However, no abnormalities were 
found in the coding sequence of zitter rat Prnp and there was no accumulation of 
aberrant PrP
D
 (Gomi et al., 1994), suggesting that the causative mutation of zitter was 
a separate point of entry into a spongiform degenerative pathway.  A similar 
encephalopathy was identified in the mahogany mutant mouse gene (He et al., 2001, 
Gunn et al, 2001, Bronson et al., 2001), which was known to be caused by a mutation 
in the attractin (Atrn) gene (see chapters 2 and 3 for discussion of this protein). At 
about the same time it was confirmed that the zitter phenotype was also due to a null 
mutation at the Atrn locus (Kuramoto et al, 2001), as was the spongiform phenotype 
of the myelin vacuolation (mv) rat (Kuwamura et al., 2002). 
 Clinically, Atrn null animals present with tremor and, in mice, hyperactivity 
(Kuramoto et al., 2001; Gunn et al, 2001). Light microscopy reveals a classical 
spongiform encephalopathic appearance, with vacuoles becoming more numerous and 
larger with age.  By two months of age, vacuolation is noticeable in Atrn null 
homozygotes and the pathology spreads to affect most regions of the brain with 
extensive vacuolation by 9 months (Bronson et al., 2001).  Some apoptotic neuron 
death has been reported to occur in the brainstem (Ookohchi et al., 1997), although it 
is not clear that extensive neural death occurs in Atrn mutant brains. Ultrastructurally, 
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vacuoles occur within axons, dendrites, and soma of neurons, as well as within the 
cytoplasm of some astrocytes and oligodendrocytes (Kondo et al., 1995; Bronson et 
al., 2001; He et al., 2003).  Oligodendrocytes evidently experience severe defects in 
membrane biosynthesis or trafficking, as these cells accumulate abnormal “whirled” 
membrane stacks within the cytoplasm in association with the nucleus, lysosomes, and 
other membrane-bound organelles (Kondo et al., 1991).  Possibly as a consequence of 
this oligodendroglial dysfunction, myelination is slow and aberrant in zitter rats 
(Kondo et al., 1992) with abnormal and split myelin sheaths becoming widespread as 
myelination of the CNS progresses. Some apparent “spongiform vacuoles” are 
therefore actually lacunae that open between concentric layers of the myelin sheath 
(Kuwamura et al., 2002).  Apparently as a result of difficulties in myelin production 
and /or maintenance, hypomyelination of the CNS is observable from an early age in 
Atrn mutant mice and rats (Kondo et al., 1992; Kuramoto et al., 2001).    
 Studies of the pathological consequences of Atrn deficiency have mostly focused 
on evaluating oxidative stress as a potential disease mechanism.  In cultured cells, 
ATRN has a protective effect against reactive oxygen species (ROS) such as peroxide 
(Muto and Sato, 2003) and against the neurotoxin MPP+, which causes the increased 
production of ROS by impairing mitochondrial function (Paz et al., 2006).  In 
addition, the antioxidant enzyme superoxide dismutase 1 (SOD1) is over-expressed in 
zitter brains, suggesting a response to elevated ROS (Gomi, Ueno, and Yamanouchi, 
1994).  Atrn
mg-3J/mg-3J 
null mutant mouse brain extracts show elevated levels of protein 
carbonyls, which is also consistent with an increase in oxidative stress (Sun, Johnson, 
and Gunn, 2007).  A likely consequence of this oxidative stress has been noted in the 
substantia nigra, in which dopaminergic neurons have been specifically noted to 
degenerate  (Nakadate et al., 2006).  Loss of dopaminergic neurons was reduced by 
treatment with the antioxidant vitamin E (Ueda et al., 2005).  It seems likely that the 
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oxidative stress observed in Atrn mutant cells and tissues is related to the impaired 
function of mitochondrial complex 4 observed in Atrn
 mg-3J/mg-3J
 brain extracts (Sun, 
Johnson, and Gunn 2007).  While it is clear that Atrn mutant cells suffer from 
oxidative stress, it is not known whether the oxidative stress contributes to spongiform 
neuropathology, is a cause of it, or occurs independently through a separate molecular 
pathway.  As oxidative stress is a common feature of many non-spongiform 
neurodegenerative diseases, the elevated ROS activity seen in Atrn mutants may 
simply be a general response of stressed neurons rather than a major underlying factor 
leading to vacuolation. 
 
Spongiform change in Mgrn1 mutant mice  
 Mice homozygous for a null mutation at the mahogunin ring-finger 1 (Mgrn1) 
locus develop a spongiform encephalopathy that appears almost identical to that seen 
in Atrn mutants, although the progression of vacuolation is somewhat delayed 
compared to the Atrn phenotype (He et al., 2003).  Vacuolation spreads throughout the 
brain of affected animals and Mgrn1 mutant brain tissue shows similar changes to Atrn 
mutants in mitochondrial function and ROS damage (Sun, Johnson, and Gunn 2007).  
The similar encephalopathic phenotype of these two mutants is especially remarkable 
as Atrn and Mgrn1 mutant mice were originally identified because of another shared 
phenotype: hyperpigmentation.  As reflected in the names given the first Atrn and 
Mgrn1 mutants identified (mahogany and mahoganoid, respectively), deficiency at 
either locus results in a darkened coat due to a reduction of yellow pigment production 
(see discussion of pigment-type switching below).  By the time these mutants were 
recognized to develop spongiform change, genetic analysis of the two loci had already 
revealed a similar epigenetic placement of mahogany and mahoganoid in what is 
known as the pigment-type switching pathway (Miller et al., 1997; for a recent review 
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of pigment-type switching see Walker and Gunn, 2010a).  The identification of a 
second area of phenotypic overlap between Atrn and Mgrn1 suggested strongly that 
Atrn and Mgrn1 cooperate in a molecular pathway that operates both in the brain, 
where it is critically important for the prevention of spongiform neurodegeneration, 
and in the pigment cell, where it mediates pigment-type switching.  This situation 
suggests that determining the mechanism by which Atrn and Mgrn1 cooperate to 
control pigment-type switching in the pigment cell will simultaneously reveal the 
mechanism by which spongiform encephalopathy occurs in the brain.  This is an 
extraordinary opportunity to study a neurodegeneration mechanism in a very tractable 
model system, as pigmentation biology benefits from over a century of investigation 
dating back to the dawn of modern genetics (Bennett and Lamoureaux, 2003). 
Therefore, this discussion now turns to what is known about Atrn and Mgrn1 in the 
pigment-type switching system. 
 
Pigment-type switching 
 Mice and other mammals produce melanin in two primary forms: a dark-brown 
or black form referred to as eumelanin, and a yellowish/reddish form known as 
pheomelanin.  In the dorsal hair follicles of many mammals, including mice, the 
pigment-producing cells (melanocytes) switch production from eumelanin to 
pheomelanin at an early point in the hair growth cycle, depositing a subapical yellow 
band on an otherwise darkly pigmented hair (Silvers, 1979).   This pigment-type 
switching event gives rise to the subtle “brushed” appearance of the agouti phenotype 
of wild-type mice (Figure 1.3A).   In the ventral hair follicles of many species of 
mammals, the same pigment type-switching pathway is activated to produce the 
primarily pheomelanic belly fur exhibited by many mammals, contributing to a 
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cryptic, counter-shaded appearance valuable for camouflage (Millar et al., 1995; 
Vrieling et al., 1994). 
 
The melanocortin-1 receptor and its ligands 
 The master regulator of pigment-type switching is the melanocortin 1 receptor 
(MC1R), a G-protein-coupled receptor (GPCR) expressed in melanocytes. In its active 
state, the MC1R signals through the stimulatory G-protein  subunit (Gs) to activate  
adenylyl cyclase, raising levels of the second messenger cyclic adenosine 
monophosphate (cAMP) (Figure 1.4), thereby activating a series of transcriptional 
events that support the production of eumelanin (discussed below). When MC1R is in 
its inactive state, cAMP levels are low and pheomelanin is produced. The phenotypes 
of Mc1r mutants illustrate the role of this receptor in pigment-type switching: mice 
carrying the continuously active sombre allele (Mc1r
E-so
) or the hyperactive tobacco 
darkening allele (Mc1r
E-tob
) have black coats (Figure 1.3B), while mice homozygous 
for an inactive truncation mutation (extension, Mc1r
e
) are yellow (Figure 1.3C) 
(Robbins et al., 1993). Similarly, loss-of-function Mc1r variants are associated with 
red hair in humans (Box et al 1997; Valverde et al., 1995). The switch between the 
eumelanogenic and pheomelanogenic signaling states of the murine MC1R is 
normally mediated by the opposing effects of a pair of ligands: -melanocyte 
signaling hormone (-MSH) and agouti signaling protein (ASP) (Figure 1.4). Much of 
the fascination of the pigment-type switching system lies in the complex way these 
ligands modulate MC1R function.  
 The primary agonist of the MC1R, -MSH, is produced in the skin by 
keratinocytes and melanocytes (Chakraborty et al., 1996; Slominski et al., 2000). It 
increases MC1R signaling through cAMP and protein kinase A (Cone et al., 1993; 
Garcia-Borrón et al., 2005) to activate genes required for pigment production (e.g., 
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Figure 1.3.  Coat color phenotypes of mouse pigment-type switching mutants.  The 
wild type (agouti) pattern is caused by production of a subapical band of yellowish-red 
pheomelanin on an otherwise black (eumelanic) hair (A).  Loss of eumelanin synthesis 
causes dark fur (B), while constitutive pheomelanin synthesis results in yellow fur (C).  
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Figure 1.4. A model of the pigment-type switching pathway. (A.) -melanocyte 
stimulating hormone (-MSH) enhances signaling through the melanocortin 1 
receptor (MC1R), leading to GDP/GTP exchange by the stimulatory G protein subunit 
 (Gs) and liberation of GTP-bound Gs from the G protein heterotrimer.  Active, 
GTP-bound Gs stimulates adenylyl cyclase (AC) to promote eumelanogenesis. (B.) 
The MC1R inverse agonist agouti signaling protein (ASP) binds to MC1R and the 
accessory receptor, attractin (ATRN) to inhibit Gs activation and reduce signaling 
through AC, leading to pheomelanogenesis. Mahogunin ring finger 1 (MGRN1) 
interacts with MC1R and is required for ASP signaling.(C:.) Canine -defensin 103 
(-D) can bind MC1R to inhibit ASP binding, promoting eumelanogenesis.  
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Tyr, Tyrp1, Dct) and melanosome biogenesis (Pmel117) and transport (Rab27), largely 
through an effect on the master melanogenic transcription factor, MITF  (Aberdam et 
al., 1998; Bertoletto et al., 1998; Le Pape et al., 2009; Levy, Khaled, and Fisher, 
2006). This effect of -MSH is reinforced by a positive feedback effect whereby -
MSH stimulus causes increased rates of translation of MC1R from a variant transcript 
(Rouzaud et al., 2003). The end result is that melanocytes treated with -MSH become 
more dendritic and produce more eumelanin (Le Pape et al., 2008; Sakai et al., 1997). 
In humans, -MSH is a critical promoter of MC1R function in pigmentation: rare 
mutations that result in loss of the -MSH propeptide, proopiomelanocortin (POMC), 
cause red hair (Krude et al., 1998). In mice, MC1R exhibits a significant level of 
constitutive activity, although administration of -MSH does increase MC1R 
signaling (Cone et al., 1993; Jackson et al., 2007; Sanchez-Mas et al., 2004). This 
constitutive activity of mouse MC1R appears to be sufficient to support eumelanin 
production, as indicated by the fact that the hairs of mice lacking POMC are only 
subtly yellower than those of wild-type mice (Slominski et al., 2005; Yaswen et al., 
1999). Pigment-type switching thus appears to require a reduction of MC1R signaling 
below baseline levels, which normally occurs when the MC1R binds its second major 
ligand, ASP. 
 In mice, ASP is secreted by cells of the dermal papilla (a structure at the base of 
the hair follicle) during days 2-7 of the first hair growth cycle, partly as a response to 
BMP signaling (Bultman et al., 1992; Millar et al., 1995; Sharov et al., 2005). ASP 
competitively binds MC1R to inhibit the pro-eumelanogenic effects of -MSH and 
promote the production of pheomelanin (Figure 1.4) (Blanchard et al., 1995; Lu et al., 
1994), but its effect is not limited to antagonizing MSH function (Hunt et al., 1995, 
Ollmann et al., 1998; Sakai et al., 1997). Pharmacologically, ASP is an inverse 
agonist of MC1R (Siegrist et al., 1997), binding the receptor not only to competitively 
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inhibit signaling by -MSH but also to reduce the intrinsic signaling of MC1R to 
below constitutive levels. It is not clear whether the mechanistic basis of this inverse 
agonism is simply the stabilization of the receptor’s inactive conformation or a more 
complex effect of alterations in MC1R trafficking, turnover, or post-translational 
modification. In addition to its effects on the activity of the MC1R proteins it binds, 
ASP also causes a reduction in the rate of new MC1R biosynthesis (Rouzaud et al., 
2003), further depressing MC1R signaling. A recent microarray study demonstrated 
that ASP blocks the transcriptional effects of -MSH and activates genes involved in 
morphogenesis and cell adhesion to cause a melanoblast-like appearance of the treated 
cells, suggesting that ASP promotes a functional de-differentiation of melanocytes (Le 
Pape et al., 2009). Interestingly, while genetic analyses confirm that all of ASP’s 
effects on pigmentation are MC1R-dependent, some effects of ASP on melanocyte 
morphology in vitro have been reported to be cAMP independent (Hida et al., 2009). 
In the absence of any known alternative ASP receptor, this suggests that some of the 
effects of ASP could involve a non-canonical pathway of MC1R signaling.   
 Genetic analysis of ASP function has benefited from the availability of a 
variety of interesting mouse mutant alleles. The fur of homozygotes for a null 
mutation (a
e
, extreme non-agouti; Hollander and Gowen, 1956) is completely black 
(Figure 1.3B), reflecting constitutive signaling through the MC1R. The pigmentary 
role of Mc1r is epistatic to that of agouti as mice with loss-of function mutations for 
both Mc1r and agouti exhibit the yellow Mc1r
e
 coat color phenotype. Conversely, 
mice heterozygous for the lethal yellow (A
y
) allele of agouti express ASP ubiquitously 
and are yellow, similar to Mc1r loss-of-function extension mutants (Figure 1.3C), 
reflecting continuous inverse agonism of the MC1R (Miller et al., 1993). The A allele 
causes the classic agouti banding pattern on hairs across the entire pelage. The A
w -
allele produces dorsal agouti-banded hairs and yellow belly hairs, the latter due to use 
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of an additional, ventral-specific promoter that drives constitutive expression of ASP 
in the ventrum (Millar et al., 1995; Vrieling et al., 1994). This counter-shaded 
coloration pattern is widely found throughout the Mammalia, suggesting that A
w 
is the 
ancestral wild-type allele. Lastly, the viable yellow agouti allele, A
vy
, provides an 
interesting model of epigenetic inheritance. The coat color of A
vy
 mice can range from 
agouti to completely yellow, reflecting variation in methylation of an intracisternal A 
particle (IAP) sequence inserted near the agouti locus (Duhl et al., 1994; Morgan et 
al., 1999). This mutant has become a valuable model for studying epigenetic 
inheritance as agouti expression in a litter of pups tends to track maternal phenotype 
and can be influenced by maternal diet (Cropley et al., 2006). In addition to this well-
characterized range of mutant agouti alleles in mice, variant agouti alleles cause 
distinct pigmentation phenotypes in other animals (Klungland and Vage, 2003).  
While the agouti-banding pattern is not seen in the hair of humans or other hominids, 
variations in ASIP have been associated with both hair and skin pigmentation traits in 
human populations  (Bonilla et al., 2005; Kanetsky et al 2002; Sulem et al., 2008; 
Voisey et al., 2006) 
  Recently, Barsh and colleagues discovered a third ligand of the MC1R by 
mapping the “K” locus that determines dominant black coat color in dogs (Kerns et 
al., 2004; Candille et al., 2007). Surprisingly, it turned out to be the gene that encodes 
-defensin 103, a member of an ancient family of small anti-bacterial peptides best 
known for their role in the innate immune system. While no murine -defensin alleles 
are known to cause pigmentation phenotypes, transgenic mice expressing either the 
black (K
B
) or the yellow (k
y
) canine allele had predominantly black coats with small 
patches of agouti-banded hairs. Biochemical investigations showed that -defensin, 
like ASP, can bind MC1R to compete against -MSH binding, without activating the 
cAMP pathway (Figure 1.4). This suggests that -defensin’s mode of action in the 
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pigment cell may involve exclusion of ASP from the binding site or interference with 
the activity of the ASP co-receptor, attractin (described below).  
 
Accessory proteins for pigment type switching: ATRN and MGRN1 
 Mahogany (mg) and mahoganoid (md) were identified in the 1960s as separate 
loci required for transduction of the ASP signal (Lane, 1960; Lane and Green, 1960; 
Phillips, 1963). Genetic studies demonstrated that loss-of-function mutations at either 
of these loci resulted in dark fur in homozygotes, even in the presence of the 
ubiquitously overexpressed A
y 
allele of agouti. The phenotypic expression of either 
mutation depends upon Mc1r, however, in that Mc1r
e/e 
mice are yellow regardless of 
their mahogany or mahoganoid genotype (Miller et al., 1997). The similar phenotype 
and identical epistatic placement of these genes in agouti-melanocortin receptor 
signaling strongly suggested that their products work together to achieve a particular 
step in the pigment type-switching pathway.  
 The mahogany locus was identified by positional cloning (Gunn et al., 1999; 
Nagle et al., 1999) as the mouse ortholog of the human attractin (ATRN) gene, which 
was named for its role in mediating clustering of immune cells (Duke-Cohan et al., 
1998). Murine Atrn encodes a type I (single-pass) transmembrane protein with a 
predicted molecular weight of ~160 kDa. Its large extracellular/lumenal domain 
contains EGF-like repeats and plexin/semaphorin/integrin motifs characteristic of 
extracellular receptors involved in cell migration, adhesion, or other developmental 
processes, as well as a CUB domain, a C-type lectin domain, and a predicted kelch 
propeller (discussed in chapter 3; see Figure 3.1).  The intracellular/cytoplasmic tail of 
ATRN is short compared to the rest of the protein (128 amino acid residues out of 
1428) and contains no named domains. Expression of full-length wild-type mouse 
Atrn under the control of melanocyte- or keratinocyte-specific promoters demonstrated 
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that ATRN is required in melanocytes to rescue the pigment-type switching phenotype 
of Atrn null mutant mice (He et al., 2001). This, along with its transmembrane 
topology, suggested that ATRN might serve as an accessory receptor for ASP (Figure 
2.2), and He et al. (2001) used surface plasmon resonance to detect an interaction 
between ATRN and the N-terminal region of ASP.  This interaction had an estimated 
Kd of  ~0.7 μM (He et al., 2001), which is in the range of values reported for other 
low-affinity or accessory receptors.  Because MC1R binds to the C-terminal portion of 
ASP (Ollmann and Barsh, 1999; Willard et al., 1995), these results suggest that ATRN 
and MC1R may simultaneously bind opposite ends of ASP to form a MC1R-ASP-
ATRN ternary complex.  While a physical association between ATRN and MC1R has 
not been reported to date, their paralogs (attractin-like 1 and the MC4R), have been 
shown to interact with each other (Haqq et al., 2003) and both ASP and its paralog, 
agouti-related protein (AGRP), can bind MC4R (Chai et al., 2005). These 
observations suggest that ATRN and MC1R are likely to be interacting partners, and 
support the consensus view that ATRN is an accessory receptor for ASP.   
 ATRN’s role as an accessory receptor appears to go beyond the mere additive 
stabilization of the MC1R-ASP interaction as it is otherwise difficult to explain how 
the loss of ATRN’s relatively weak ASP-binding ability could completely abolish 
pigment-type switching, even in mice overexpressing ASP. One possibility is that 
ATRN binds the N-terminus of ASP in a way that greatly increases the affinity of the 
bound ASP for MC1R.  It is interesting to note that the N-terminus of AGRP inhibits 
the interaction of AGRP with the MC4R and is actually cleaved off by proprotein 
convertase 1 to release the pharmacologically active C-terminal peptide (Creemers et 
al., 2006).  ASP is not known to undergo any similar cleavage event, suggesting that if 
the N-terminal end of ASP has a similar autoinhibitory effect on MC1R binding, 
sequestration of this end of the molecule by ATRN could be a way of relieving the 
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inhibition.  Another possibility is that ATRN, when bound to ASP and MC1R in a 
ternary complex, couples MC1R to a downstream event such as lysosomal trafficking 
of the ternary complex, recruitment of additional inhibitory factors, or activation of a 
non-canonical signaling pathway. This would make the effect on MC1R of binding 
both ASP and ATRN qualitatively different from the effect of binding ASP alone, 
explaining the absolute requirement for ATRN in pigment-type switching. It is 
noteworthy in this respect that Atrn null mutant melanocytes have a normal cAMP 
response to ASP treatment but exhibit an impairment of the cAMP-independent ASP-
induced morphological changes reported by Hida et al. (2009). These morphological 
changes also require the N-terminal portion of ASP, which binds ATRN. Taken 
together, these observations suggest that ATRN does more than simply stabilize an 
“inactive” conformation of MC1R.  Likewise, ASP seems to do more than simply 
“switch MC1R off,” as shown by the fact that ASP-overexpressing mice are darker 
(rather than lighter as one might expect) in the absence of functional MC1R (Jackson 
et al., 2007; Ollmann et al., 1998).  The explanation of this counterintuitive situation 
seems likely to involve ATRN. 
 The second major accessory locus required for pigment-type switching, 
mahoganoid, encodes a novel RING-domain-containing protein (He et al., 2003; Phan 
et al., 2002). Now referred to as Mahogunin ring finger 1 (Mgrn1), its gene product 
belongs to the large class of E3 ubiquitin ligase proteins, which serve as specificity 
factors in catalyzing the transfer of the multifunctional ubiquitin tag onto target 
proteins, as either single units or polyubiquitin chains (reviewed by Deshaies and 
Joazeiro, 2009). The consequences of ubiquitination are diverse and include targeting 
proteins for proteasomal degradation or trafficking through the endo-lysosomal protein 
degradation pathway. Ubiquitination can also alter the conformation or accessibility of 
sequences in target molecules to mediate changes in active state, subcellular 
  27 
localization, and/or participation in protein complex formation (for recent reviews see 
Acconcia et al., 2009; Ardley and Robinson, 2005; Chen and Sun, 2009; Li and Ye, 
2008; Nandi et al., 2006; Wickliffe et al., 2009).  This diversity of effects makes E3 
ligases important players in development, cell division, cell signaling, and disease 
pathways.   
 Given the many roles of E3 ubiquitin ligases, exactly how Mgrn1 mediates 
pigment-type switching has remained a fertile field for speculation. A long-standing 
hypothesis is that MGRN1 may ubiquitinate MC1R to direct its lysosomal 
degradation. This hypothesis is compatible with observations that ASP treatment 
reduces MC1R protein levels in cultured melanocytes and in rat skin (Rouzaud et al., 
2003; Yang et al., 2004). A strong link between MGRN1 and the endo-lysosomal 
trafficking pathway has emerged from identification of the tumor susceptibility gene 
101 product (TSG101) as a target of MGRN1-mediated ubiquitination (Jiao et al., 
2009a; Kim et al., 2007). TSG101 is a member of the Endosomal Complex Required 
for Trafficking I (ESCRT-I) group of proteins, which act at the surface of incipient 
multivesicular bodies (MVBs) to sort monoubiquitinated transmembrane proteins into 
the lumenal vesicles of the MVB (reviewed by Saksena et al., 2007, and discussed in 
greater detail in Chapter 5). The contents of the lumenal vesicles are subsequently 
transported to the lysosome for degradation. MGRN1-dependent ubiquitination of 
TSG101 appears to be important for its function: upon depletion of MGRN1 in HeLa 
cells, TSG101-mediated lysosomal trafficking of the epidermal growth factor receptor 
was impaired (Kim et al., 2007). In the mouse brain, Mgrn1 deficiency led to the 
accumulation of insoluble, multiubiquitinated TSG101 (Jiao et al., 2009a).  
 Whether MGRN1 acts through TSG101 in the melanocyte to promote 
pigment-type switching remains an open question. Because TSG101 knockout mice 
are inviable as homozygotes (Wagner et al., 2003), the consequences of loss of 
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TSG101 function on pigment production are not known. If pigment-type switching 
does require a MGRN1-dependent function of TSG101, this would suggest that ASP-
mediated inverse agonism of MC1R requires lysosomal trafficking, most likely of the 
MC1R itself.  It is interesting to note that MGRN1 could hypothetically promote 
lysosomal trafficking of MC1R either by monoubiquitinating MC1R, or at the level of 
regulating TSG101/ESCRT activity.  These hypotheses are not mutually incompatible.  
A scenario incorporating both roles for MGRN1 is an intriguing object for 
contemplation as it would represent a novel role for a single ubiquitin ligase as an 
integrator of the “supply” (target availability) and “demand” (ESCRT complex 
activation) sides of the lysosomal protein degradation pathway.   Determining whether 
lysosomal trafficking of the MC1R contributes to pigment type-switching, and if so, 
how MGRN1 acts to enable this trafficking event, stand as important questions. 
 While hypotheses linking the role of MGRN1 in pigment type-switching to 
lysosomal trafficking are appealing, they have been challenged by a line of evidence 
suggesting that MGRN1 may directly disrupt MC1R signaling by uncoupling the 
receptor from its G proteins. Perez-Oliva et al. (2009) recently reported that, in 
HEK293T cells, transient expression of MGRN1 significantly decreased signaling by 
MC1R without altering its cell surface expression or changing its rate of turnover. 
Further experimentation established that MGRN1 binds the MC1R and that this 
decreases the interaction of MC1R with the Gs, thereby uncoupling the receptor 
from its downstream effector, adenylyl cyclase (Figure 1.4). Overexpression of Gs 
counteracted the effect of MGRN1 on MC1R signaling, suggesting that MGRN1 and 
Gs may compete for a binding site on MC1R, although these data are also 
compatible with MGRN1 stabilizing the MC1R in an inactive conformation or 
targeting MC1R to an intracellular location less conducive to Gs interaction  As 
Perez-Oliva et al. (2009) showed that MGRN1 interacted with, but did not appear to 
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ubiquitinate, the MC1R, what role (if any) the E3 ligase ability of MGRN1 plays in 
this proposed regulatory mechanism is a mystery.  Interestingly, Perez-Oliva et al. 
reported that when they immunoprecipitated MC1R from cells transfected with 
MGRN1, immunoblotting the precipitated proteins with an anti-ubiquitin antibody 
revealed the presence of a high molecular weight, ubiquitinated protein of unknown 
identity.  The identity of this mystery molecule, which seems likely to be both an 
interaction partner of the MC1R and a ubiquitination target of MGRN1, is an obvious 
point of interest.  It is even possible that the mystery molecule could turn out to be 
attractin, which is approximately the same molecular weight as the observed band. 
Should attractin turn out to be a ubiquitination target of MGRN1, the close phenotypic 
overlap and similar epistatic mapping of Atrn and Mgrn1 would probably be 
explained: the reason would likely be that Mgrn1 mutants display all the phenotypes 
of Atrn mutants because ATRN has to be ubiquitinated by MGRN1 to function.  
However, even this hypothetical result would leave open many questions regarding the 
significance of the ubiquitination event to the Gs uncoupling mechanism, as well as 
raising questions about whether MGRN1-dependent ubiquitination of ATRN could 
point to a role for ATRN in the endosomal/lysosomal trafficking-related mechanisms 
discussed previously.  
 As the discussion above indicates, when one considers ATRN or MGRN1 
individually, several plausible hypotheses may be proposed to explain their effects on 
signaling through the MC1R.  As a starting point for investigation, the challenge is to 
synthesize these hypotheses with the relevant genetic, biochemical, and bioinformatics 
data, to develop a working hypothesis that places ATRN and MGRN1 together as 
partners in MC1R regulation.  To that end, this study turns now to bioinformatic and 
genetic analyses of ATRN and its homologs. 
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CHAPTER TWO 
BIOINFORMATIC AND GENETIC STUDIES OF ATTRACTIN HOMOLOGS
1
 
 
Chapter Overview 
 Bioinformatic analysis of a gene of interest is a useful first step towards 
understanding its function.  In this chapter, I show that murine ATRN is one member 
of an ancient family of similar receptor-like proteins and infer a likely conserved 
physical and functional interaction between MGRN1 and members of this family.  I 
also show that a second member of the ATRN-like protein family (attractin-like 1 or 
ATRNL1) is capable of rescuing the phenotypes of Atrn mutant mice when 
transgenically overexpressed.  The integration of this genetic information with what is 
known about the interactions of ATRNL1 and the melanocortin 2 receptor (MC2R) 
suggests a physical interaction between the cytoplasmic tails of ATRN and MC1R. 
Taken together, these bioinformatic and genetic studies provide guidance and 
motivation for the experiments described in Chapter Three and Chapter Four. 
  
Introduction to the ATRN protein 
 Bioinformatic tools are valuable resources for the elucidation of gene function.  
While computational methods are far from perfect predictors of protein function, motif 
and domain prediction software programs are useful for identifying potentially 
important functional sequences in a protein of interest.  By coupling these predictions 
with analysis of sequence conservation patterns across species, it is possible to identify 
higher-likelihood putative functional motifs on the basis of their evolutionary 
conservation.   As the number of available animal genome sequences grows, and as 
genome-wide phenotypic information becomes available for model organisms, it is 
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becoming increasingly possible to gain biological insight on the potential functions of 
a gene of interest by thoughtful integration of available genetic and molecular 
evolutionary information.  For Atrn, as for any other gene of interest in the post-
genomic age, to find an answer to the question “how does this gene work?” it is 
helpful to turn first to an examination of its predicted protein structure. 
 As mentioned briefly in the previous chapter, the extracellular/lumenal region 
of mammalian ATRN contains several recognizable domains and motifs (Figure 2.1).  
One of the two large domains is a CUB domain, a compact globular domain named for 
its presence in the Cls/Clr proteins of the complement system, Uegf of sea urchin, and 
Bone morphogenetic protein 1/pro-collagen C proteinase (mTolloid) (Bork and 
Beckmann, 1993; Romero et al., 1997). CUB domains occur in a diverse set of animal 
proteins with no obvious functional relationship, such as spermadhesins, the vitamin 
B12 receptor, and SCUBE3 (Moestrup et al., 1998; Wu et al, 2004; Yang et al., 2007).   
The importance of the CUB domain for the function of ATRN is not known.  The 
second large domain in ATRN is a C-type lectin domain.  This calcium-dependent 
carbohydrate binding domain typically mediates interactions with polysaccharide 
groups of N-glycosylated proteins, which may be significant for ATRN’s function 
given that ATRN, MC1R, and ASP are all glycosylated (Duke-Cohan et al., 1998; 
Willard et al, 1995; Sanchez et al., 2002). ATRN also contains multiple EGF-like 
repeats, Plexin/Semaphorin/Integrin (PSI) repeats, and kelch repeats.  EGF-like 
repeats occur in a several growth factor receptors and laminins, while PSI repeats are 
components of a variety of proteins involved in cell adhesion, axon guidance, and 
extracellular matrix interactions.  The kelch repeats of ATRN are predicted to form a 
“kelch propeller,” a structure that has been observed to mediate protein-protein 
interactions.  The relatively short intracellular/cytoplasmic domain of ATRN contains 
no named domains, but does contain motifs of potential functional importance, such as  
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Figure 2.1. Protein and exon structure of murine ATRN/Atrn.  A. Predicted domains 
and motifs of murine ATRN, shown to scale.  B. Exon structure of Atrn transcript, 
with exons (numbered boxes) represented to scale underneath corresponding ATRN 
protein regions.  Affected regions of known mutant alleles are indicated. 
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the highly conserved MASRPFAXVXV sequence that is found in ATRN homologs as 
evolutionarily divergent as mice, nematodes, and sea anemones, as discussed in a 
subsequent section.  
 
Attractin mutant alleles in mouse and rat 
 There are several well-characterized mouse and rat Atrn alleles (Figure 2.1, 
Table 2.1).  In mouse, two spontaneous alleles are null or near-null mutations:  
Atrn
mg-3J 
and Atrn
mg-6J
. The Atrn
mg-6J
 mutation was described by Bronson et al. (2001) 
as exhibiting dark coat color, tremor, hypomyelination, and spongiform 
neurodegeneration by 2 months of age.  This allele arose from a genomic deletion 
removing most of the codons that contribute to the extracellular/lumenal portion of the 
protein (and resulting in no detectable Atrn transcript), hence this is expected to be a 
null allele.  The Atrn 
mg-3J
 homozygote is completely black on a C3H/HeJ genetic 
background, has a tremor, and rapidly develops spongiform neurodegeneration, with 
vacuoles evident in many brain regions by 1 month of age (Gunn et al., 2001). 
Hypomyelination also occurs in this mutant (Kuramoto et al., 2001).  Expression of 
the Atrn
mg-3J 
transcript is greatly reduced due to a 5 bp deletion at codon 937, which 
produces an early stop two codons downstream that presumably triggers nonsense-
mediated decay of the mutant transcript (Nagle et al., 1999; Gunn et al., 1999).  By 
western blot, Atrn
mg-3J
 homozygotes produce no detectable ATRN protein (Gunn et 
al., 2001). The original mahogany (Atrn
mg
) mutation shows somewhat less severe 
phenotypes than these two null alleles (Gunn et al., 2001).  Atrn
mg
 homozygotes lack 
an obvious tremor, and develop spongiform change at a slower rate than do Atrn
mg3J 
homozygotes, although vacuoles are readily observable by four months of age.  
Pheomelanogenesis is much reduced but not completely impaired, as C3H/HeJ Atrn
mg
 
mice produce some sub-apically striped hairs along their flanks and in the ventral fur.  
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The causative molecular lesion is a ~5kb intracisternal A particle (IAP) insertion in the 
26
th
 intron of the Atrn locus.  By Western blot, ATRN protein from Atrn
mg
 
homozygotes is abundant but appears smaller than wild-type ATRN by approximately 
20 kD, suggesting that the IAP insertion prevents normal splicing into the 27
th
 exon, 
with concomitant loss of most of the 17kD cytoplasmic domain including the very 
highly conserved MASRPFAS sequence. The trace ATRN functionality evident in 
these mutants may be due to very low levels of normally spliced Atrn transcript, or 
may represent slight residual function of truncated ATRN.  Either scenario implicates 
the cytoplasmic tail as an important mediator of ATRN’s function in pigment-type 
switching and CNS function. 
 The least severe phenotypes of any known Atrn mutation are seen in the 
mahogany “Leicester” allele, Atrn
mg-L 
(Gunn et al., 2001).  This hypomorph has a 
moderate pigment-type switching defect on the C3H/HeJ genetic background, 
resulting in a narrow dorsal region of completely black fur with increasing amounts of 
yellow pigment seen in lateral and ventral areas.  Atrn
mg-L 
mice develop spongiform 
vacuoles at a greatly reduced rate compared to Atrn
mg
 or Atrn
mg-3J
 animals, with a 
histological appearance indistinguishable from wild-type animals at 4 months of age 
and only mild vacuolation occurring by 8 months (by which time both Atrn
mg 
and 
Atrn
mg-3J 
homozygotes have developed severe widespread vacuolation). Like Atrn
mg
, 
this mutation is the result of an IAP insertion, in this case into the 27
th
 intron of Atrn.  
This appears to disrupt normal splicing to some extent, as abnormally large transcripts 
that evidently terminate within the IAP sequence are evident on Northern blots of 
brain RNA from Atrn
mg-L
 mice.  However, normally sized Atrn transcript is still 
produced in reduced quantity, and slightly reduced levels of a wild-type-sized ATRN 
protein are observable by Western blot.  The mild phenotypical expression of this 
mutant is probably explained by the presence of wild-type ATRN at a reduced level, 
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although it is tempting to speculate that the severity of the mutation’s effect on the 
functionality of any mutant ATRN produced may also be lessened by the location of 
the IAP insertion relative to conserved regions of the cytoplasmic tail.  The IAP 
insertion in the Atrn
mg-L 
allele is several codons downstream of the highly conserved 
MASRPFAS sequence, suggesting that any protein translated from the aberrantly 
spliced transcripts would contain MASRPFAS and might retain related function. 
 In addition to these spontaneous mutations in Atrn, a gene-trap allele has been 
generated that joins the first five exons of Atrn with a -geo cassette (Leighton et al., 
2001).  As expected for an Atrn null allele, mice homozygous for the gene-trap allele 
Atrn
Gt(PST112)Byg
 are black and develop severe spongiform change and hypomyelination 
(Walker et al., 2007).  
 In  rat, two Atrn mutations have been identified.  The zitter (zi) mutation was 
noticed first for the tremor, hypomyelination, and spongiform degeneration it caused 
in homozygotes, as it arose on the albino Sprague-Dawley background which masked 
its pigment-type switching defects (Rehm et al., 1982; Yamada et al., 1989).  
However, after Atrn mutant mice were shown to develop spongiform encephalopathy, 
the similarity of spongiform change in the rat mutants was noted and zitter was found 
to be a splice site donor mutation in exon 12 of rat Atrn (Kuramoto et al., 2001).  On a 
non-albino genetic background, Atrn
zi 
homozygotes have a dark agouti phenotype, 
consistent with the presence of reduced amounts of normal-sized Atrn transcript by 
Northern blot.  The second rat Atrn mutation, myelin vacuolation (mv), was more 
recently identified on an albino genetic background, like zitter as a spontaneously 
arising tremorous mutant, and was discovered to be the result a 3.6 kb deletion which 
includes the first exon of Atrn  (Kuwamura et al., 2002).  This mutation causes 
spongiform encephalopathy in both grey and white matter and pronounced 
hypomyelination and dysmyelination, similar to zitter mutants.  Interestingly, although 
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Atrn
mv 
is almost certainly a null allele, when placed on a non-albino background it 
causes only a partial loss of pigment-type switching similar to that seen in zitter rats.  
Atrn
mv 
homozygotes are darker than Atrn
+/+ 
animals but not as dark as nonagouti rats, 
indicating that ASP can function with reduced efficiency in the rat pigment-type 
switching system in the absence of ATRN. 
 
The attractin gene family 
 Attractin is one of a family of three mouse proteins with a similar domain 
organization (Figure 2.2).  A second member of this family, attractin-like 1 
(ATRNL1), is clearly a paralog of ATRN, with an almost identical arrangement of 
named domains and motifs and 58% amino acid identity to ATRN.  The third family 
member, Multiple EGF-like domains 8 (MEGF8), is a larger protein that lacks the C-
type lectin domain and has a tandem duplication of much of its extracellular/lumenal 
region.  In addition to their similar domain organization, ATRN, ATRNL1, and 
MEGF8 share a conserved cytoplasmic motif (MASRPFAXVXV) of unknown 
function. 
 Our knowledge of the functions of ATRNL1 and MEGF8 is limited.  Haqq et 
al. (2003) demonstrated that ATRNL1 and MC4R interact through their respective 
cytoplasmic tails, suggesting that, like ATRN, ATRNL1 may have a role in 
melanocortin receptor signaling.  The effect of loss of ATRNL1 seems to be subtle, 
however, as Atrnl1 knockout mice show no overt phenotypic abnormalities (Walker et 
al., 2007).  Interestingly, Atrn/Atrnl1 double mutants develop a progressive 
cardiomyopathy (Walker et al., 2007), indicating that the presence of functional 
ATRN may compensate for loss of ATRNL1 and mask Atrnl1 mutant phenotypes. 
Unlike Atrnl1 mutants, Megf8 mutants exhibit obvious phenotypes.  These mice have 
aberrant establishment of the left-right body axis, resulting in heterotaxy and cardiac  
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Figure 2.2. The murine ATRN family of proteins.  EGF: Epidermal Growth Factor.  
PSI: Plexin/Semaphorin/Integrin motif. 
 
 defects (Aune et al., 2008; Zhang et al., 2009).  The histopathological and molecular 
characteristics of these left-right patterning defects are remarkably similar to those 
reported for Mgrn1 mutant mice (Cota et al., 2006), suggesting that MEGF8, like 
ATRN, may depend on MGRN1 for proper function. 
 To gain insight into the structure/function relationships that underlie the 
phenotypes of Atrn mutants, I reconstructed the evolutionary history of the Atrn gene 
family by identifying and comparing members of the family (and their associated 
mutant phenotypes) across metazoan phyla.  This analysis suggests that the members 
of the Atrn family of genes diverged from an ancient MEGF8-like gene in a 
prometazoan common ancestor and have subsequently been co-opted into different 
functional roles.  To test the functional importance of motifs differing between ATRN 
and its most similar homolog, ATRNL1, I introduced transgenically overexpressed 
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Atrnl1 into an Atrn null mutant background and examined the phenotypes of the 
resulting mice. 
 
Materials and Methods 
Bioinformatics 
 Refseq protein sequences for vertebrate ATRN, ATRNL1, and MEGF8 
proteins were downloaded from Ensembl release 57 (See Table 2.2 for Genbank and 
Ensembl reference ID numbers of sequences used in this study). A within-vertebrates 
sequence conservation analysis was performed using ClustalW (Larkin et al., 2007), 
and named domains and motifs were identified using the SMART protein architecture 
research tool (Schultz et al., 1998, Letunic, Doerks, and Bork, 2008).  Invertebrate 
ATRN family genes were identified by BLAST against the amino acid sequence of 
mouse ATRN, and analyzed for conservation of domain organization using SMART.  
The cytoplasmic tails of ATRN family members were analyzed for putative linear 
motifs using the Eukaryotic Linear Motif online tool (Puntervoll et al., 2003; Gould et 
al., 2010), and analyzed with the COILS utility for identification of high-likelihood 
coiled-coil forming regions (Lupas, Van Dyke, and Stock, 1991). 
 
Atrnl1 transgenic mice 
 The Atrnl1 transgenic mice used for this study were generated by Ke-Yu Deng 
of the Cornell Transgenic Mouse Core Facility, using a DNA construct made by Dr. 
Chelin Jamie Hu, as described by Walker et al. (2007).  Transgenic founders were 
identified by PCR using primers in exons 4 and 5 (GCTGGTCCAGGGATAAAATG 
and GCTGGCACAGTCAGCATATC) to amplify a 1,093-bp band from the 
endogenous locus and a 226-bp band from the transgene. Three founders were bred to 
C3H/HeJ-Atrn
mg-3J
 and 129S1/SvImJ-Atrn
Gt(PST112)Byg
 (Atrn
PST112
)
 
mice and transgenic 
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Table 2.2.  Protein sequences used in this study. 
 
Species Homolog Accession number 
Anopheles gambiae (mosquito) ATRN/ATRNL1 ENSANGP00000003873 
Aedes aegypti (mosquito) ATRN/ATRNL1 AAEL007331-PA 
Branchiostoma floridae (lancelet) ATRN/ATRNL1 XP_002601127.1 
Branchiostoma floridae (lancelet) MEGF8 XP_002613359.1 
Canis familiaris (dog) ATRN ENSCAFP00000009513 
Canis familiaris (dog) ATRNL1 ENSCAFP00000017303 
Caenorhabditis elegans (nematode) ATRN/ATRNL1 NP_001024625 
Ciona intestinalis (tunicate) ATRN/ATRNL1 ENSCINP00000013249 
Ciona savignyi (tunicate) ATRN/ATRNL1 ENSCSAVP00000008291 
Drosophila melanogaster (fruit fly) ATRN/ATRNL1 NP_651571.3 
Drosophila melanogaster (fruit fly) MEGF8 NP_609180.2 
Gallus gallus (chicken) ATRN ENSGALP00000025782 
Gallus gallus (chicken) ATRNL1 ENSGALP00000014887 
Gasterosteus aculeatus (stickleback) ATRN ENSGACP00000005821 
Gasterosteus aculeatus (stickleback) ATRNL1 ENSGACP00000015076 
ENSGACP00000008795 
Homo sapiens (human) ATRN ENSP00000262919 
Homo sapiens (human) ATRNL1 ENSP00000347152 
Macaca mulatto (rhesus macaque) ATRN ENSMMUP00000029333 
Macaca mulatto (rhesus macaque) ATRNL1 ENSMMUP00000002545 
Monodelphis domestica (opossum) ATRN ENSMODP00000005644 
Monodelphis domestica (opossum) ATRNL1 ENSMODP00000012047 
Monosiga brevicollis (choanoflagellate protist) MEGF8 XP_001748540.1 
Mus musculus (mouse) ATRN NP_033860.2 
Mus musculus (mouse) ATRNL1 ENSMUSP00000076514 
Mus musculus (mouse) MEGF8 NP_001153872.1 
Oryzias latipes (medaka) ATRN ENSORLP00000022537 
Oryzias latipes (medaka) ATRNL1 ENSORLP00000004353 
ENSORLP00000006305  
Pan troglodytes (chimpanzee) ATRN ENSPTRP00000022608 
Pan troglodytes (chimpanzee) ATRNL1 ENSPTRP00000039368 
Rattus norvegicus (rat) ATRN ENSRNOP00000028847 
Rattus norvegicus (rat) ATRNL1 ENSRNOP00000023414 
Takifugu rubripes (pufferfish) ATRN SINFRUP00000144197  
Takifugu rubripes (pufferfish) ATRNL1 SINFRUP00000156274 
SINFRUP00000128200 
Tetraodon nigroviridis (pufferfish) ATRN GSTENT00019974001 
Tetraodon nigroviridis (pufferfish) ATRNL1 GSTENP00018764001 
GSTENP00034986001 
Trichoplax adhaerens (placozoan) MEGF8 XP_002112184.1 
Xenopus tropicalis (frog) ATRN ENSXETP00000009491 
Xenopus tropicalis (frog) ATRNL1 ENSXETP00000051348 
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F1 pups mated back to the appropriate Atrn mutant strain. One founder did not 
transmit the transgene, a second founder probably did not express the transgene (no 
rescued phenotypes were evident in pups from this founder) and was not characterized 
further, and the third, B4, was used for all experiments as it bred well, transmitted the 
transgene, and rescued Atrn mutant phenotypes.  
 
Histology  
 Brains were collected into cold phosphate-buffered saline and fixed in 
phosphate-buffered 4% paraformaldehyde or 10% formalin. Dehydrated tissues were 
embedded in paraffin and 5-μm sections stained with hematoxylin and eosin (H&E). 
Myelination was assessed by Luxol fast blue staining on 10-μm spinal cord sections 
following a standard protocol (Sheehan and Hrapchak, 1980). 
 
Northern blot verification of Atrnl1 overexpression 
 RNA was prepared from brains of transgenic and non-transgenic 
Atrn
Gt(PST112)Byg/+ 
mice by Trizol extraction and run on a denaturing 
MOPS/formaldehyde agarose gel.  RNA was transferred to charged nylon membrane 
(Immobilion) and hybridized with a 
32
P-dCTP-labeled probe complementary to a 
~500bp sequence of Atrnl1 (IMAGE clone 1616940 and a probe amplified using 
primers AGTGAGGGGTAACGAGACCGT and GTGACGTTGCCATCACTGGT). 
 
Results 
Evolution of the Atrn gene family 
 The Atrn family of genes is widely conserved in the eumetazoa, indicating an 
ancient origin.  Comparison of their domain organization reveals that the ancestral 
structural arrangement of all ATRN family members is a CUB domain flanked by 
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EGF repeats, followed by kelch repeats, PSI motifs, a second set of EGF repeats, and a 
transmembrane helix (Figure 2.3).   “Short-form” family members such as mouse 
ATRN and ATRNL1 consist of a single instance of this basic pattern.   In the case of 
“long-form” members of the family such as mouse MEGF8, the basic sequence is 
repeated (except for the transmembrane helix) as a tandem array.  Remarkably, 
genomes from every eumetazoan phylum examined -- from chordates, to cnidarians, to 
the most primitive extant multicellular animal, Trichoplax -- contain a protein-coding 
gene with essentially the same domain organization as Megf8.  This universal 
distribution indicates that a “long-form” Megf8-like gene was present in the last 
eumetazoan common ancestor.  The basic architecture of this founding member of the 
Atrn family appears to have been invented by a common ancestor of the eumetazoa 
and their closest protozoan sister group, the choanoflagellates, as a more distant 
homolog of Megf8 is recognizable in the genome of the choanoflagellate Monosiga, 
and not in any other protistan phylum (Figure 2.4). 
 The tandem structure of the ancestral eumetazoan Megf8 gene may have made it 
susceptible to homology-mediated deletion of one of the tandem repeats.  Such an 
event seems likely to be responsible for the appearance of the “short-form” subclass of 
ATRN family members.  This innovation apparently occurred very early in metazoan 
evolution, prior to the divergence of the Bilateria from the radially symmetrical 
animals such as sea anemones.  The resulting two-member gene family, comprising a 
single “long-form” Megf8-like gene and a single “short-form” Atrn/Atrnl1-like gene, is 
the ancestral arrangement for all modern eumetazoan phyla except, possibly, 
Trichoplax (Figure 2.4).  It is retained in diverse organisms including the starlet 
anemone Nematostella, arthropods such as the fruit fly Drosophila, and in primitive 
chordates including the lancelet Branchiostoma and the tunicate Ciona.  The 
nematodes Caenorhabditis briggsae and C. elegans lack the Megf8-like member of the 
  43 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.  ATRN family proteins across eukaryotic phyla.  Representations are to 
scale, except for the large MEGF8-like protein of Monosiga, which is shown at 50% 
of scale. 
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Figure 2.4.  Innovations in the ATRN family on the tree of life.  Eumetazoan branches 
for which genomic data are not available are omitted. 
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family, which has apparently been secondarily lost in this lineage. 
 While hemichordates (acorn worms) and primitive chordates retain the ancestral 
two-member complement of Atrn family members, several notable innovations 
appeared specifically in the vertebrate clade.  A new feature, the C-type lectin domain, 
was added to the ancestral “short-form” family member, while the “long-form” protein 
lost one of its two CUB domains. At about the same time, a segmental duplication 
event occurred at the genomic locus of the shorter family member, splitting the 
ancestral gene into a pair of paralogs, the descendants of which are the modern 
vertebrate Atrn and Atrnl1.   
 
Sequence analysis of Atrn and Atrnl1 
 As expected for genes that arose from an ancient duplication event, Atrn and 
Atrnl1 are each embedded in a small block of paralogous sequence, with each gene 
occurring immediately adjacent to a glial cell line-derived neurotrophic factor family 
receptor alpha homolog (Gfra4 and Gfra1, respectively, in non-fish vertebrates).   The 
named domains and motifs are highly conserved across vertebrates, and they are very 
similar between the two paralogs within each species (Figure 2.5).   
 Because the cytoplasmic tail region of the proteins contains no named domains 
but is likely to mediate important interactions with cytoplasmic proteins, I examined 
this region at the sequence level.  Figure 2.6 shows a multiple alignment of the 
primary sequence of mouse ATRN and ATRNL1, with fruit fly and roundworm 
ATRN cytoplasmic tail. This analysis reveals that the cytoplasmic tails of ATRN and 
ATRNL1 can be divided into 4 regions.  The most membrane-proximal 40 amino 
acids of mouse ATRN and ATRNL1 differ at only five residues and include the highly 
conserved MASRPFAXVXV sequence also shared by fly and worm ATRN.  There 
follows a short stretch of low sequence conservation from residues 41-52, and then a 
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Figure 2.5.  Conservation of ATRN and ATRNL1 across vertebrates. Top panel: 
Schematic figure of murine ATRN and conservation trace showing amino acid 
conservation across a multiple alignment of vertebrate species.  Middle panel: 
schematic figure of murine ATRNL1 and conservation trace showing amino acid 
conservation across a multiple alignment of vertebrate species.  Bottom panel: 
Conservation trace showing sequence similarity between murine ATRN and 
ATRNL1.   
 
  48 
second region of high conservation at residues 53-104.  This region is made up of two 
conserved groups of hydrophobic residues, each of which is flanked by evolutionarily 
conserved prolines.  The two hydrophobic stretches each contain a conserved serine or 
threonine, and are connected by a glycine-rich linker sequence. As indicated in Figure 
2.6, the sequence downstream of MASRPFAXVXV in ATRNL1 contains two regions 
which are each sufficient to confer the ability to interact with the MC4R cytoplasmic 
tail (Haqq et al., 2003); the second of these MC4R interaction domains of ATRNL1 
corresponds to the first set of conserved proline-flanked hydrophobic residues (53-76) 
of ATRN.  Following this conserved region, the C-terminal ends of mouse ATRN and 
ATRNL1 have little sequence similarity and are not evolutionarily conserved.  COILS 
analysis of the cytoplasmic tail regions shows that the conserved membrane-proximal  
regions of ATRN and ATRNL1 are each predicted to participate in the formation of a 
 
Figure 2.6. Multiple alignment of ATRN family cytoplasmic tail sequences, showing 
proposed functional motifs. 
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coiled-coil motif.    The ELM motif recognition tool identifies a pair of  
endosomal/lysosomal targeting motifs (EPPDLI and RRREQLL) in ATRN, the latter 
of which is also present in ATRNL1.  As the high overall similarity of ATRN and 
ATRNL1 suggests that the two proteins might exhibit functional redundancy (perhaps 
enabling a dissection of the structure/function relationships of ATRN by enabling the 
assignment of rescued phenotypes to regions of the protein displaying high inter-
paralog sequence similarity).  I therefore tested whether overexpression of Atrnl1 
construct could rescue Atrn mutant phenotypes. 
 
Rescue of Atrn mutant phenotypes by Atrnl1 overexpression 
 I mated Tg(Atrnl1)B4Tmg mice (which express mouse Atrnl1 from the human -
actin promoter) to two different Atrn mutants on two different genetic backgrounds. 
The Atrn coat color phenotype was completely rescued in Atrn
PST112/PST112
; 
Tg(Atrnl1)B4Tmg animals, while Atrn
mg-3J/mg-3J
; Tg(Atrnl1)B4Tmg mice only 
displayed a partial rescue, having ‘‘dark agouti’’ hairs (Figure 2.7 and Table 2.2). The 
difference in the extent of coat color rescue by the Atrnl1 transgene is most likely 
caused by genetic differences between the C3H and the 129 strain backgrounds (upon 
which the Atrn
mg-3J
  and Atrn
GT(PST112)Byg 
alleles are maintained, respectively) as 
previous phenotypic and molecular studies indicate that both alleles are null (Gunn et 
al., 2001).  
 To ascertain whether Atrnl1 over-expression could also compensate for loss of 
Atrn in the CNS, brains of 3-month-old transgenic and nontransgenic Atrn mutants 
were examined histologically.  Nontransgenic mice homozygous for either the 
Atrn
GT(PST112)Byg 
or Atrn
mg-3J
 allele showed pronounced spongiform vacuolation, while 
age-matched Atrn mutants carrying the Atrnl1transgene showed robust rescue of this 
phenotype with only sparse, scattered vacuoles evident in their brains (Figure 2.7 and 
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Figure 2.7. Ubiquitous over-expression of Atrnl1 compensates for loss of ATRN. 
(A,B) Overexpression of Atrnl1 rescues the pigmentation defect of Atrn mutant mice. 
Although the pigmentation phenotype of 129S1/SvImJ; Atrn
GT(PST112)Byg
 mutants was 
rescued completely (A), C3H/HeJ; Atrn
mg-3J
 mutants expressing the transgene were 
darker than wild-type agouti mice but not as dark as Atrn
mg-3J/mg-3J
 mice (B), consistent 
with a strain background-dependent effect on pigment type switching. (C-R) 
Overexpression of Atrnl1 in the brains of Atrn null mutant mice protects against 
spongiform neurodegeneration. High-magnification views of H&E-stained sections 
from 3- and 6-month-old Atrn
mg-3J/mg-3J
 mice (left panel) and Atrn
mg-3J/mg-3J
; 
Tg(Atrnl1)B4Tmg mice (right panel) showing cerebral cortex (C,D,K,L), hippocampus 
(E,F), cerebellum (G,H,O,P), pons (I,J,Q,R) and thalamus (K,L). Although 
nontransgenic Atrn
mg-3J/mg-3J
 mutants showed extensive, progressive spongiform 
changes, Atrn
mg-3J/mg-3J
; Tg(Atrnl1)B4Tmg mice showed no significant vacuolation at 3 
months of age and only mild, scattered vacuolation at 6 months of age. (S–U) Partial 
rescue of hypomyelination of Atrn
mg-3J
 mutants. Representative Luxol fast blue stained 
sections from 1-month-old mice showing normal myelination in spinal cord from 
Atrnl1 mice (S), hypomyelination in Atrn
PST112/PST112
 mutants (T), and an intermediate 
level of myelination in Atrn
PST112/PST112
; Tg(Atrnl1)B4Tmg mice (U). (V) Northern blot 
analysis confirmed significant overexpression of Atrnl1 in the brains of mice carrying 
Tg(Atrnl1)B4Tmg relative to nontransgenic mice. Upper panel: Atrnl1 (probe against 
exons 4–8). Transgenic (4.4 kb) and endogenous (6.1 kb) transcripts are indicated. The 
endogenous transcript was more apparent with a longer exposure. A small, non-
specific band was observed in all samples. Lower panel: -actin (Actb) probe, used to 
verify equal RNA loading. 
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Table 2.2. Rescue of Atrn mutant phenotypes by Atrnl1 transgene. 
Genotype Coat color CNS pathology at 3 
months 
CNS pathology at 6 
months 
Atrn
pst112/pst112 
5/5 Black 3/3 Widespread 
vacuolation 
2/2 Extensive 
vacuolation 
Atrn
pst112/pst112
; 
Tg(Atrnl1)B4Tmg 
7/8 Agouti, 
1/8 Dark agouti 
5/5 no significant 
vacuolation 
3/3 Sparse to mild 
vacuolation 
Atrn
mg-3J/mg-3J 
6/6 Black 2/2 Widespread 
vacuolation 
2/2 Extensive 
vacuolation 
Atrn
mg-3J/mg-3J
; 
Tg(Atrnl1)B4Tmg 
8/8 Dark agouti 5/5 No significant 
vacuolation 
3/3 Sparse to mild 
vacuolation 
 
Table 2.2). Rescue of the spongiform neurodegeneration phenotype was similarly 
robust for both Atrn mutant alleles, indicating that strain background effects do not 
detectably influence the onset or progression of vacuolation in this study. A similar 
phenomenon has been observed in the case of C3H/HeJ and C57BL/6J mice; Atrn
 mg-3J
 
homozygotes are darker on the former compared with the latter background, but the 
extent of vacuolation is identical on both backgrounds (Teresa Gunn, personal 
communication). To determine whether overexpression of Atrnl1 prevented 
spongiform neuropathology in Atrn mutants altogether or only delayed its appearance, 
a second cohort of mice was examined at 6 months of age. Profound spongiform 
vacuolation was observed in most regions of the brains of nontransgenic Atrn mutants, 
while Atrn mutants carrying the Atrnl1 transgene showed some areas of mild-to-
moderate vacuolation (Figure 2.7 and Table  2.2). Thus, the onset of spongiform 
neuropathology in Atrn mutants was significantly delayed but not completely 
prevented by overexpression of Atrnl1. I also examined whether overexpression of 
Atrnl1 ameliorated the hypomyelination observed in Atrn mutants by performing 
Luxol fast blue staining on sections of spinal cord from 1-month-old mice. Staining 
levels in Atrn
GT(PST112)Byg
 mutants carrying the Atrnl1 transgene were intermediate to 
those of nontransgenic Atrn
GT(PST112)Byg
 mutants and control mice (Figure 2.7).  
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 As transgenic overexpression of Atrnl1 compensated for loss of Atrn in the skin 
and the brain despite the fact that both genes are normally expressed in these tissues 
(Walker et al., 2007), I hypothesized that abnormally high levels of Atrnl1 expression 
may be required to compensate for loss of Atrn. I performed Northern hybridization of 
brain RNA from transgenic and nontransgenic Atrn mutants. Atrnl1 expression was 
significantly elevated over endogenous levels in Tg(Atrnl1)B4Tmg mice (Figure 2.7V).  
 
Discussion 
Function of attractin family genes in evolutionary history 
 As I have described, homologous genes with the distinctive domain organization 
of Atrn and its close relative, Megf8, appear to be nearly universal features of 
eumetazoan genomes.  From its conservation in such a diverse assemblage of phyla, 
we can infer that Atrn has been a part of the basic eumetazoan “genomic toolbox” 
since very close to the origin of animal multicellularity, over 600 million years ago.  
Given these ancient origins, it is ironic that Atrn is currently best understood for its 
role as a modulator of signaling by melanocortin receptors, which are a comparatively 
recent innovation restricted to the vertebrate lineage.  Obviously, Atrn’s co-option into 
the melanocortin signaling pathway is a relative evolutionary novelty.  It is interesting 
to speculate about what the “original” function of Atrn was, given what we know 
about the phenotypes of Atrn family mutants in modern organisms.  In mammals, Atrn 
clearly plays roles in maintaining nervous system function, modulating melanocortin 
signaling, energy homeostasis, and immune function.  In invertebrates the 
consequences of Atrn mutations are not well-studied, but some phenotypic information 
is available for fruit flies and in C. elegans.  The Atrn homolog in the Drosophila 
genome is known as distracted and its loss causes neurological abnormalities in adult 
flies: in a fascinating similarity to the neurological phenotype of Atrn null mice, 
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distracted fruit flies develop vacuolated neurons in the optic and antennal lobes of 
their CNS (Thomas, 2005). The occurrence of spongiform neurodegeneration in 
Atrn/distracted mutant mice and flies suggests that Atrn plays a deeply conserved role 
necessary for maintaining neuronal integrity. While Atrn (tag-53) mutant C. elegans 
have not been studied in detail, they have been reported to display an uncoordinated 
phenotype, which may indicate a neurological defect.  The other overt phenotypes of 
Atrn mutant C. elegans are “dumpy” morphology, high rate of egg infertility, and the 
abnormal vulval morphology (Wormbase website, www.wormbase.org.  Release 
WS213, April 24 2010). 
 
 Phenotypic overlap between Mgrn1 and Atrn-family mutations indicates an ancient 
functional relationship between Mgrn1 and Atrn family members 
 In the mouse, Atrn and Mgrn1 null mutants are remarkable for their significant 
degree of phenotypic overlap.  Both mutants develop spongiform neurodegeneration, 
and both have a defect in pigment-type switching, which indicates that their gene 
products may cooperate as part of a molecular mechanism that is deployed in both the 
pigment cell and the neuron.   Because Mgrn1 apparently participates both in Atrn’s 
“modern” role in melanocortin receptor signaling and its more ancient role in the 
neuron, it is interesting to ask whether the association between the two genes is unique 
to mammals, or an ancient legacy of the evolutionary past.  Unlike ATRN, MGRN1 
lacks an easily recognizable signature sequence of protein domains.  Also, the major 
bioinformatically identifiable feature of Mgrn1, its RING domain, is shared by 
hundreds of other E3 ligases, making the confident identification of Mgrn1 orthologs 
across distantly related phyla somewhat more difficult than is the case with Atrn.  
However, Mgrn1 orthologs can be identified in both C. elegans and Drosophila 
melanogaster by reciprocal best-hit protein-protein BLAST (data not shown).  
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Remarkably, worms with mutations in the Mgrn1 ortholog, C11H1.3, demonstrate 
complete phenotypic overlap with Atrn (tag-53) mutant worms.  Both mutants display 
uncoordinated movement, “dumpy” morphology, low fertility, and the “P-vulva” 
phenotype (Wormbase website, www.wormbase.org.  Release WS213, April 24 2010).  
Thus Atrn and Mgrn1 are linked by a notable correspondence of pleiotropic overlap 
both in mice and in worms, suggesting that a functional relationship between the two 
genes may have been established very early in eumetazoan evolution.  If this is the 
case, one might predict that the neurological defects seen in distracted fruit flies will 
be present in Drosophila Mgrn1 mutants as well.  To date, the only phenotypic 
information available concerning the physiological function of the Drosophila Mgrn1 
ortholog, CG9941, came from an RNAi study that revealed a role in heart 
development (Kim et al., 2004).   
 It also will be of interest to determine whether Mgrn1 orthologs have a 
functional relationship with orthologs of the other major member of the Atrn gene 
family, Megf8.  To date, nothing is known about the phenotypic consequences of loss 
of fly Megf8, and the rich genomic resources in the C. elegans model system not 
informative because worms in this genus appear to lack a Megf8 ortholog.  In the 
mouse, however, there are striking similarities between the left-right (L-R) patterning 
and cardiac defects reported in Mgrn1
 
null mutants and a syndrome of abnormal L-R 
patterning and heart defects that was recently reported in mice homozygous for an 
ENU-induced mutation in Megf8 (Cota et al., 2006, Aune et al., 2008; Zhang et al., 
2009).  Both mutations appear to disrupt left-right patterning downstream of the initial 
symmetry break at the embryonic node.  In wild-type embryos, asymmetric expression 
of Nodal at the embryonic node is the initial symmetry-breaking developmental event, 
which leads to expression of Nodal in the left lateral plate mesoderm (LPM) and a left-
side specific activation of the “leftness” identity-establishing transcription factors 
Lefty1, Lefty2, and Pitx2 (Shiratori and Hamada, 2006).  In both Mgrn1 and Megf8 
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mutant embryos, the initial symmetry break by Nodal at the node occurs normally, but 
apparently fails to propagate correctly to the LPM, leading to aberrant expression of 
Lefty1, Lefty2, and Pitx2.  In Megf8 mutants, normal expression of Nodal in the left 
LPM is also disrupted. The consequences of these defects in early embryonic 
patterning are similar in both mutants, which exhibit elevated rates of embryonic death 
due to heart defects, and cardiac malformations characteristic of heterotaxy with 
elevated frequencies of situs inversus.  This situation is highly reminiscent of the 
phenotypic overlap seen between Mgrn1 and Atrn mutants in mouse and nematodes, 
which is likely to stem from a conserved functional relationship between MGRN1 and 
ATRN proteins.  Given the high similarity between ATRN and MEGF8, and the 
similarity of the L-R patterning phenotypes of Megf8 and Mgrn1 mutations, it seems 
reasonable to speculate that MGRN1 and MEGF8 have an analogous functional 
relationship to that between MGRN1 and ATRN.  If this speculation is correct, it will 
explain why the several phenotypes of Mgrn1 mutant mice map so precisely onto 
either Atrn or Megf8 mutant phenotypes (Figure 2.8). 
 In C. elegans, the phenotypes of Mgrn1 mutants completely overlap with those 
of worms bearing mutations in the single nematode Atrn family member.  In mice, 
Atrn and Megf8 mutants phenocopy different subsets of Mgrn1 mutant phenotypes.  
The implication is that MGRN1 and ATRN family members share a conserved 
functional relationship.  If this functional relationship is mediated by a direct physical 
interaction between MGRN and ATRN-family proteins, it is likely that the interaction 
occurs between a conserved region of MGRN1 and the cytoplasmic tail of 
ATRN/MEGF8.  By examining the alignment of mouse ATRN, mouse MEGF8, and 
worm ATRN, it may be possible to predict which regions of the cytoplasmic tail are 
important for this hypothesized interaction, based on their conservation of sequence 
across these three proteins.  As shown in Figure 2.9, the MASRPFAXVXV motif is an 
excellent candidate motif for this hypothesized interaction with Mgrn1.  
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Figure 2.8. Phenotypic overlap of mouse Mgrn1 and Atrn family members.  Megf8 and 
Mgrn1 mutants share similar L-R patterning defects and developmental cardiac 
abnormalities, suggesting cooperation between their gene products in an unknown 
developmental mechanism.  Similarly, the correspondence of mutant phenotypes in 
Mgrn1 and Atrn suggests a functional relationship between the proteins encoded by 
these two genes.  While no phenotypes of Atrnl1 single mutants have been reported, 
ATRNL1 appears to be able to act similarly to ATRN in these pathways if 
overexpressed, and Atrn/Atrnl1 double mutants have a cardiomyopathy that likely 
reveals a redundant function of these two proteins which is not dependent on Mgrn1. 
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Figure 2.9.  Conserved cytoplasmic tail sequence across murine and nematode Atrn-
family genes identifies the highly conserved MASRPFAXVXV sequence as a 
candidate MGRN1-interaction motif. 
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The role of Atrnl1 
 Paralogous genes often have partly or wholly redundant functions, a fact that is 
frequently a source of frustration to geneticists: redundant components of a genetic 
pathway are difficult to identify by forward genetic approaches, and pathways made 
robust by redundant components are difficult to disable by reverse genetic approaches.  
Atrnl1 and Atrn present an unusual case study of paralogous proteins.  From the 
standpoint of gain-of-function mutations, the two paralogs are redundant, as 
overexpression of ATRNL1 largely rescues the pigmentation and neurodegenerative 
defects of Atrn mutants.  However, from the standpoint of loss-of-function mutations, 
the paralogs are non-redundant, as the presence of endogenous levels of ATRNL1 
does not mask or ameliorate either the coat color phenotype or the neurodegenerative 
syndrome of Atrn mutants.  As endogenous ATRNL1 is widely expressed with similar 
tissue-level patterns of expression to ATRN (Walker et al., 2007), and since ATRNL1 
protein is clearly capable of compensating for ATRN when overexpressed, one might 
expect that endogenous ATRNL1 would mask the loss of endogenous ATRN.  
Obviously, this is not the case.  The simplest explanation of these observations is that 
endogenous levels of ATRNL1 may simply be too low (at least in the relevant cell 
types) to have a detectable effect on pigment type switching or neurodegeneration.  
Interestingly, Atrn
-/-
; Atrnl1
-/-
 double mutants were reported to develop a progressive 
cardiomyopathy that is not exhibited by either single mutant (Walker et al., 2007), 
indicating that ATRN and ATRNL1 may both be required in cardiac tissue to promote 
normal function.  No progressive cardiomyopathy has been reported in Mgrn1 mutant 
mice, suggesting that this function of ATRN/ATRNL1 is Mgrn1-independent (Figure 
2.8).  This conclusion has one caveat, however: it is possible that some functions of 
Mgrn1 may be masked in Mgrn1 mutants by the potentially redundant function of the 
vertebrate-specific Mgrn1 paralog, ring finger protein 157 (Rnf157). 
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 ATRNL1 was identified by yeast two-hybrid screen as an interactor of the 
cytoplasmic tail of MC4R, leading to the suggestion that ATRNL1 might mediate 
anorexigenic AGRP-dependent signaling through this receptor, analogous to the 
apparent mediation by ATRN of ASP-dependent signaling through the MC1R (in wild 
type melanocytes) and MC4R (in hypothalamic neurons of lethal yellow mice 
ectopically expressing ASP).  This hypothesis is appealing, but it is challenged by my 
results.  Because ATRNL1 overexpression rescues the pigmentation phenotype of Atrn 
mutants, it seems likely that ATRNL1 interacts with ASP, and yet endogenous 
ATRNL1 is not sufficient to support obesity in Atrn
-/-
, A
Y 
mice.  This suggests that 
despite fairly widespread expression of ATRNL1 in MC4R+ neurons, ATRNL1 may 
not be expressed in the critical MC4R+ neuron population involved in energy 
homeostasis.  (In light of this observation, it would be interesting to determine whether 
Atrn null mice overexpressing both agouti and Atrnl1 become obese.) Furthermore, no 
overt energy homeostasis phenotype has been reported for Atrnl1 mutants to date. The 
conclusive experiment will be to test Atrnl1 null animals (and Atrn/Atrnl1 double 
mutants) for resistance to AGRP-induced obesity.  
 I have suggested that the MASRPFAXVXV motif common to all ATRN family 
members may be a MGRN1 interaction motif.  Given that the neurodegenerative, coat 
color, curly hair, L-R patterning, and cardiac development phenotypes of Mgrn1 
mutant mice are phenocopied by mutations in either Atrn or Megf8, an obvious 
question of interest is whether the craniofacial abnormalities of Mgrn1 mice might 
appear in Atrnl1 mutants, thereby indicating that these phenotypes could be assigned 
to a functional interaction between Mgrn1 and this third member of the murine Atrn 
gene family.  This is not the case (Walker et al., 2007), meaning that an explanation of 
these phenotypes of Mgrn1 mutants must be sought elsewhere.   
 The apparent functional exchangeability of ATRN and ATRNL1 in vivo is 
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useful for predicting which regions of ATRN are important for its function in the skin 
and CNS.  Although many protein domains are conserved in ATRN homologs across 
vertebrate and invertebrate genomes, the C-type lectin domain is a vertebrate-specific 
motif found in both ATRN and ATRNL1.  One possibility is that this motif facilitates 
interactions with melanocortin receptors, which arose in the vertebrate lineage at 
approximately the same time as the split of the ancestral Atrn into two paralogs.  As 
this domain typically mediates interactions with N-linked glycosyl groups, and both 
ASP and MC1R are reported to be glycosylated (Willard et al, 1995; Sanchez et al., 
2002), this seems a possibility worthy of investigation.  Because the MC4R-
interacting region of ATRNL1 has been mapped, it is possible to make predictions 
regarding a likely MC1R-interacting region of ATRN.  The MC4R-interacting region 
of ATRNL1 spans the 36 amino acid residues immediately following the 
MASRPFAXVXV motif (Haqq et al, 2003).  The second half of this region is almost 
identical between ATRNL1 and ATRN, suggesting that any interaction between 
ATRN and the cytoplasmic tail of MC1R is likely to be mediated by this region.  
 
Predictions regarding functional regions of the ATRN cytoplasmic tail 
 The bioinformatic and genetic analysis of ATRN homologs presented in this 
chapter underlies several hypotheses concerning putative functional sequences in the 
cytoplasmic tail of ATRN. These include a coiled-coil-forming juxtamembrane region, 
which is potentially a dimerization motif; the MASRPFAXVXV motif, hypothesized 
to be a MGRN1 interaction region; and a likely site of interaction with MC1R, 
homologous to the MC4R-interaction region of the ATRNL1 cytoplasmic tail.  These 
proposed interactions form the basis of a mechanistic explanation of the genetic 
interactions of Atrn, Mgrn1, Mc1r, and agouti.  The next chapter will explore the cell 
biology, colocalization, and interactions of ATRN, MGRN1, and MC1R. 
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CHAPTER THREE 
CELL BIOLOGY AND MOLECULAR INTERACTIONS OF ATTRACTIN, 
MAHOGUNIN RING-FINGER 1, AND MELANOCORTIN RECEPTOR 1 
 
Chapter Overview 
 This chapter describes experiments testing the hypotheses derived from the 
bioinformatic and genetic analyses of Chapter Two.  Specifically, data are presented 
demonstrating physical interactions between ATRN and both MGRN1 and MC1R, and 
tagged ATRN and MC1R are shown to colocalize and to traffic through the 
endosomal/lysosomal pathway in transiently transfected HEK293T cells. These 
observations suggest that ATRN may function as a MGRN1- and ASP-dependent 
lysosomal targeting factor for MC1R, a hypothesis that will be further investigated in 
the melanocyte model in Chapter Four.  
 
Introduction to Melanocortin Receptor 1 biology 
 To place the data of this chapter in context, it will be useful to have in mind a 
brief overview of G-protein-coupled receptor (GPCR) signaling biology. The 
canonical view of GPCR signaling imagines the receptor as occupying an equilibrium 
state between “active” and “inactive” conformations, where agonist binding stabilizes 
the active conformation and inverse agonist binding stabilizes the inactive 
conformation.  The active conformation allows the receptor to interact with a G 
protein  (G) subunit in a way that promotes GDP-GTP exchange and causes the 
release of the GTP-bound G from the G protein heterotrimer.  Downstream events 
depend on the G subunit binding specificity of the receptor in question; for MC1R, 
signaling occurs through the stimulatory Gs molecule, which functions in the 
melanocyte to activate adenylyl cyclase.  Because MC1R has a high constitutive rate 
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of signaling, this receptor stimulates cAMP production even in the absence of the 
agonist, MSH. 
 Signaling from GPCRs is limited by several fairly well-understood processes 
(Figure 3.1).  First, the GTP-bound G-protein  subunits produced by GPCR activity 
have an intrinsic GTP hydrolysis ability that limits the signaling lifetime of each 
individual activated G protein.  In addition, ligand binding causes many GPCRs to be 
removed from the plasma membrane into early endosomes, which in many cases 
promotes dissociation of the GPCR from its ligand due to the relatively low pH of the 
endosomal lumen.   At this point, internalized GPCRs are subject to desensitization, 
which canonically occurs when agonist-bound GPCRs are phosphorylated by G-
protein-coupled receptor kinases (GRKs), recruiting arrestins which decouple them 
from their G proteins and render them temporarily insensitive to further stimulation 
(reviewed by Moore, Milano, and Benovic, 2007). MC1R has been shown to undergo 
desensitization upon phosphorylation by GERK2 and GERK6 (Sanchez-Mas et al., 
2005). From the early endosome, internalized GPCRs can follow a “fast” recycling 
pathway directly back to the plasma membrane, or a “slow” recycling pathway that 
leads to the plasma membrane by way of a large tubulovesicular sorting station, the 
Rab11-positive endosomal recycling complex (ERC).  Recycled GPCRs are thus 
returned to the plasma membrane and made available for a second round of ligand 
binding and G protein-coupled signaling.  However, some GPCRs follow an 
alternative pathway from the Rab5-labeled early endosome and are sorted towards the 
lysosome for degradation.  The critical decision point in this process occurs at the 
surface of incipient late endosomes, referred to as multivesicular bodies (MVBs) due 
to their complex “vesicles within a vesicle” morphology.  There, receptors and other 
transmembrane proteins destined for lysosomal degradation are recognized by proteins 
of the Endosomal Complex Required for Transport (ESCRT) machinery, frequently on  
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Figure 3.1. GPCR recycling and lysosomal trafficking. Endocytosed GPCRs in early 
endosomes (EEs) may recycle to the plasma membrane directly through the fast 
endosomal recycling pathway, or indirectly through the endosomal recycling complex 
(ERC). Monoubiquitinated receptors may be recognized by proteins of the ESCRT 
complex and sorted into the intracisternal vesicles of late endosomes/multivesicular 
bodies (LEs/MVBs). Fusion of the MVB with the lysosome delivers ESCRT cargo to 
lysosomal hydrolases for degradation. 
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the basis of a monoubiquitin tag attached to a lysine residue of the target protein.  
Proteins so recognized are handled sequentially by three major complexes of ESCRT 
proteins (ESCRT I-III) and sorted into the intracisternal vesicles of the MVB, 
topologically sequestering any active receptors from their effectors and effectively 
silencing them.  The limiting membrane of the mature MVB then fuses with a 
lysosome, releasing the intracisternal cargo into the lysosomal lumen for degradation 
by lysosomal hydrolases. This highly effective mechanism of receptor 
downregulation is well-characterized for the yeast  mating pheromone receptor, the 
GPCR Ste2p.  Ligand-bound Ste2p is ubiquitinated by the Nedd4 family E3 ubiquitin 
ligase Rsp5p, causing the receptor to be sorted by ESCRT proteins into the 
intracisternal vesicles of the MVB, leading to the lysosomal trafficking and 
degradation of the receptor (Hicke and Reizman, 1996; Dunn and Hicke, 2001; for a 
review of ubiquitin-mediated receptor downregulation through the endolysosomal 
pathway see Katzmann, Odorizzi, and Emr, 2002). Compared to the first two 
mechanisms, lysosomal degradation is an especially potent, irreversible means of 
limiting GPCR signaling. Whether MC1R undergoes a regulated lysosomal trafficking 
event as part of the agouti-mediated pigment-type switching mechanism is not known, 
but it is interesting to note that ASP treatment has been reported to induce a reduction 
in MC1R protein levels in cultured melanocytes and in rat skin (Rouzaud et al., 2003; 
Yang et al., 2004).  If this reduction requires active MC1R protein degradation (as 
opposed to decreased MC1R biogenesis and unaltered protein turnover rates), it is 
probable that this degradation occurs via the lysosomal degradative pathway.   
 These canonical modes of GPCR signaling regulation are relatively well 
understood, at least for model GPCRs such as the yeast mating pheromone receptors.  
However, recent lines of investigation have revealed additional levels of complexity in 
signaling of some GPCRs.  It has been recognized that many, if not most, GPCRs 
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form dimers or higher-order oligomers, and that this oligomerization may be important 
for their function (Reviewed in Milligan 2007; Gurevich and Gurevich 2008). 
Analysis of the functional importance of GPCR oligomerization is complicated by the 
fact that some GPCRs actually participate in GPCR “heteromers” made up of more 
than one type of GPCR (e.g., Harikumar et al, 2008; Pello et al., 2008; Vidi et al., 
2008.)  MC1R is known to form homodimers (and probably higher-order oligomers), 
which appear to form from domain-swapping interactions between the subunits 
(Zanna et al., 2008).  These oligomers are stabilized by the presence of conserved 
cysteines and are reducible with -mercaptoethanol, indicating that intermolecular 
disulfide bonds probably contribute to their structure.  Furthermore, the dimerization 
of MC1R appears to be critical for its function, as non-dimerizing mutants fail to 
localize to the plasma membrane.  Whether the oligomerization state of MC1R is 
affected by ASP treatment or by interaction with ATRN or MGRN is not known. 
 Another emerging theme in GPCR signaling is that signaling from the receptor 
is not necessarily confined to plasma membrane-localized GPCRs. It has recently 
become apparent that so-called “signaling endosomes” containing active GPCRs, G 
proteins, and effectors can be internalized from the plasma membrane and persist as 
signaling centers in the cytoplasm over long periods of time (e.g., see Calebiro et al., 
2009).  In some cases, coupling of GPCR signaling to downstream signaling pathways 
may be dependent on GPCR internalization to endosomes, suggesting that the details 
of post-endocytosis GPCR trafficking may be important in determining the 
physiological effects of ligand binding (reviewed in Jalink and Moolenaar, 2010). This 
realization potentially adds a new layer of complexity to interpretations of ASP 
signaling, raising the possibility that ASP-bound MC1R may not merely be “turned 
off” with respect to cAMP production but could also have altered coupling to a non-
cAMP-mediated signaling pathway.  This scenario is one possible explanation of the 
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curious observation that ASP-overexpressing mice are actually yellower than Mc1R 
null animals (Jackson et al., 2007; Ollmann et al., 1998), which is difficult to explain 
if ASP is strictly an inactivator of MC1R signaling.  
  Another interesting development in GPCR signaling biology is the growing list 
of transmembrane receptor accessory proteins that act as modulators of GPCR 
function.  A particularly pertinent example are the Melanocortin Receptor Accessory 
Proteins (MRAPS), which are single-pass transmembrane proteins that act as 
bidirectional trafficking regulators of melanocortin receptors (Chan et al., 2009). 
Signaling from the melanocortin 2 receptor is profoundly reduced in the absence of 
MRAPS.  Another GPCR, the calcitonin receptor (CTR), interacts with a trio of 
glycosylated single-pass transmembrane proteins, the Receptor Accessory Membrane 
Proteins (RAMPS) (Parameswaran and Spielman, 2006) which affect the CTR’s 
cellular localization, signaling efficiency, and even its substrate specificity.  Both of 
these examples underscore the importance of proper intracellular trafficking for 
regulation of signaling, and demonstrate that receptor accessory proteins can be 
important modifiers of such trafficking events. 
 If a single theme emerges from the considerations outlined above, it is that 
understanding how a GPCR is trafficked may be helpful to understanding the 
regulation of its signaling.  Post-internalization trafficking events can lead to the 
recycling of GPCRs to the plasma membrane, the transfer of signaling GPCRs to 
signaling endosomes, or to the lysosomal trafficking and degradation of the GPCRs.  
Interactions with receptor accessory proteins and ubiquitination by E3 ligases can be 
decisive in sending a GPCR down one trafficking pathway or another, suggesting that 
interacting with ATRN and/or MGRN1 could affect MC1R signaling by altering its 
trafficking fate.   
 When specific antibodies are not yet available for a protein of interest (as was 
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true for both ATRN and MC1R when I began this project), the use of fluorescently 
tagged expression constructs can be a powerful approach for gaining insight into the 
protein’s interactions and cellular behavior.  The tags can be used as epitope “handles” 
for coimmunoprecipitation assays, and the tagged proteins can be observed under the 
confocal microscope to determine their location within the cell, their dynamic 
trafficking behavior, and whether they colocalize with other proteins of interest.  
While both the presence of the tag and the overexpression of the protein introduce 
caveats to the interpretation of the results, the ease of generation of the tagged 
constructs and the wide variety of data that can be gathered using them make this 
approach especially valuable for initial characterization of proteins of interest.  To 
begin my exploration of the molecular interactions and behavior of ATRN, MGRN1, 
and MC1R, I used fluorescent-tagged forms of these proteins to characterize their 
colocalization, intracellular trafficking, and physical interactions. 
 
Materials and Methods 
Construction of tagged ATRN and MC1R expression plasmids 
 All cloned cDNAs and partial cDNAs were amplified using the iProof high-
fidelity Pfu DNA polymerase (Bio-Rad, Hercules, CA). The full-length murine Atrn 
coding sequence (CDS) (excepting the stop codon) was amplified from a cDNA clone 
using primers CACCAGCACTGATTGGCCTAC and AATGCAGGTTCCAGGC.  
The gel-purified PCR product was recombined into the pENTR/DTOPO entry vector 
(Invitrogen, Carlsbad, CA) and sequence verified to generate clone DTOPO-
AtrnCDS-7.  The full-length (single exon) Mc1R CDS was amplified directly from 
genomic DNA of a C57Bl/6J mouse using primers 
CACCATGTCCACTGAGGAGCC and CCAGGAGCACAGCAGCACCTCC and 
recombined with the pENTR/DTOPO vector to generate sequence-verified clone 
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DTOPO-Mc1r 23.  The Atrn cytoplasmic tail was amplified using forward primer 
CACCATGTGGAAGATCAAGCAGAGCTGT and reverse primer 
AATGCAGGTTCCAGGC.  A series of truncated Atrn cytoplasmic tail constructs 
were made using the same reverse primer and the forward primers 
CACCATGCAACAGATGGCCAG (AtrnCyto1), 
CACCATGACAGATGAAGAACCTC (AtrnCyto2), or 
CACCATGAGGCTCCCTCGAGGAC (AtrnCyto3), using DTOPO-ATRN-CDS7 as 
template.  
 The fluorescent protein-encoding plasmids pEGFP-N1 and pdsRed-monomer-
N1 (Clontech, Mountain View, CA) were modified by insertion of an in-frame 
Gateway cassette to make destination vectors pDEST-EGFP and pDEST-dsRed.  The 
entry vectors described above were recombined with the destination vectors using LR 
clonase (Invitrogen, Carlsbad, CA) to generate C-terminal tagged expression 
constructs.  
 
Other plasmids 
 GFP-tagged Rab5 and Rab7 plasmids were the kind gift of Cecilia Bucci, and 
have been described previously (Deinhadt et al., 2006).  YFP-Rab11 was created by 
Craig Roy as described in Guignot et al. (2004). Lamp1-DsRed and CD63-dsRed have 
been described (Sherer et al., 2003) and were kindly supplied by Volker Vogt. The 
MGRN1-GFP and MGRN1(AVVA)-GFP plasmids have been described in Jiao et al., 
2009a; the MGRN1(AVVA) sequence differs from wild type by the conversion to 
alanines of two conserved cysteines in the RING domain, which results in a MGRN1 
protein without E3 ubiquitin ligase activity.   
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Transfection and cell culture 
 HEK293T cells and Neuro2A cells were cultured under 5% CO2 in DMEM 
supplemented with L-glutamine, 10% FBS, and penicillin/streptomycin (all medium 
components from Gibco [Invitrogen], Carlsbad, CA), and transfected by the calcium 
phosphate method (Kingston, Chen, and Rose, 2003).  Cells to be transfected were 
passaged 1:6 or 1:8, approximately 18 hours before transfection, and given fresh 
medium 2 hours before transfection.  For a 6cm plate of cells, 4 ug total DNA was 
added to 10 uL of filter-sterilized 2.5 M CaCl2 and brought to 100 uL with sterile 
water.  A DNA-hydroxyapatite precipitate was produced by the addition of 100 uL of 
filter-sterilized 2X HBS (50 mM HEPES, 280 mM NaCl, 1.5 mM NaPO4), allowed to 
incubate for 1-5 minutes until fine precipitate was visible at 10x magnification, then 
added to culture plates. For evaluation of lysosomal trafficking by live-imaging 
confocal microscopy, Lysotracker Red (Molecular Probes, Eugene, OR) was applied 
to cells at 200nM for 30 minutes prior to imaging.  Lysosomal inhibition was carried 
out overnight using 50 mM ammonium chloride or 100μM chloroquine (Sigma-
Aldrich, St. Louis, MO).  Results presented are representative of at least two 
independent replicate experiments. 
 
Confocal microscopy 
 Transiently transfected HEK293T cells were inspected using a Zeiss LSM510 
Meta confocal microscope and the LSM510 software package.  For comparisons of 
signal intensity between experimental and control conditions, imaging was performed 
under identical microscope settings and any post-processing of images was applied to 
all images equally.  
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Western blotting 
 Cells were collected 24-72 hours after transfection and lysed in solubilization 
buffer (50uM Tris-HCl pH 8.0, 1 mM EDTA, 10 mM iodoacetamide, 1% Igepal CA-
630) containing Complete protease inhibitor cocktail (Roche).  Lysates were 
centrifuged at 13,000 rpm in a benchtop microcentrifuge for 5 minutes to pellet debris, 
and the protein concentration of the cleared supernatant was measured by bicinchonic 
acid assay (Pierce).  Loading samples were made by addition of a 3X SDS sample 
buffer (180 mM Tris-HCl pH 6.8, 15% glycerol, 9% SDS, .075% bromophenol blue, 
with or without 3M -mercaptoethanol), and 10-50 ug protein/lane of each sample was 
run on polyacrylamide gels under standard Laemmli conditions (Laemmli, 1970) prior 
to wet electrophoretic transfer to Immobilon P membrane (Millipore).  Samples were 
routinely heated before loading at 95
o
C for 5 minutes, except for samples for 
demonstration of MC1R-GFP, which were not heated as heating irreversibly denatures 
this protein and inhibits blotting.  Blots were blocked in 5% dry milk in TBS/T (100 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20) prior to incubation with 
antibodies. 
 
Antibodies 
 Polyclonal rabbit anti-GFP antibody A11122 was obtained from Invitrogen 
(Carlsbad, CA) and used for Western blot at a dilution of 1:2000. Anti-HA mouse 
antibody HA.11 (used for Western at 1:1000) was from Covance.  The anti-ATRN
60
 
rabbit polyclonal (used for Western at 1:1000) was raised against an epitope from the 
extracellular domain of mouse ATRN and is from the lab of Dr. Gregory Barsh. The 
rabbit anti-human MGRN1 polyclonal #11285 (used for Western at 1:600) was 
obtained from ProteinTech (Chicago, IL).  Horseradish peroxidase (HRP)-conjugated 
goat anti-mouse secondary antibody was from BD Biosciences (San Jose, CA). 
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Coimmunoprecipitation 
 Cells were collected 48 hours after transfection, rinsed with PBS, and lysed in 
Cytobuster protein extraction reagent (Novagen, Madison, WI).  Cells were precleared 
with protein A/G agarose beads and mouse IgG (Santa Cruz Biotechnology, Santa 
Cruz, CA) before immunoprecipitation with 1 ug anti-HA antibody and binding to 40 
uL protein A/G agarose beads (Novabiochem).  Non-complexed proteins were 
removed by filtration over an agarose-binding mini spin column (Novagen, Madison, 
WI) and washed with GrabIt buffer (Novagen) before elution in 1X SDS buffer 
(Novagen). 
 
Results 
ATRN-GFP forms oligomers and occupies endosome-like structures. 
 ATRN-GFP expressed in HEK293T cells occupies mobile, punctate, endosome-
like structures within the cell (Figure 3.2AA).  ATRN has also been shown to occupy 
endosome-like structures in neurons of the rat CNS by immunohistochemistry 
(Nakadate, Sakakibara, and Ueda; 2008), suggesting that the tagged ATRN retains at 
least some of the trafficking features of the native protein. When visualized by western 
blot using an antibody against the C-terminal GFP tag, ATRN-GFP forms a band of 
the expected molecular weight (~240 kD), representing monomeric ATRN-GFP 
(Figure 3.2D).  A secondary band at high molecular weight, and a very high molecular 
weight “smear” of ATRN-GFP signal are observable when non-reducing 
electrophoretic conditions are used, and are likely to represent oligomeric species of 
ATRN.  These high-molecular-weight bands collapse into a single band at monomeric 
size if -mercaptoethanol is included in the sample loading buffer, suggesting that 
intermolecular disulfide bonds contribute to the structure of the oligomeric species.  
This single band can be resolved into a doublet under longer gel separation times, 
reflecting an unknown difference in post-translational modification.  Besides the 
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signal coming from full-length ATRN-GFP, some GFP signal is also visible at 
approximately 30kD in western blots from ATRN-GFP-transfected cells (data not 
shown).  This is approximately the molecular weight of native GFP, suggesting that 
some subset of the ATRN-GFP molecules are subject to a cleavage event near the end 
of the cytoplasmic tail of ATRN or else within the primary sequence of the GFP tag 
itself.   
 
Colocalization of fluorescent-tagged ATRN, MC1R, and MGRN1 proteins 
 I examined HEK293T cells co-transfected with ATRN-dsRED and GFP-tagged 
MC1R to determine whether these proteins co-localize.  GFP-tagged MC1R forms 
several bands by western blot (Figure 3.2E), presumably due to oligomerization of the 
receptor as reported by Zanna et al. (2008). Under the confocal microscope, tagged 
MC1R primarily localized to endosome-like structures, similar in appearance to those 
occupied by ATRN (Figure 3.2B).  Tagged ATRN and MC1R proteins clearly 
colocalized in a substantial proportion of endosome-like structures when cotransfected 
into HEK293T cells (Figure 3.2E). As MGRN1 has been reported to decorate the 
surface of endosomes (Kim et al., 2007), I attempted similar colocalization 
experiments with MGRN-GFP.  Unambiguous demonstration of meaningful 
colocalization of this construct with ATRN-dsRed was problematic, as the MGRN-
GFP fusion protein produces GFP signal both on punctate, apparently membrane-
bound structures and diffusely in the cytosol. Furthermore, cotransfection with 
MGRN1-GFP seemed to cause a marked reduction in ATRN-dsRed levels, making it 
impossible to get satisfactory images of ATRN-dsRed and MGRN-GFP.  
Interestingly, this apparent reduction of ATRN-dsRed levels was not seen when 
ATRN-dsRed was cotransfected with the catalytically inactive MGRN(AVVA)-GFP 
construct (data not shown).
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Figure 3.2. Expression and colocalization of fluorescent-tagged ATRN, MC1R, and 
MGRN1. ATRN-GFP (A) and MC1R-GFP (B) are detectable by western blot using an 
antibody against GFP. ATRN-GFP (C) and MC1R-GFP (D) signal decorates 
endosome-like structures in transfected HEK293T cells. ATRN-GFP colocalizes with 
MC1R-dsRed in a subset of endosomes (E).   
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ATRN-GFP traffics through the endosomal/lysosomal pathway 
 That ATRN colocalizes with both MGRN1 and MC1R in endosome-like 
structures suggests that this subcellular location may be important for the ordinary 
functions of these proteins in the pigment-type switching pathway.  To further 
characterize this endosome-like subcellular compartment, I cotransfected tagged 
ATRN with fluorescent markers of endosomes, lysosomes, and the trans-Golgi 
apparatus.  Tagged ATRN showed little colocalization with the early endosome 
marker RAB5-GFP, but clearly occupied late endosomes marked with the late 
endosome marker RAB7-GFP, and also colocalized extensively with the lysosome 
marker Lysotracker Red (Figure 3.3 A-C).  Under the confocal microscope,  ATRN-
GFP-labeled endosome-like structures were clearly observed trafficking to and fusing 
with Lysotracker Red-labeled late endosomes/lysosomes over a time scale of seconds 
to minutes. By time-lapse confocal imaging, transient occupation of the RAB11-YFP-
labeled endosomal recycling compartment by tagged ATRN was also observed (time-
lapse data not shown).  MC1R was observed in RAB5-GFP-labeled early endosomes, 
and occupied some RAB7-GFP-labeled late endosomes and CD63-dsRed-labeled late 
endosomes/lysosomes (Figure 3.3 D-F).  Interestingly, RAB7-GFP coexpression 
appeared to cause a marked intensification of MC1R-dsRed signal at the plasma 
membrane (Compare 3.3E and 3.3 D or F). 
 
ATRN-GFP accumulates in cells treated with lysosomal protease inhibitors 
 The observation of ATRN in late endosomes and lysosomes suggested that 
ATRN may traffic to the lysosome for degradation by lysosomal proteases.  To test 
this hypothesis, I used confocal microscopy to examine ATRN-GFP-transfected cells 
that had been treated overnight with 45 uM chloroquine or 25 mM NH4Cl to inactivate 
lysosomal proteases.  Either treatment caused the accumulation of ATRN-GFP in  
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Figure 3.3. Tagged ATRN and MC1R traffic through the endosomal/lysosomal 
pathway.  ATRN shows little colocalization with the early endosome marker RAB5-
GFP (A), but is visible occupying late endosomes marked with RAB7-GFP (B, arrow) 
and extensively colocalizes with the late endosome/lysosome marker, Lysotracker Red 
(C).  MC1R-dsRed occupies early endosomes marked with GFP-RAB5 (D, arrow), 
late endosomes marked with RAB7-GFP (E, arrow), and late endosomes/lysosomes 
labeled with CD63-dsRed (F, arrow. CD63-dsRed signal is false-colored grey in this 
image).  
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Figure 3.4. Lysosomal inhibition causes accumulation of ATRN-GFP.  Representative 
cells imaged under identical conditions show increased ATRN-GFP signal in cells 
treated with the lysosomal inhibitors chloroquine (B) or ammonium chloride (C) 
compared to control cells (A).  Red signal is Lysotracker Red.  (Note that the 
lysosomal deacidifier, ammonium chloride, inhibits efficient labeling of lysosomes 
with the acidotrophic dye Lysotracker Red.) 
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large, bright vesicular structures, with a strong increase in GFP signal relative to 
control cells (Figure 3.4).  While treatment with 25mM NH4Cl deacidifies late 
endosomes/lysosomes to the point that they are no longer labeled by Lysotracker Red 
(note lack of Lysotracker Red signal in Figure 3.4 panel C), Lysotracker Red still 
labels late endosomes/lysosomes in cells treated with 45 μM chloroquine (Figure 3.4, 
panel B).  Colocalization of Lysotracker Red with ATRN-GFP signal in chloroquine-
treated cells confirmed that the large, bright vesicles full of ATRN-GFP are swollen 
late endosomes or lysosomes. (Accumulation of ATRN-GFP in chloroquine-treated 
cells was confirmed by Western blot by Caroline Wee, an undergraduate in the lab, as 
part of her honors thesis project – data not shown). The accumulation of ATRN-GFP 
after treatment with lysosome inhibitors suggests that ATRN-GFP is normally 
degraded by lysosomal proteases.   
 
ATRN and MGRN1 physically interact 
 The colocalization of ATRN and MGRN1, along with the genetic interactions 
between Atrn and Mgrn1 outlined in the first chapter, suggested that ATRN and 
MGRN1 might physically interact.  Therefore, reciprocal coimmunoprecipitation 
experiments were performed using Neuro2A mouse neuroblastoma cell line lysates, 
which strongly expresses endogenous ATRN and MGRN1.  As shown in Figure 3.5, 
ATRN and MGRN1 coimmunoprecipitated.  
 
ATRN and MC1R cytoplasmic tails physically interact 
 As discussed in Chapter One, several lines of evidence suggest that MC1R and 
ATRN may physically interact with each other and that this interaction would be 
likely to involve their cytoplasmic tails. I tested this hypothesis by cotransfecting 
ATRN-Cyto-GFP and HA-tagged MC1R-Cyto-GFP into HEK293T cells and 
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Figure 3.5.  ATRN physically interacts with MGRN1 and MC1R. (A) Endogenous 
ATRN from N2A cells is coimmunoprecipitated by an anti-MGRN1 antibody, but not 
by non-specific control -immunoglobulins (IgG) or by the IgG-binding column 
without IgG. (B) Endogenous MGRN1 coimmunoprecipitates with an anti-ATRN 
antibody, but not by non-specific control IgG of by the IgG-binding column without 
IgG. (C) GFP-tagged ATRN cytoplasmic domain (ATRN-CYTO-GFP) 
coimmunoprecipitates with HA-tagged MC1R cytoplasmic domain (HA-MC1R-
CYTO).  
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performing co-immunoprecipitation experiments using an anti-HA antibody.  (The 
reciprocal experiment was not performed, as the small size [~3 kD] of the HA-MC1R-
CYTO peptide makes it unsuitable for immunoblotting.)  As shown in Figure 3.5, 
ATRN-Cyto-GFP coimmunoprecipitated with the HA-tagged MC1R cytoplasmic tail. 
 
 MGRN1-sensitive punctate localization of the cytoplasmic tail domain of ATRN 
 As suggested in the previous chapter, the conserved MASPFAXVXV sequence 
of the ATRN cytoplasmic tail is an attractive candidate to be the MGRN1-interacting 
region. In addition, by analogy to the demonstrated MC4R/ATRNL1 interaction, the 
interaction between MC1R and ATRN is likely to be mediated by the 37 residue 
sequence immediately C-terminal to the MASRPFAXVXV. Finally, the predicted 
coiled-coil region of the ATRN cytoplasmic domain is a possible dimerization motif.  
To create tools for future dissection of the interacting domains of the ATRN 
cytoplasmic tail, I built a series of ATRN-CYTO truncation constructs (presented 
schematically in Figure 3.6E). Surprisingly, even though it lacks a transmembrane 
helix, the AtrnCYTO-GFP fusion protein showed a distinctly punctate distribution 
within HEK293T cells (Figure 3.6A).  This punctate distribution was dependent on the 
sequence QQMASRPFAXVNVALE, as AtrnCYTO1, but not AtrnCYTO2 or 
AtrnCYTO3, also showed a punctate cellular distribution (Figure 3.6B-D).  Because 
comparative genomic analysis (see Chapter One) suggested that the conserved 
MASRPFAXVNV sequence may be a MGRN1-interacting motif, I cotransfected 
ATRN-GFP with HA-MGRN1 and with the RING mutant HA-MGRN1(AVVA) 
construct, which is expected to act as a dominant negative MGRN1 mutant.  
Overexpression of either of the wild-type or mutant protein caused a redistribution of 
AtrnCYTO-GFP signal from its native, punctate localization to a diffuse cytoplasmic 
localization, similar to the cellular distribution of AtrnCYTO deletion mutants lacking  
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Figure 3.6. Punctate localization of the ATRN cytoplasmic domain is dependent on 
the QQMASRPFASVNVALE sequence and is ablated by overexpression of MGRN1.  
Top: the ATRN Cyto-GFP and Cyto1 constructs (A & B), but not the Cyto2 and 
Cyto3 constructs (C & D), localize to punctate cytoplasmic foci in HEK293T cells. 
Middle: schematic of the ATRN cytoplasmic tail deletion series (E). 
Bottom: Punctate distribution of AtrnCytoGFP in HEK293T cells (F) is lost upon 
cotransfection with HA-MGRN1 (G) or HA(AVVA)MGRN1 (H). Images are 
representative of three independent replicate experiments. 
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the QQMASRPFAXVNVALE sequence (Figure 3.6 F-H). 
 
Discussion 
 While the genetic interactions of ATRN, MC1R, and MGRN1 have long 
prompted speculation that these proteins are physical interaction partners, the data in 
this chapter are the first reported evidence of a physical interaction between ATRN 
and the other two proteins.  Combining these newly mapped interactions with the 
report of a MGRN1-MC1R interaction by Perez-Oliva et al. (2009), I propose a model 
whereby ATRN, MGRN1, and MC1R interact in a ternary complex (see figure 3.7).  
In this model, the ATRN cytoplasmic tail mediates an interaction with the cytoplasmic 
tail of MC1R, possibly by an analogous interaction to that reported for the cytoplasmic 
tails of ATRNL1 and MC4R (Haqq et al., 2003). The coordinated binding of ASP by 
both ATRN and MC1R may strengthen the association of the two membrane proteins 
to activate the pigment-type switching mechanism.  While I have not demonstrated 
that the MGRN1-interacting motif of ATRN is in the cytoplasmic tail, the cytoplasmic 
tail is presumably the only portion of ATRN that is topologically accessible to 
MGRN1, as indicated in Figure 3.7. 
 As expected for interacting proteins, fluorescent-protein-tagged ATRN and 
MC1R colocalize.  Interestingly, this colocalization was observed within the cell in 
endosomal compartments, rather than at the plasma membrane. This suggests that 
ATRN does not function merely to promote binding of ASP over MSH at the cell 
surface, as might be expected if ATRN were “only” an accessory receptor for a 
classical antagonist.  Instead, ATRN’s effect on MC1R signaling seems likely to occur 
within the endosomal trafficking system. 
 The most striking behavior of tagged ATRN observed in this study is its high 
rate of trafficking along the endosomal/lysosomal pathway.  In conjunction with my  
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Figure 3.7. Model of ATRN interactions with MC1R and MGRN.  (A): The 
cytoplasmic tail of ATRN interacts with MGRN1 and with the cytoplasmic tail of 
MC1R. The three proteins are shown in a ternary endosomal complex, with MGRN1 
also interacting with MC1R as reported by Perez-Oliva et al. (2007).  The interaction 
of ATRN and MC1R is presumably strengthened by their mutual binding of ASP.  
Note that while proteins are shown singly for clarity, ATRN and MC1R are likely to 
occur as dimers or higher-order oligomers. (B): Hypothetical function of ATRN as a 
trans-acting ubiquitinated lysosomal sorting signal for MC1R.  Ubiquitinated ATRN is 
shown being recognized by the ubiquitin-interacting motif of the ESCRT I protein, 
TSG101, triggering ESCRT sorting of ATRN/MC1R into the intracisternal vesicles of 
an incipient MVB, leading to lysosomal degradation of ATRN/MC1R.  MGRN1 is 
portrayed in a hypothetical role as the E3 ligase responsible for ubiquitination of 
ATRN.  (C): Alternative or additional roles for MGRN1 in promoting lysosomal 
trafficking of the ATRN/MC1R complex.  As MGRN1 is known to localize to 
endosomal membranes through its interaction with the ESCRT I protein TSG101, 
MGRN1’s interactions with ATRN and MC1R may directly recruit ATRN/MC1R to 
sites of ESCRT activity.  In addition, MGRN1 monoubiquitination of TSG101 has 
been reported to promote normal ESCRT function (Kim et al., 2007) and may be an 
important prerequisite for lysosomal trafficking of ATRN/MC1R.  
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observations of ATRN/MC1R interaction and endosomal colocalization, this behavior 
suggests a mechanism by which pigment-type switching could occur.  Coordinated 
binding of ASP by ATRN and MC1R would be likely to promote the interaction of 
their cytoplasmic tails, and perhaps also promote interactions between their 
extracellular/lumenal domains.  The strengthened MC1R/ATRN interaction could tie 
the trafficking fate of MC1R to that of ATRN, leading to the lysosomal trafficking and 
degradation of MC1R and a strong reduction of MC1R signaling (Figure 3.7B).  This 
proposed mechanism is consistent with observations by other groups (Rouzaud et al., 
2003; Yang et al., 2004) that ASP treatment causes a reduction in MC1R protein 
levels. If the lysosomal trafficking of ATRN and MC1R does underlie pigment-type 
switching, the genetic interactions discussed in Chapter One suggest that MGRN1 
facilitates this trafficking event. There are several plausible mechanisms by which 
MGRN1 could promote lysosomal trafficking of ATRN/MC1R.  The simplest 
possibility is that MGRN1 could monoubiquitinate ATRN to provide the signal 
directing ATRN to the lysosome.  MC1R seems unlikely to be a direct target of 
monoubiquitination by MGRN1 as an interaction between MGRN1 and MC1R has 
been reported but this interaction did not result in the ubiquitination of MC1R (Perez-
Oliva et al., 2009). Monoubiquitination of membrane proteins is a canonical means of 
targeting them to the lysosome, as the monoubiquitin tag is recognized by the 
HRS/STAM complex (sometimes referred to as “ESCRT 0”) which initiates sorting of 
the monoubiquitinated proteins into the intracisternal vesicles of the incipient 
multivesicular body (MVB).  Monoubiquitination of ATRN by MGRN1 could 
therefore provide a trans-acting lysosomal sorting signal for ATRN-associated MC1R.   
It is interesting to note that a related GPCR, the delta opioid receptor [DOR], has been 
reported to be lysosomally degraded in a ubiquitin and ESCRT-dependent manner, 
without being ubiquitinated itself (Tanowitz and Von Zastrow, 2002; Hislop, Marley, 
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and Von Zastrow, 2004).  This apparent paradox could be explained if the DOR is 
escorted into the lysosomal trafficking pathway by a trans-acting ubiquitinated sorting 
factor.  
 Since MGRN1 is localized to (presumptive) late endosomal membranes by its 
own interaction with the ESCRT I protein TSG101 (Kim et al., 2007), another 
possibility is that MGRN1 could promote the lysosomal trafficking of ATRN/MC1R 
by directly recruiting it to the site of ESCRT activity, perhaps delivering 
ATRN/MC1R directly to the ESCRT processing machinery.  My observations on the 
punctate distribution of the ATRN cytoplasmic tail are of interest with regard to this 
possibility. As discussed in Chapter 2, genomic analysis suggests that the 
MASRPFAS sequence in the ATRN cytoplasmic tail may be a conserved MGRN1 
binding motif.  I observed that inclusion of this sequence confers a punctate 
distribution on ATRN-CYTO1-GFP, suggesting that direct recruitment of ATRN-
CYTO-GFP by MGRN1 through MASRPFAS may be responsible for the punctate 
cellular distribution I observed.  It will be interesting to determine whether ATRN-
Cyto-GFP is being recruited to the same endosomal site of TSG101/MGRN1 
interaction reported by Kim et al. (2007).  Direct recruitment of ATRN by MGRN1 is 
also compatible with my observation that HA-MGRN overexpression disperses 
ATRN-CYTO-GFP diffusely into the cytoplasm.  Presumably, overexpressed 
MGRN1 saturates the endogenous endosomal binding sites on Tsg101, leaving an 
excess of free cytoplasmic MGRN1 to compete with normally localized MGRN1 for 
ATRN-CYTO-GFP binding.  Interactions with this free cytoplasmic MGRN1 may 
underlie the dispersal of ATRN-CYTO-GFP by overexpression of MGRN1.  Finally, 
even if MGRN1 does not directly ubiquitinate ATRN or deliver it to the ESCRT 
machinery, MGRN1 may be important for ATRN/MC1R lysosomal trafficking simply 
because of its functional relationship with its known ubiquitination target, the 
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TSG101.  MGRN1-depleted cells have impaired ESCRT-dependent lysosomal 
trafficking of the epidermal growth factor receptor (EGFR), suggesting that loss of 
MGRN1 may cause a general defect in lysosomal trafficking (Kim et al., 2007).    
 As useful as GFP-tagged constructs are for investigating intracellular trafficking, 
there are important caveats for their use in degradation studies. For example, the 
normal, physiologically relevant, degradative pathways involved in regulating levels 
of a protein of interest may become saturated upon overexpression of the tagged 
protein, leading to loss of sensitivity in assays designed to measure the physiologically 
normal route of degradation and perhaps leading to the processing of “excess” tagged 
proteins through physiologically atypical channels.  In addition, the presence of the tag 
itself may be sufficient to alter the trafficking behavior or degradative dynamics of the 
proteins of interest. These considerations make it of paramount importance to examine 
the behavior of endogenous proteins whenever possible.  In the case of the molecules 
of the pigment-type switching system, the use of pigment cells rather than 
heterologous cell types may also be especially important as the mechanism of pigment 
type switching is tightly regulated and may be dependent on unknown details of 
melanocyte biology.  I will therefore turn to an investigation of ATRN, MGRN1, and 
MC1R in the melanocyte in the next chapter. 
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CHAPTER FOUR 
STUDIES OF ATRN, MGRN, AND MC1R IN MELANOCYTES 
 
Chapter Overview 
 Following up on the observations of tagged ATRN and MC1R in HEK293T cells 
reported in the previous chapter, Chapter Four extends the studies of ATRN, MGRN1, 
and MC1R to endogenous proteins and to the physiologically relevant cell type, the 
melanocyte. 
 
Introduction 
 Melanocytes are the major pigment-producing cells of the mammalian skin, 
occurring in hair follicles and scattered throughout pigmented epidermis. Melanocytes 
differentiate from neural-crest-derived precursors, migrating into their final locations 
during embryogenesis and maturing into highly dendritic cells specialized for the 
production and transfer of melanosomes to recipient keratinocytes.  The first mouse 
melanocyte lineages to be cultured in vitro were aggressively malignant cells derived 
from melanomas (Fidler, 1975), but methods were later developed for the culture of 
melanocyte precursors (melanoblasts) and eventually for the culture of mature 
melanocytes isolated from neonatal skin (Bennett, Cooper, and Hart, 1987).  Mature 
melanocytes can be immortalized by culturing with cholera toxin and the tumor 
inducer 12-O-tetradecanoylphorbol-13-acetate (TPA), allowing the establishment of 
immortal lines of melanocytes from different strains.  Melanocyte lines have been 
established from a wide selection of mouse pigmentation mutants, providing a rich 
resource for researchers wishing to use the pigment cell as a model system 
(Sviderskaya, Kallendar, and Bennett, 2010). To investigate my hypothesis that ATRN 
functions as a MGRN1-dependent, trans-acting lysosomal sorting factor for MC1R, I 
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studied ATRN, MGRN1, and MC1R in wild type and mutant melanocytes. 
 
Materials and Methods 
Melanocyte culture 
 Wild-type melan-a melanocytes (originating from C57Bl/6J mice and described 
in Bennett et al, 1987) were a gift from Dr. Dorothy Bennett.  Mutant melanocytes 
bearing null mutations in Atrn (melan-mg1, Atrn
mg-3J/mg-3J
), Mgrn1 (melan-md2, 
Mgrn1
md-nc/md-nc
) and Mc1r (melan-e, Mc1r
e/e
) were generated by Dr. Elena 
Sviderskaya at the Wellcome Trust Functional Genomics Cell Bank, in collaboration 
with Drs. Gregory Barsh and Dorothy Bennett, and have been described (Hida et al., 
2009). Cells were maintained under conditions described by Sviderskaya et al. (1997) 
with modifications for low CO2 culture.  Briefly, cells were grown in 5-6% CO2 in 
RPMI1640 culture medium supplemented with 10% fetal bovine serum (FBS), 2mM 
glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. FBS was obtained from 
SAFC Biosciences (Lenexa, Kansas). RPMI and culture medium supplements were 
obtained from Cellgro (Manassas, VA). Culture medium pH was adjusted to 7.0 with 
hydrochloric acid, and 200 nM TPA (Sigma-Aldrich, St. Louis, MO) was added 
before use. 
 
ASP and MSH treatment of melanocytes 
 Purified recombinant agouti protein was a generous gift from Drs. Elodie Le 
Pape and Vincent Hearing.  Its production has been described by Le Pape et al. 
(2008). ASP was added to culture medium at a dosage of 5 μl/ml, which was sufficient 
to cause a morphological change in recipient melanocytes (as also observed by Le 
Pape et al. [2008]).  MSH was purchased from Sigma-Aldrich and applied at 100nM. 
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Transfection of melanocytes 
 Melanocytes were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA) at a ratio of 9 μl Lipofectamine / 3μg DNA (for one well of a 6-well plate; 
quantities were scaled for other culture vessel sizes). The plasmids used are described 
in Chapter Three.  Transfection efficiency ranged from 2-10%.  
 
Confocal microscopy 
 Melanocytes were imaged using a Zeiss LSM510 Meta confocal microscope and 
images were collected using the LSM510 software package.  For visualization of 
lysosomes, melanocytes were treated with Lysotracker Red (Invitrogen, Carlsbad, CA) 
at 50-100 nM.  Cells were imaged 48 hours after transfection. 
 
Antibodies 
 The rabbit anti-mouse ATRN polyclonal antibodies ATRN-60 and ATRN-
1408 were produced against peptides from the cytoplasmic and extracellular region of 
ATRN, respectively; these antibodies were generous gifts from Dr. Gregory Barsh.  
All ATRN westerns depicted below were performed using the ATRN-60 antibody 
unless otherwise noted.  A rabbit anti-rat ATRN polyclonal was generously provided 
by Dr. Shuichi Ueda (Described in Nakadate et al., 2009), and Dr. Vincent Hearing 
kindly shared the pep-19 rabbit anti-mouse MC1R antibody (Rouzaud et al., 2003).  
Anti-ATRN antibodies were used for western blotting at 1:1000 dilution.  Other 
antibodies were purchased from commercial sources, including rabbit anti-MGRN1 
(Proteintech, Chicago, IL), the FK2 mouse monoclonal anti-ubiquitin (Biomol, 
Plymouth Meeting, PA), rabbit anti-SUMO1 (Cell Signaling Technologies, Beverly, 
MA), and the goat anti-MC1R polyclonals N-19 and L20 (Santa Cruz Biotechnology, 
Santa Cruz, CA). 
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Western Blotting   
 Confluent 10 cm plates of melanocytes were scraped and lysed in 200 uL of a 
cell lysis buffer (50 mM Tris-HCl, pH 8.0; 1% Igepal CA-630; 1 mM EDTA; 10 mM 
iodoacetamide), frozen and thawed once, and spun at 2000 rpm in a benchtop 
microcentrifuge for 5 minutes at 4
o
C to pellet cell debris.  The protein concentration of 
the cleared supernatant was measured by bicinchonic acid (BCA) assay (Pierce) using 
a Nanodrop spectrophotometer, and 10 ug total protein was combined with a 3X SDS 
sample buffer (180 mM Tris-HCl pH 6.8, 15% glycerol, 9% SDS, 0.075% 
bromophenol blue).  Samples were routinely boiled before loading, unless MC1R was 
to be visualized, and -mercaptoethanol was omitted from samples for anti-ATRN 
immunoblot as it greatly reduced the strength of the signal.  Samples were run under 
standard SDS-PAGE conditions (Laemlli, 1970) in 8-15% polyacrylamide gels and 
transferred electrophoretically to Immobilion-P membrane (Millipore, Billerica, MA).  
After blocking for one hour with 5% dry milk in TBS/T (100 mM Tris, pH7.5; 0.9% 
NaCl; 0.1% Triton X-100), primary antibodies were applied diluted in TBS/T for 1-3 
hours.  After incubation with horseradish-peroxidase (HRP) conjugated secondary 
antibodies and washing in TBS/T, blots were visualized using SuperSignal West Pico 
or Dura chemiluminescent substrates (Pierce Biotechnology, Rockford, IL). 
For deglycosylation of proteins, cleared cell lysates prepared as for western blotting 
were denatured at 95 
o
C for 5 minutes in 1% SDS.  1% NP-40 and 1.5 U/μg peptide 
N-glycosidase (PNGase F; New England Biolabs, Ipswich, MA,) were added and the 
lysates were incubated at 37 
o
C for three hours.  SDS sample buffer was added and the 
samples were heated to 95 
o
C for 5 minutes before separation by SDS-PAGE and 
analysis by Western blot.  
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Results 
ATRN-GFP traffics through the endosomal/lysosomal pathway in melanocytes 
 Melan-a cells were transfected with ATRN-GFP in order to observe the 
trafficking behavior of ATRN in this physiologically relevant cell type. ATRN-GFP in 
melanocytes exhibited a primarily endosomal distribution, similar to that seen in 
HEK293T cells. The low transfection efficiency obtained in melanocytes made 
cotransfection with compartment-specific marker proteins impracticable; however, 
treatment with Lysotracker Red revealed significant colocalization of ATRN-GFP 
signal with late endosomes/lysosomes.  Time-lapse images recorded ATRN-GFP-
labeled endosomes fusing with late endosomal/lysosomal compartments (Figure 
4.1A). Trafficking of ATRN-GFP was not unidirectional; in some instances, ATRN-
GFP signal could be observed fusing transiently with late endosomes/lysosomes and 
then withdrawing, suggesting that ATRN-GFP may occupy the limiting membrane of 
MVBs rather than the intralumenal vesicles. 
Lysosomal targeting of ATRN-GFP is lost in MGRN1-null melanocytes. 
 As described in Chapter Three, overexpression of MGRN1 caused a 
relocalization of the GFP-tagged ATRN cytoplasmic tail construct, suggesting that 
MGRN1 may be required for normal late endosomal/lysosomal trafficking of ATRN.  
Therefore, I transfected Mgrn1 null (melan-md2) cells with ATRN-GFP and compared 
the lysosomal trafficking of ATRN-GFP in these cells with that of wild-type cells, 
using Lysotracker Red.  In melan-a cells, ATRN-GFP-labeled endosomes were 
observed actively trafficking to and fusing with Lysotracker Red-labeled structures 
over a time scale of minutes (Figure 4.1A).  In melan-md2 cells this trafficking was 
lost; rather than occurring in small endosomes that trafficked to lysosomes, ATRN-
GFP was localized to large, amorphous compartments that were static over the time 
scale observed (3 minutes) and did not colocalize with Lysotracker Red (Figure 4.1B). 
  96 
Appearance of ATRN by Western blot 
 Because artifacts associated with overexpression of tagged constructs can cause 
trafficking abnormalities, it is desirable to examine the behavior of the endogenous 
protein using an appropriate antibody.  To that end, I characterized several available 
antibodies generated against fragments of the ATRN protein.  A commercial rabbit 
anti-mouse ATRN polyclonal (Abcam) and a rabbit anti-rat ATRN polyclonal kindly 
shared by Shuichi Ueda and used by his lab for extensive characterization of ATRN 
protein expression in the rat brain (Nakadate, Sakikibara, and Ueda, 2008) failed to 
produce specific signal (that is, signal not also evident in extracts from Atrn
mg-3J/mg3J
 
cells) in my hands, and failed to label ATRN-GFP in extracts from cells transfected 
with the tagged construct (data not shown).  Better results were seen with the rabbit 
polyclonal antibody Atrn-60, which was raised against a peptide from the 
extracellular/lumenal domain of ATRN and which specifically labels a ~220-240 kD 
 
Figure 4.1.  A. ATRN-GFP traffics to lysosomes in wild-type melanocytes. Frame 
from a representative time-lapse image showing rapid trafficking of ATRN-GFP-
labeled endosomes to lysosomes labeled with Lysotracker Red.  B. Loss of lysosomal 
trafficking of ATRN in Mgrn1
md-nc/md-nc
 melanocytes. Frame from a representative 
time-lapse image showing ATRN-GFP in large, amorphous, static compartments that 
do not traffic to lysosomes in Mgrn1- deficient cells.  
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doublet in wild-type melan-a cells (Figure 4.2).  The appearance of the doublet is 
reminiscent of the doublet seen for ATRN-GFP and presumably represents a 
difference in the post-translational modification state of some of the ATRN molecules.  
An identical set of bands was seen on blots probed with the anti-ATRN antibody 
ATRN-1408, which was raised against a peptide from the cytoplasmic tail of ATRN 
(data not shown). For unknown reasons, the inclusion of -mercaptoethanol in the 
sample-loading buffer greatly reduced signal intensity (data not shown). As was seen 
for the ATRN-GFP tagged construct (see Chapter Three), a high-molecular-weight 
smear was visible in anti-ATRN western blots of unreduced lysates, suggesting that 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Appearance of ATRN by Western blot of melanocyte lysates.  Most ATRN 
signal occurs as a doublet of approximately 220-240 kD. Higher molecular weight 
signal is likely to represent an ATRN dimer or oligomer.  Asterisk marks faint ATRN 
signal at approximately 160 kD, near the predicted mass of the unmodified native 
protein (158 kD) and perhaps representing nascent ATRN without post-translational 
modifications. 
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dimerization or oligomerization of ATRN is a feature of the native protein and not an 
artifact caused by the GFP tag.  A faint specific band at approximately 160 kD was 
sometimes observed.  As this is near the predicted molecular weight (158 kD) of the 
unmodified ATRN peptide, this band may represent nascent ATRN without post-
translational modifications. 
 
Melanosomal ATRN does not accumulate during lysosomal inhibition 
 Because ATRN-GFP can be observed trafficking to lysosomes in melanocytes, I 
expected that endogenous ATRN would accumulate if lysosomal proteases were 
inhibited by addition of chloroquine to the culture medium.  Contrary to this 
expectation, overnight chloroquine treatment (100uM) reduced levels of endogenous 
ATRN protein (Figure 4.3A).  Chloroquine treatment disproportionately affected the 
lower band of the ATRN doublet, causing its near disappearance.  
 
Melanosomal ATRN does not accumulate during lysosomal inhibition 
 Because ATRN-GFP can be observed trafficking to lysosomes in melanocytes, I 
expected that endogenous ATRN would accumulate if lysosomal proteases were 
inhibited by addition of chloroquine to the culture medium.  Contrary to this 
expectation, overnight chloroquine treatment (100uM) reduced levels of endogenous 
ATRN protein (Figure 4.3A).  Chloroquine treatment disproportionately affected the 
lower band of the ATRN doublet, causing its near disappearance.  
 
Behavior of ATRN upon ASP and MSH treatment 
 To determine whether either of the ligands of the mouse MC1R have an effect 
on ATRN protein levels or post-translational modification, I treated melan-a cells with 
recombinant murine ASP (1:100 dilution) or MSH (100nM) overnight.  Neither  
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Figure 4.3. Response of endogenous ATRN to lysosomal inhibition and treatment with 
ligands of the MC1R.  All lanes represent independent replicates.  Each experiment 
was performed twice with similar results.  A. Upper panel: ATRN protein levels were 
reduced after 12 hour treatment with 100μM chloroquine, with an especially 
pronounced reduction of the lower band of the monomer doublet. Lower panel: a 
lower region of the blot showing several non-specific bands to demonstrate even 
loading.  B. Upper panel: overnight treatment with 10 μl/ml ASP caused no change in 
ATRN protein levels but appeared to increase the intensity of ATRN signal at high 
molecular weight. Lower panel: lower region of blot stained with Ponceau S red to 
demonstrate even loading. C. Upper panel: modest reduction in ATRN protein levels 
after overnight treatment with 100 nM MSH. Lower panel: GAPDH loading control.  
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treatment caused an obvious change in the appearance of the ATRN doublet, and ASP 
did not affect the level of ATRN protein in treated cells (Figure 4.3B).  MSH 
treatment resulted in a slight decrease in ATRN protein levels (Figure 4.3C).  
Treatment with ASP appeared to increase the relative intensity of ATRN signal at high 
molecular weight, perhaps reflecting an increase in formation of ATRN oligomers. 
 
N-linked glycosylation of ATRN is abnormal in Mgrn1 mutant melanocytes 
 Since lysosomal inhibition caused a change in the relative intensity of the bands 
of the ATRN doublet, it seemed possible that the loss of MGRN1-directed lysosomal 
trafficking of ATRN might also cause a change in the post-translational modification 
state of ATRN.  To test this possibility, extracts of melan-a and melan-md2 cells were 
run on SDS-PAGE gels side-by-side and blotted for ATRN.  MGRN1-deficient cells 
showed a decrease in ATRN protein levels as well as a decrease in the apparent 
molecular weight of the ATRN bands (Figure 4.4a). Instead of forming a normal 
ATRN doublet at 220-240 kD, the majority of ATRN signal in melan-md2 cells was 
seen at an apparent molecular weight of ~160 kD.  To determine whether direct 
ubiquitin ligase or SUMO ligase activity of MGRN1 might contribute to the observed 
size difference, ATRN was immunoprecipitated from melan-a and melan-md2 cells 
and SDS-PAGE-separated proteins from the immunoprecipitations were 
immunoblotted with antibodies against SUMO1 and ubiquitin.  No ubiquitinated or 
sumoylated ATRN was observed (data not shown).  As human ATRN has been 
reported to be N-glycosylated (Duke-Cohan et al., 1995) I treated extracts of melan-a, 
melan-md2, and melan-mg1 cells with peptide N-glycosidase F (PNGase F) to remove 
N-linked polysaccharides.  Upon PNGase F treatment, the appearance of 
deglycosylated ATRN in melan-a and melan-md2 cells was identical, demonstrating 
that the difference in apparent molecular weight of ATRN in MGRN1-deficient cells  
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Figure 4.4. ATRN is abnormally glycosylated in Mgrn1 null melanocytes. A & B. 
melan-md2 cells lose most of the higher m.w. band of the ATRN doublet and have 
reduced ATRN levels overall. Withdrawal of TPA from the culture medium promotes 
strong appearance of the ~160 minor ATRN band in melan-md2 cells. C. Size 
differential of ATRN bands disappears after PNGase F treatment. Blots are 
representative examples of at least three independent replicate experiments. 
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was due to aberrant or incomplete N-linked glycosylation. Upon deglycosylation, the 
ATRN signal in either cell type appears at an apparent molecular weight of ~130 kD, 
with additional bands at ~110 and ~100 kD (Figure 4.4C).  I observed that the 
intensity of the ~160 kD ATRN band in melan-md2 cells was sometimes especially 
pronounced on blots made using quiescent cells.  Withdrawal of TPA (which 
stimulates proliferation of melanocytes by activation of adenylyl cyclase) for 24 hours 
similarly increased the intensity of the 160 kD band (Figure 4.4B).  If the 160 kD band 
represents nascent peptide that is not yet fully glycosylated, the increase in the 
intensity of this band in melan-md2 cells grown without TPA suggests that 
proliferating melanocytes downregulate the production of ATRN, and also suggests a 
delay in maturation of nascent ATRN in Mgrn1 mutant cells. 
 
MC1R-GFP traffics to lysosomes in melanocytes. 
 As described in the previous chapter, MC1R-GFP transiently expressed in 
HEK293T cells trafficked through the endosomal/lysosomal pathway.  To determine 
whether this behavior also occurs in melanocytes, MC1R-GFP-transfected melan-a 
cells 
were treated with Lysotracker Red and imaged by confocal microscopy  (Figure 
4.5A).  Some colocalization of MC1R-GFP with lysosomes was visible in control 
cells, 
control cells, and MC1R-GFP labeled vesicles were observed trafficking to and fusing 
with lysosomes.  Colocalization of MC1R-GFP signal with Lysotracker Red was 
prominent in many cells treated with ASP for four hours prior to imaging (Figure 4.5).  
However, the high degree of variability in MC1R-GFP expression from cell to cell 
made it difficult to determine whether the apparent increase in colocalization was real, 
or an artifact of different transfection efficiencies from plate to plate.  
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 Figure 4.5. MC1R-GFP traffics to late endosomes/lysosomes in melanocytes.  A. 
Melan-a cells were transfected with MC1R-GFP and acidic organelles were labeled 
with Lysotracker Red.  Note colocalization of MC1R-GFP signal with Lysotracker 
Red signal.  B. Melan-a cells transfected with MC1R-GFP were treated with 
recombinant ASP for 3 hours prior to Lysotracker Red treatment and visualization.  
Some cells were identifiable with high levels of MC1R-GFP/lysosome colocalization, 
although cell-to-cell variability in MC1R-GFP expression from complicates 
interpretation of relative colocalization rates compared to untreated control (see text).  
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Characterization of MC1R antibodies 
 That ATRN-GFP and MC1R-GFP both traffic to lysosomes in melanocytes 
suggests that endogenous ATRN could target MC1R to the lysosome by an ASP and 
MGRN1-dependent process.  As transient transfection of melanocytes resulted in 
mostly weak and generally variable MC1R-GFP expression levels, colocalization of 
MC1R-GFP with lysosomes was difficult to quantify with confidence.  An alternative 
experimental approach was therefore pursued using antibodies against endogenous 
MC1R. The detection of MC1R protein by western blot presents special challenges. 
The protein is small and consists largely of hydrophobic transmembrane helices, 
which make poor epitope targets for antibody generation.  Furthermore, the highly 
hydrophobic nature of the receptor is likely to make it vulnerable to irreversible 
aggregation during routine pre-loading boiling of the sample, leading to inability of 
the MC1R aggregates to enter the electrophoretic gel and resulting in loss of signal 
(Sturm et al., 2003; Eberle, 1988; Schioth et al., 1996).  Unfortunately, this problem is 
not universally recognized in the field and several groups have reported MC1R signal 
from boiled lysates, sometimes without showing adequate controls to demonstrate the 
specificity of the band reported (e.g., Chakraborty and Pawelek, 1993; Moustafa et al., 
2002; Salazar-Onfray et al., 2002; Rouzaud et al., 2003; Rouzaud et al., 2006), fueling 
contention in the field over the question of what tissue types express MC1R (e.g. see 
Roberts, Newton, and Sturm, 2007).  In my hands, the use of boiled lysates resulted in 
the total loss of MC1R-GFP signal from anti-GFP western blots (data not shown), 
supporting concerns about irreversible aggregation of MC1R by heat.  Two highly 
cited commercially available MC1R antibodies (the N-19 and L-20 goat anti-rabbit 
polyclonals from Santa Cruz Biotechnology) failed to detect MC1R-GFP expressed in 
HEK-293T cells, and the bands that they recognized on blots from melanocyte lysates 
were unaffected by boiling. The pep-19 rabbit polyclonal (Rouzaud et al., 2003; 
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Rouzaud et al, 2004; Rouzaud et al., 2006) similarly failed to recognize tagged MC1R 
in HEK293T lysates, or any heat-labile band in melanocyte lysates. These 
observations suggest that these antibodies do not recognize mouse MC1R.   
 
Discussion  
Loss of endo/lysosomal trafficking of ATRN in Mgrn1 mutant melanocytes suggests 
trafficking of ATRN is important for pigment-type switching and CNS integrity  
 As was observed for heterologous cell types in Chapter Three, ATRN-GFP 
traffics constitutively to late endosomes/lysosomes in wild-type melanocytes. 
Significantly, the data presented in this chapter demonstrate that this trafficking is lost 
in Mgrn1 null mutant melanocytes.  Because Mgrn1-null homozygotes develop similar 
pigmentation and neurodegeneration phenotypes to those seen in Atrn mutants, this 
observation suggests that loss of Atrn trafficking through the endolysosomal pathway 
causes hyperpigmentation and spongiform change in both Atrn and Mgrn1 mutants.  
My observation of Mgrn1-dependent endolysosomal trafficking of ATRN-GFP in 
melanocytes is consistent with data produced by others in our laboratory, who have 
shown that ATRN-GFP is degraded in lysosomes of HEK293T cells, and that 
overexpression of a catalytically inactive mutant MGRN1 prevents lysosomal 
degradation of ATRN (Caroline Wee, personal communication).  Unlike 
overexpressed ATRN in HEK293T cells, however, endogenous ATRN does not 
appear to be rapidly degraded in lysosomes, as inhibition of lysosomal proteases does 
not cause a buildup of ATRN in melanocytes.   As ATRN-GFP signal could 
sometimes be observed trafficking out of Lysotracker Red-labeled compartments after 
transient fusion, it is possible that endogenous ATRN in melanocytes preferentially 
occupies the limiting membrane of the MVB and is recovered after lysosomal fusion 
via a retrograde trafficking pathway.  If ATRN is a lysosomal sorting factor for 
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associated signaling receptors such as the MC1R, retrieval of ATRN for repeated use 
in the endolysosomal trafficking system would increase the efficiency with which 
target receptors are degraded.  The well-studied cathepsin lysosomal trafficking 
pathway offers canonical examples of an analogous arrangement.  Cathepsins are 
soluble lysosomal hydrolases that reach the lysosome with the assistance of 
transmembrane helper proteins, the best known of which are the mannose-6-phosphate 
receptors (M6PR) (for review see Ghosh, Dahms, and Cornfeld, 2003; Braulke and 
Bonifacino, 2009).  These receptors recognize phosphorylated N-glycosyl groups 
applied to cargo molecules in the trans-golgi , and escort the proteins so decorated 
from the trans-Golgi to late endosomes.  After delivering its cargo to the endosomal 
pathway, M6PR is retrieved from the late endosomal membrane and returned to the 
trans-Golgi through a retrograde trafficking pathway.  The example of the M6PR and 
other lysosomal enzyme sorting proteins such as sortilin (Canuel et al., 2008) shows 
that for accessory sorting proteins, traffic to the late endosome need not be a one-way 
trip.   
 
The cell biology of MC1R-GFP in melanocytes is compatible with a role for ATRN as 
an ASP-activated, MGRN1-dependent, trans-acting lysosomal targeting factor for 
MC1R. 
 My observations of MC1R-GFP trafficking to lysosomes in melanocytes are 
consistent with the hypothesis of MC1R downregulation by ATRN-dependent 
lysosomal targeting. A model incorporating my observations with the known genetic 
and biochemical features of pigment-type switching is presented in Figure 4.6.  As 
argued above, the observation that the lysosomal trafficking of ATRN is MGRN1-
dependent suggests that the lysosomal trafficking of ATRN is important for 
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Figure 4.6. A unified model showing the proposed mechanism of action of ATRN and 
MGRN1 in pigment-type switching.  MC1R encounters ASP at the cell surface and 
forms a ternary complex with ASP and ATRN either at the cell surface or in an 
endosomal compartment.  Interactions with MGRN1 promote the sorting of both 
proteins to regions of ESCRT protein activity on incipient multivesicular bodies 
(MVBs), and ubiquitination of TSG101 by MGRN1 also promotes ESCRT function.  
MC1R is sorted by ESCRT activity into the intralumenal vesicles of the MVB, which 
fuses with lysosomes to deliver MC1R for degradation by lysosomal hydrolases. ERC: 
Endosome Recycling Complex.  Ub: ubiquitin. 
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downregulation of MC1R signaling.  Mutual binding of ATRN and MC1R to ASP is 
likely to promote the demonstrated physical interaction of the ATRN and MC1R 
cytoplasmic tails, potentially linking the trafficking fate of MC1R to that of ATRN.  
MGRN1-dependent trafficking of ATRN could therefore promote MC1R delivery to 
the lysosome, providing a plausible explanation for the ASP, ATRN, and MGRN1-
dependent nature of pigment-type switching and for observations by others that ASP 
administration causes a reduction in MC1R protein levels.  As efforts by myself and 
by Perez-Oliva et al. (2009) have failed to show that MGRN1 ubiquitinates either 
ATRN or MC1R, MGRN1 is depicted in Figure 4.6 as using its known interactions 
with MC1R, ATRN, and TSG101 to promote both the sorting of MC1R to ESCRT, 
and the function of the ESCRT complex itself.   
 This model predicts that MC1R protein levels in wild-type melanocytes will 
decrease upon ASP treatment, but not upon concurrent treatment with ASP and 
lysosomal inhibitors such as chloroquine; conversely, lysosome-dependent MC1R 
degradation will not occur in ASP-treated Atrn or Mgrn1 mutant cells.  The major 
obstacle to testing these predictions is the lack of a validated antibody capable of 
specifically identifying endogenous MC1R from mouse melanocytes.  Future efforts 
towards refining the model of pigment-type switching presented here should focus on 
overcoming this technical obstacle. 
 
Future directions: abnormal glycosylation status of ATRN is a novel signature of 
MGRN1 deficiency 
 The data related here demonstrate an unexpected feature of ATRN in Mgrn1 
mutant melanocytes: abnormal N-linked glycosylation.  Whereas wild-type cells show 
a doublet at 220-240 kD, in proliferating melan-md2 cells ATRN is represented 
primarily by the 220 kD band (with a trace of signal representing the attenuated upper 
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band of the doublet).  In addition, the 160 kD band is intensified in melan-md2 cells 
under conditions of TPA deprivation.  All of these protein mobility differences 
between ATRN in melan-a and melan-md2 cells disappear when the lysates are treated 
with PNGase F before electrophoresis, strongly suggesting that the difference in 
apparent molecular weight is due to abnormal N-linked glycosylation of ATRN in 
Mgrn1 mutants.   
 Glycosylation is important for many aspects of function in different proteins, so 
there are many ways in which abnormal glycosylation might adversely affect the 
functionality of ATRN.  Glycosylation is believed to be important for efficient protein 
folding in the ER because the large carbohydrate groups increase the solubility of 
nascent polypeptide chains, simultaneously shielding transiently unfolded 
hydrophobic surfaces from participating in inappropriate interactions.  Incorrect 
glycosylation can also trigger the intervention of ER quality control machinery and 
inhibit protein export from the ER.  Therefore, a failure of glycosylation resulting in 
ER retention could explain the aberrant localization of ATRN-GFP in melan-md2 
cells.   Outside of the biosynthetic pathway, abnormal glycosylation can adversely 
affect protein function by altering ligand binding specificity or avidity, or by altering 
interactions with components of the extracellular matrix.  ATRN in Mgrn1 mutant 
cells might therefore have impaired ability to bind MC1R and/or ASP.  Additionally, 
the presence of a conserved C-type lectin carbohydrate-binding domain on ATRN 
suggests that interactions with glycosyl groups are important for its function, so 
altered glycosylation of ATRN could adversely affect its ability to participate in 
homo-oligomerization interactions through its C-type lectin domain.  In light of this 
possibility, it’s interesting to note that the intensity of the high molecular weight 
“oligomeric ATRN” smear appears to increase in intensity in cells treated with ASP 
(Figure 4.3 B), while consistently appearing reduced in intensity on western blots of 
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melan-md3 lysates (Figure 4.4 A&B).   If oligomerization is important for ATRN 
function, these observations would suggest that ASP promotes oligomerization in a 
MGRN1-dependent manner.  
 How exactly MGRN1 deficiency causes abnormal ATRN glycosylation is an 
interesting question for future study.  It is not obvious how MGRN1’s effect on 
lysosomal trafficking of ATRN could feed into the canonical pathway of N-linked 
glycosylation, which occurs in the secretory pathway in the ER and Golgi apparatus.  
As endogenous ATRN appears not to be degraded in the lysosome in melanocytes, it 
is possible that a retrograde trafficking pathway analogous to that followed by the 
M6PR could be responsible for cycling ATRN back to the Golgi or trans-Golgi, where 
repeated exposure to Golgi-resident glycosylation-modifying enzymes could effect the 
glycosylation state of ATRN over repeated rounds through this compartment.  A block 
in ATRN trafficking in Mgrn1 mutant cells could alter this trafficking itinerary in a 
way that prevents formation of the higher molecular weight band of the 220-240 kD 
doublet.   For unknown reasons, the upper band of the ATRN doublet that is lost in 
Mgrn1 mutant melanocytes becomes the major ATRN band (at the expense of the 
lower band of the doublet) in the presence of chloroquine (Figure 4.3A).  It is not clear 
what this means.  It is interesting to note that lysosomal inhibition caused a decrease in 
ATRN protein levels, a counterintuitive result that may represent a downregulation of 
Atrn transcription by stressed melanocytes.  Since the higher molecular-weight band 
of the doublet is the only remaining band in this situation, this could be interpreted as 
a “fully mature” form of ATRN, representing the final state of the last bolus of ATRN 
peptide to persist after ATRN biosynthesis shuts down. The question of how ATRN 
protein levels are reduced in the absence of lysosomal function is a puzzling one; as a 
transmembrane protein, ATRN would be expected to undergo degradation mainly 
through lysosomal or autophagic pathways (which also require lysosomal function). 
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While lysosomal inhibition does stress the cells (cell death is evident in plates of 
melanocytes treated with chloroquine or ammonium chloride for 24 hours), under the 
conditions used cell death at 12 hours did not occur. This rules out the possibility that 
average ATRN levels go down in chloroquine-treated plates because of selective death 
of cells expressing the most ATRN.  Since ATRN levels fall during lysosome 
inhibition, it is possible that chloroquine-treated cells may reduce ATRN levels 
through an unexpected non-lysosome-dependent pathway such as cleavage by 
secretases or secretion in exosomes. Regarding this last possibility, it should be noted 
that melanocytes in cell culture do shed plentiful small membrane-bound structures 
(possibly melanosomes or exosomes) into the culture medium (data not shown).  
Whether these structures could act as sinks for ATRN under conditions of lysosomal 
inhibition is unknown. 
 
From the melanocyte to the brain: implications for the mechanism of spongiform 
neurodegeneration. 
 This chapter presents a model of ATRN and MGRN function in the pigment-
type switching pathway that attempts to explain the shared pigmentation phenotypes 
of Atrn and Mgrn1 mutant mice.  A question of major interest is whether this model 
can be extended to the central nervous system to explain the shared neuropathological 
phenotype of these mutants.  The next chapter explores the implications of my studies 
of Atrn and Mgrn1 function for the mechanism of spongiform neurodegeneration.   
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CHAPTER 5 
 NEURODEGENERATION AS A CONSEQUENCE OF ESCRT DYSFUNCTION 
 
Chapter Overview 
 This chapter returns to the subject of spongiform change reviewed in Chapter 
One, extending the model of ATRN/MGRN1 interaction proposed for the pigment cell 
to hypothesize that failure of endo/lysosomal trafficking at the point of multivesicular 
body sorting by ESCRT proteins could cause an accumulation of abnormal 
intracellular membrane, thereby giving rise to the vacuoles of spongiform 
neurodegeneration.  The literature on the consequences of neural ESCRT loss-of-
function is reviewed, and a proof-of-concept experiment is described which tests this 
hypothesis by knocking out the ESCRT gene Tsg101 in the neurons of the adult mouse 
forebrain.  Preliminary data supporting the hypothesis are reported.  These results are 
integrated with the known biology of spongiform neurodegeneration in retroviral and 
prion-related diseases, and a unified hypothesis of spongiform change is proposed 
suggesting that the immediate cause of spongiform change in these diseases is ESCRT 
sequestration by exogenous (in the case of retrovirus-associated disease) or 
endogenous (in the case of prion disease) retroviral capsid proteins. This hypothesis 
suggests that antiretroviral therapy could be an efficacious treatment for prion 
diseases. 
 
There and back again: from pigment-type switching to spongiform 
neurodegeneration 
 As discussed in Chapter One, the goal of my studies of ATRN and MGRN1 in 
the pigment cell model system is to understand the mechanism that, when disrupted, 
leads to spongiform change in the brain.  In the pigment-type switching pathway, loss 
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of ATRN and loss of MGRN1 produce identical phenotypes.  As described in 
Chapters Three and Four, studies of these proteins in cell culture demonstrate that 
MGRN1 is important for the normal lysosomal trafficking of ATRN. Taken together, 
these observations suggest that loss of normal lysosomal trafficking (of ATRN and 
perhaps also ATRN-interacting proteins such as MC1R) may be the fundamental 
defect underlying the shared phenotypes of Atrn and Mgrn1 mutant mice.  This 
hypothesis is supported by the recent realization that MGRN1 interacts with and 
ubiquitinates TSG101, a component of the lysosomal protein sorting ESCRT 
machinery (Kim et al., 2007; Jiao et al., 2009a). By what mechanism might loss of 
ATRN’s normal lysosomal trafficking underlie spongiform change in both Atrn and 
Mgrn1 null mutants?  In the melanocyte, this impairment seems likely to prevent the 
downregulation of signaling through the ATRN interactor, MC1R, perhaps suggesting 
that similar dysregulation of an unknown ATRN-interacting GPCR in the brain could 
underlie spongiform change in Atrn and Mgrn1 mutants through an unknown 
pathological pathway. (Dysregulation of MC1R in the brain cannot explain 
spongiform neurodegeneration in these mutants, as hyperactive mutant alleles of Mc1r 
produce no overt neurological phenotypes.)  A more interesting possibility is that the 
failure of a subset of lysosomal protein trafficking events per se, rather than the 
dysregulation of any particular GPCR, underlies spongiform neurodegeneration in 
these mutants.  One can imagine that transmembrane proteins such as ATRN and 
MC1R, if unable to traffic normally to the lysosome, might simply accumulate along 
with their associated membrane.  In long-lived, non-dividing cells (such as most 
neurons of the CNS), this abnormal accumulation of membrane could eventually 
appear as an intracytoplasmic vacuole. To the extent that such a primary defect in 
lysosomal protein trafficking would impede housekeeping functions such as clearance 
of autophagosomes (which requires autophagosomal fusion with functioning 
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lysosomes) or myelination and myelin maintenance (which makes tremendous 
demands on the membrane-trafficking machinery of oligodendrocytes in the CNS), 
additional membranous abnormalities could accumulate as a secondary consequence 
of a lysosomal protein trafficking defect. 
 
ESCRT dysfunction and the “class E vps compartment” 
 In fungi and in mammalian cells, abnormal membranous accumulations have 
been shown to occur as a consequence of ESCRT protein depletion.  As discussed in 
Chapter Three, ESCRT proteins form large complexes on the limiting membranes of 
incipient multivesicular bodies (MVBs), where they sort lysosomally targeted 
membrane proteins into intralumenal vesicles in preparation for their delivery to the 
lysosome (Reviewed by Saksena et al., 2007).  Deletion of members of this class of 
proteins in yeast severely disrupts normal trafficking of target proteins to the yeast 
vacuole (a large lysosome-like organelle) (Raymond et al., 1992).  The morphological 
consequence of this disruption is the “class E vacuolar protein sorting (vps) 
compartment,” which is an accumulation of an abnormal multilamellar membranous 
structure within the cytoplasm (Rieder et al., 1996, see Figure 5.1A)  The class E vps 
compartment contains vacuole-targeted proteins such as vacuolar hydrolases and 
vacuolar H(+)-ATPase subunits, suggesting that it represents a “stalled” prevacuolar 
compartment that is unable to progress toward fusion with the yeast vacuole.   
 A similar aberrant compartment has been reported to form in mammalian cells 
depleted of the ESCRT protein (and MGRN1 ubiquitination target) TSG101 (Doyotte 
et al., 2005; see figure 5.1B).  As MGRN1 appears to be important for the normal 
function of TSG101 (Kim et al., 2007), it is possible that Mgrn1 mutant cells in the 
CNS experience ESCRT dysfunction and develop a class E vps compartment.  Could 
this be the origin of the vacuoles of spongiform change in these mutants?  As shown in 
  117 
Figure 5.1, images of class E vps compartments in yeast and mammalian cells 
consistently show tightly laminated, concentric layers of membrane, which at first 
glance do not greatly resemble the more open cytoplasmic vacuoles of spongiform 
change.  Why the class E vps compartment adopts this tightly laminated morphology 
is not understood.  As these compartments are experimentally induced using RNAi 
transfection or temperature-sensitive yeast mutants, it is also not known whether the 
compact multilamellar morphology is maintained over time periods of more than a 
few days, or if indeed the initially compact morphology of a newly generated class E 
vps compartment is only an ephemeral stage that gives way over time to more 
disorganized vacuolar appearance. 
 
 
Figure 5.1. Appearance of class E vps compartments in yeast and mammalian cells. A. 
Class E vps compartment in vps28 mutant yeast (Rieder et al., 1996). B: Class E vps 
compartment in TSG101-depleted HeLa cells (Doyotte et al., 2005). Scale bar in B is 
0.5 μm. Images used by permission. 
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Downstream consequences of ESCRT malfunction: autophagosome accumulation 
provides another potential source of vacuolar membrane. 
 Whether or not the class E vps compartment directly contributes to accumulation 
of spongiform vacuoles, it seems clear that the consequences of ESCRT disruption can 
extend beyond impairment of the endosomal-lysosomal pathway to affect related 
pathways in the intracellular trafficking network.  These downstream trafficking 
disruptions must also be considered as potential sources of aberrant membranous 
accumulations.  Depletion of the ESCRT-III protein SNF7-2 causes not only the 
disruption of ESCRT sorting, but also the accumulation of autophagosomes in Snf7-2 
RNAi-treated neurons in culture (Lee et al, 2007).  Along with the accumulation of 
morphologically identifiable autophagosomes, these neurons also develop non-
compact membranous abnormalities ultrastructurally reminiscent of the spongiform 
vacuoles observed in Atrn mutants and prion diseases (Figure 5.2 B).  Similar 
abnormalities are seen in neurons transfected with a mutant form of the SNF7-2-
interacting protein CHMP2B, another member of ESCRT-III (Figure 5.2 A).   The 
mutant form of CHMP2B, known as CHMP2B
exon5
, binds avidly to SNF7-2 and 
inhibits the repeated rounds of ESCRT-III assembly and disassembly that are 
necessary for ESCRT-III function (Lee et al., 2007).  Depletion of SNF7-2 or 
transfection with CHMP2B
exon5
 appears to induce autophagosome accumulation by 
causing a block in autophagosome maturation (Lee and Gao, 2008). As 
autophagosome maturation involves fusion of the autophagosome with MVBs (Lecocq 
and Walker, 1997; Bampton et al, 2005; Eskelinen 2005), it is not surprising that the 
disruption of MVB formation by ESCRT impairment should feed forward to impair 
autophagosome maturation as well.   In cell culture, this accumulation of 
autophagosomes appears to be directly neurotoxic, as SNF7-2-depleted neurons 
exhibit high mortality that is partly suppressed by autophagy inhibitors (Lee, Liu, and 
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Gao, 2009).  Given the considerable ultrastructural resemblance between the vacuoles 
of spongiform change and the non-compact “vacuolar” structures in ESCRT-III 
depleted cells, it is tempting to speculate that autophagosome accumulation 
downstream of a block in MVB maturation could be an additional source of 
spongiform vacuolar membrane. Data to support or refute this hypothesis are few; to 
date, neither Snf7-2 nor Chmp2B disruption has been studied in the context of the 
whole mouse brain.  Interestingly, however, the Chmp2B
exon5
 mutation does occur in 
one Danish kindred, in which it causes an autosomal dominant form of familial 
frontotemporal dementia (FTD) (Brown et al., 1995; Skibinski et al, 2005; Momeni et 
al., 2006).  Available autopsy reports, while describing the major neuropathological 
feature of this rare form of FTD as a global cortical and central atrophy, do each 
briefly mention the presence of cortical “spongiosus” or “microvacuolation” (Gydesen 
et al., 2002; Yancopoulou et al, 2003).  The contribution of autophagosome 
accumulation to spongiform neurodegeneration in ESCRT mutants thus remains an 
intriguing possibility. 
 
Figure 5.2. Abnormal vacuolar structures derived from accumulated autophagosomes 
in ESCRT-III depleted cells.  A: Autophagosome accumulation in Drosophila neurons 
expressing CHMP2B
intron5
. B: Autophagosome accumulation in cultured mouse 
cortical neurons expressing Snf7-2 RNAi construct. Scale bars are 1 μm. Images from 
Lee et al., 2007 and are used by permission. 
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 PI(3,5)P2 regulatory mutants display a classical spongiform pathology and impaired 
ESCRT function. 
 As discussed in Chapter One, mice with mutations in Fig4 or Vac14 have 
aberrant regulation of the endosomal signaling lipid PI(3,5)P2, a probable resident of 
the late endosomal membrane which is important for multiple trafficking events 
centered around late endosomes.  The phenotypic consequence of dysfunction at either 
locus is spongiform neurodegeneration (Figure 5.3; Zhang et al., 2007; Chow et al., 
2007).  Interestingly, there are clear links between PI(3,5)P2 and ESCRT function.  
PI(3,5)P2 production is essential for MVB sorting (Odorizzi, Babst, and Emr, 1998), 
and the ESCRT-III protein CHMP3/VPS24 has been shown to preferentially interact 
with PI(3,5)P2 and can be made to accumulate on the class E vps compartment in a 
PI(3,5)P2 – dependent fashion (Whitley et al., 2003).  This suggests that PI(3,5)P2 
regulatory mutants have impaired ESCRT function and that accumulation of a class E 
vps-like compartment (and/or downstream effects such as autophagosome 
accumulation) could underlie spongiform change in Fig4 and Vac14 mutants.  
 
Figure 5.3. Spongiform neurodegeneration in PI(3,5)P2 regulatory mutants. A: 
Spongiform vacuoles in brainstem of Fig4
-/- 
mouse (Chow et al, 2007). Scale bar is 
25μm. B: Spongiform vacuoles in trigeminal ganglion of Vac14-/- mouse (Zhang et al., 
2007). Scale bar is 100 μm. Images used by permission. 
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Consistent with this hypothesis, spongiform vacuoles in Vac14 mutants contain 
lysosome associated membrane protein 2 (LAMP2) (Zhang et al., 2007), strongly 
suggesting a late endosomal/lysosomal contribution.  
 
Atrn and Mgrn1 point to MVB sorting / ESCRT dysfunction as an underlying cause of 
spongiform neurodegeneration  
 In the preceding chapters, I have provided evidence to support the hypothesis 
that ATRN and MGRN1 function together to accomplish the regulated 
endosomal/lysosomal trafficking of MC1R.  As Atrn and Mgrn1 null mutants also 
develop spongiform encephalopathy, I suggest that a similar loss of an 
endosomal/lysosomal trafficking event in cells of the CNS underlies the formation of 
spongiform vacuoles.  As discussed above, impairment of the master regulators of 
endosomal/lysosomal trafficking (the ESCRT proteins) causes accumulation of 
abnormal endosomal membrane in the “class E vps” compartment in mammalian cells 
in culture and of additional membrane in cultured neurons by feeding into a defect in 
autophagosome clearance. ESCRT dysfunction therefore provides two fairly well-
understood mechanisms for accumulation of abnormal intracellular membrane.  When 
ESCRT dysfunction happens within cells of the CNS, does the resulting membranous 
accumulation develop into the characteristic vacuoles of spongiform change?  The 
remarkably similar spongiform neurodegenerative phenotypes of Mgrn1, Fig4, and 
Vac14 mutants suggest that this could be the case, as both the MGRN1-dependent 
ubiquitination of the ESCRT-I protein TSG101 and the Fig4/Vac14-dependent 
production of PI(3,5)P2 are important for ESCRT function.  These considerations 
motivate the following hypothesis: that the vacuoles of spongiform change are 
essentially neuronal or glial class E vps compartments induced by defects in 
endosomal/lysosomal trafficking, and possibly augmented by accumulation of 
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autophagosomal membrane secondary to impaired MVB maturation.  If this is the 
case, deletion of a class E vps gene in the brain should cause spongiform 
neurodegeneration. To test this hypothesis, I deleted Tsg101 within neurons of the 
adult mouse brain.     
  
Practical considerations regarding Tsg101 deletion in mouse brain 
 Tsg101 was originally described as a tumor repressor when knockdown of the 
gene was discovered to cause transformation of NIH3T3 cells (Li and Cohen, 1996).   
As TSG101 is now known to function in the lysosomal trafficking and degradation of 
membrane proteins (Babst et al., 2000), including growth factor receptors, impairment 
of TSG101 function may lead to elevated growth factor receptor signaling and 
consequent hyperproliferation in certain cell types.  Nevertheless, TSG101 loss-of-
function does not necessarily promote cell proliferation in all cellular contexts, most 
likely because of its importance for general “housekeeping” functions (Wagner et al., 
1998; Krempler et al., 2002). Consequently, homozygous null Tsg101 mouse embryos 
fail to develop normally and die before day 6.5 of gestation (Ruland et al., 2001; 
Wagner et al., 2003). This suggests that deletion of TSG101 in neurons of the 
developing embryo could result in a general failure of brain development, which 
would be counterproductive for a study of the development of spongiform 
neuropathology.  Therefore, I pursued a conditional gene inactivation strategy by 
using a loxP-flanked Tsg101 conditional knockout (cKO) mouse allele in combination 
with a tamoxifen-inducible CreER
T2
 transgene under the control of the CaMKII 
promoter, which is active in neurons of the mouse forebrain (Erdmann, Schutz, and 
Berger, 2007).  Upon administration of tamoxifen, the estrogen receptor ligand 
binding domain of the CreER
T2
 fusion protein directs translocalization of CreERT2 
from the cytoplasmic to the nucleus, where the Cre recombinase domain excises loxP-
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flanked DNA sequences (Feil et al., 1997; Indra et al, 1999).  Using this approach, 
gene deletion can be spatiotemporally restricted to only those cells in which the 
CreER
T2
 promoter is active at the time of tamoxifen administration; in this case, 
Tsg101 would be deleted in CaMKII-positive neurons of the adult mouse forebrain.  
The brains of these mice were inspected for spongiform neurodegeneration. 
   
Materials and Methods 
Mice 
 Animals used in this study were housed in standard conditions at the Animal 
Resources Facility of the McLaughlin Research Institute for Biomedical Sciences in 
Great Falls, MT.  The Tsg101 conditional knockout mouse (Tsg101 cKO) was the kind 
gift of Dr. Kay-Uwe Wagner, and has been described elsewhere (Wagner et al., 2003).  
This allele was created and is maintained on a 129/SvJ genetic background.  The cKO 
allele has loxP sites 3kb upstream and 230 bp downstream of the first coding exon of 
Tsg101. Cre recombinase activity at the Tsg101 cKO allele thus results in excision of 
the proximal promoter region and the first exon of Tsg101, resulting in a null allele.  
Frozen CamKCreER
T2
 transgenic mouse embryos were obtained from the European 
Mutant Mouse Archive (EMMA) and implanted into surrogate mothers by the 
McLaughlin Research Institute Transgenic Mouse facility.  The CamKCreER
T2
  mice 
were created and characterized by Erdmann, Schutz, and Berger (2007). The ROSA26 
reporter strain has been described by Soriano (1999). 
 
Genotyping 
 Animals were genotyped using PCR assays on tail-snip DNA isolated by a 
standard alkaline lysis protocol.  Tail snips <5mm long were collected from mice 
within 7 days of weaning and lysed in tail lysis buffer (50 mM Tris [pH8], 50 mM 
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EDTA, 0.5% SDS, 0.1 M NaCl, with protease K [10mg/ml]) at 65 
o 
C followed by 
ethanol precipitation and resuspension in water.  Presence of the wild type Tsg101 
allele was demonstrated using primers GTTCGCTGAAGTAGAGCAGCCAG and 
CATTTCTGGAGTCCGATGCGCAG. For the floxed allele, primer sequences 
AGAGGCTATTCGGCTATGACTG and TTCGTCCAGATCATCCTGATC were 
used. CamKCreER
T2
 transgene genotyping was performed using primers 
GGTTCTCCGTTTGCACTCAGGA, CTGCATGCACGGGACAGCTCT, and 
GCTTGCAGGTACAGGAGGTAGT to produce a band for the wild type allele at 290 
bp and for the transgene at 375 bp. The ROSA26 reporter transgene was detected by 
PCR using the common forward primer sequence AAAGTCGCTCTGAGTTGTTAT 
and the reverse primer sequences GGAGCGGGAGAAATGGATATG (wt) and 
GCGAAGAGTTTGTCCTCAACC (ROSA+).  All genotyping was performed using 
GoTaq green polymerase (Promega, Madison, WI) and 30 cycles of PCR (95
o
C, 30 s; 
63
 o
C, 60 s; 72
 o
C, 60 s). 
 
Activation of Cre-ER 
 Gene excision was induced in 6 week-old mice (with or without CreER
T2
, either 
homozygous or heterozygous for Tsg101
cKO
) 
 
by twice-daily intraperitoneal injection 
of 0.5ug tamoxifen (Sigma) for five consecutive days.  Tamoxifen was dissolved to 5 
ug/ml in a 1:9 mixture of absolute ethanol and pharmacopoeial grade sunflower oil 
(Sigma).  Some animals received injections of the 1:9 ethanol:oil vehicle mixture 
without tamoxifen as a control treatment.  Body weight data were gathered for later 
cohorts of injected mice; mice were weighed once daily. 
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Verification of Cre recombinase activity 
 Cre activation of LacZ expression in ROSA26 mice was visualized at 6 weeks 
after injection of tamoxifen.  Animals were deeply anesthetized with avertin and 
perfused with 4% paraformaldehyde in PBS.  Whole brains and coronal sections were 
incubated for up to 8 hours in X-gal staining solution (5mM EGTA, 2mM MgCl2, 
0.01% sodium deoxycholate, 10 mM potassium ferricyanide, 10 mM potassium 
ferrocyanide, 0.02% Triton X-100, 0.5 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside [X-gal] in 1x PBS) as described by Erdmann, Schutz, and Berger 
(2007). Cre recombinase deletion of the floxed Tsg101 sequence was verified by 
PCR of genomic DNA isolated from dissected brain regions (hippocampus, cerebral 
cortex, cerebellum, striatum, and hindbrain posterior to pons) of vehicle- and 
tamoxifen-injected animals, as well as from brains of CreER
T2
(-) animals as a further 
negative control. Presence of the Tsg101 null allele was detected using the primer pair 
GATGGTCATACCTGGTTAGAAAGC and CATTTCTGGAGTCCGATGCGCAG.  
 
Histology 
 Animals were humanely euthanized either by CO2 asphyxiation or by deep 
avertin anesthesia and transcardial perfusion with 4% paraformaldehyde in PBS, and 
brain tissue was postfixed in paraformaldehyde overnight.  Brains were processed by 
standard methods and embedded in paraffin, with care taken to avoid long exposure to 
70% ethanol, which is known to cause artifactual vacuolation in rodent nervous tissue 
(Chladny and Ehrhardt, 2000).  Paraffin-embedded brains were sectioned at 6 um and 
stained with hematoxylin and eosin (H&E) by standard methods prior to examination 
for spongiform neurodegeneration under the light microscope. 
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Results 
Activity of CamKCreER
T2
 in mouse forebrain 
 To verify the activity of the CamKCreER
T2
 transgene under the tamoxifen 
treatment regime, I crossed the transgene into the ROSA26 strain, which expresses a 
Cre-inducible LacZ allele under the control of a ubiquitously active promoter 
(Soriano, 1999).  Brains of tamoxifen- and control- (ethanol/ sunflower oil vehicle 
only) injected mice were collected 6 weeks after initiation of tamoxifen treatment and 
examined for -galactosidase expression.  Upon treatment with X-gal, whole mount 
brain preparations of CamKCreER
T2
 (+), ROSA26 (+), tamoxifen-injected animals 
showed extensive CreER
T2
 activity as demonstrated by the formation of the blue -
galactosidase reaction product (Figure 5.4).  X-gal staining was most intense in the 
hippocampus and cerebral cortex, with low levels of staining in the striatum and 
thalamus, and no detectable staining in the cerebellum. Vehicle-injected 
CamKCreER
T2 
(+), ROSA26 (+) brains showed detectable recombination at the -
galactosidase activity only in the hippocampus, reflecting a low level of tamoxifen-
independent CreER
T2
 activity in this anatomical location. This pattern of 
CamKCreER
T2
 activity replicates that reported for this transgene by Erdmann, Schutz, 
and Berger (2007).  As expected, ROSA26 (+) mice lacking the CreER
T2
 transgene 
showed no detectable blue staining after tamoxifen treatment, similar to ROSA26 (-) 
controls (Figure 5.4). To determine whether the CamKCreER
T2
 transgene had any 
activity outside of the brain, I performed X-gal staining on heart, lung, liver, spleen, 
stomach, gut, kidney, skin, bone, muscle, uterus, ovary, testis, and seminal vesicle of 
tamoxifen-injected, vehicle-injected, and Rosa26(-) animals.  No -galactosidase 
activity over background was observed in any of these locations (data not shown). 
 To visualize excision of Tsg101 sequence in tamoxifen-injected animals, I 
performed PCR with primers specific for the null allele on DNA isolated from cerebral 
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Figure 5.4. Inducible CamKCreER
T2
 activity in brains of ROSA26 mice.  X-gal 
staining revealed robust CreER activation of ß-galactosidase in brains of tamoxifen-
treated CamKCreER
T2
 (+); ROSA26(+) mice (A), but only limited CreER activity in 
brains of similar mice receiving control injections (B).  No X-gal staining was evident 
in ROSA26(+) mice lacking CamKCreER
T2
 (C), or in ROSA26(-) controls (D). 
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cortex, hippocampus, midbrain, hindbrain, and cerebellum of tamoxifen-injected and 
control animals.  As expected based on the pattern of Rosa26 activation seen in Figure 
5.4, Tsg101 null allele generation was not detectable in tamoxifen-injected, 
CamKCreER
T2
(-) animals, but was evident in all brain areas except for cerebellum in 
tamoxifen-injected, CamKCreER
T2
(+) animals (Figure 5.5). Background activity of 
the CamKCreER
T2
 transgene was confined to the hippocampus, as previously seen in 
the Rosa26 mice.   
 
 
Figure 5.5. Generation of Tsg101 null allele in different brain regions of tamoxifen-
treated Tsg101 cKO/+ mice.  PCR amplification of a null-allele-specific product was 
seen in all brain regions except cerebellum of tamoxifen-treated CamKCreER
T2
(+) 
mice, (left).  Only background levels of CreER
T2
 activity were seen in hippocampus of 
vehicle-treated CamKCreER
T2
(+) mice (center).  Generation of the null Tsg101 allele 
was not detectable in the absence of the CamKCreER
T2
 transgene (right).  
 
Response of mice to neuronal Tsg101 ablation 
 Tsg101 cKO/cKO, CamKCreER
T2
(+) mice treated with tamoxifen exhibited a 
period of rapid weight loss beginning around the eighth day after their first treatment 
with the drug (Figure 5.6).  By the end of the second week post-injection, these mice 
lost an average of 6 grams of body weight and exhibited a rough coat appearance, 
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kyphotic (hunched) posture, lethargy/weakness, and an abnormal “high-stepping” gait.  
This effect was seen only in CamKCreER
T2
(+); Tsg101
cKO/cKO 
mice that received 
tamoxifen.  Control animals of the same genotype given vehicle injections only, or 
tamoxifen-injected animals bearing a wt Tsg101 allele or lacking CamKCreER
T2
, did 
not lose weight and did not show signs of illness (Figure 5.6 and Table 5.1).  
 
Figure 5.6.  Tsg101 deletion in forebrain neurons causes rapid weight loss. Mice 
received tamoxifen injection or a vehicle control during days 1-5. Reported values of n 
for each class are numbers of mice for which weight data are available. Error bars 
indicate one standard deviation.  
 
 The condition of these mice reached a point of crisis at approximately day 15, 
at which point some mice died (or were euthanized in accordance with principles of 
humane treatment) and other mice began to recover. The four mice that survived this 
crisis point (out of 17 mice that became ill from Tsg101 gene deletion) rapidly 
regained their lost weight and returned to apparent health within another week.  Figure 
5.7 shows the patterns of weight loss and recovery experienced by the two survivors 
  130 
for which body weight data were collected.  Notably, these two mice had the highest 
starting weights recorded among all the mice that experienced acute weight loss 
(starting body weight ranged from 16g-26.5g), suggesting that the additional energetic 
reserves accompanying high body mass protects the mice from succumbing during the 
acute weight loss phase. 
 
 
Table 5.1. Effects of Tsg101 gene deletion in neurons of adult mouse forebrain. Mice 
were scored as “sick” if they displayed kyphotic posture and rough coat.  
Tsg101 
genotype 
CamKCreERT2 
genotype 
Treatment n # sick  
at day 
15 
# alive 
at day 
30 
cKO/cKO (+) Tamoxifen 17 17 4 
cKO/cKO (-) Tamoxifen 20 0 20 
cKO/+ (+) Tamoxifen 16 0 16 
cKO/+ (-) Tamoxifen 10 0 10 
cKO/cKO (+) Vehicle  8 0 8 
 
 
 Figure 5.7. Weight loss is transient for Tsg101-deleted mice that survive the “day 15 
crisis.”  Data are shown for the two individual mice for which body weight data are 
available beyond day 16. 
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Neuropathological findings 
 H&E-stained sections of brains from euthanized at day 14 were examined.  
The overall brain architecture was intact and no spongiform change was evident (data 
not shown).  The brains of the oldest surviving tamoxifen injected Tsg101
cKO/cKO
, 
CamKCreER-T2(+) mouse and a tamoxifen-injected Tsg101
cKO/cKO
, CamKCreER-T2(-
) control were examined at 8 weeks after tamoxifen injection (of the other three 
Tsg101-depleted animals that survived past the second week, two died from accidental 
causes and were not used for histology. The remaining animal from the most recent 
experimental cohort was left to age to a later time point.). This brain showed atrophy 
of the cerebral hemispheres on gross examination (Figure 5.8) with greatly expanded 
lateral ventricles and apparent thinning of the cerebral cortex apparent during 
sectioning. Microscopic inspection of H&E-stained 6 μm sections revealed severe 
hippocampal degeneration. Vacuoles similar in appearance to spongiform change were 
seen in the cerebral cortex (and also in the cerebellum) of the CamKCre-T2(+) animal 
which were not evident in the CamKCre-T2(-) control (Figure 5.9 and data not 
shown). 
 
Discussion 
Unexpected weight loss in TSG101-ablated mice 
 This study revealed an unexpected acute consequence of neuronal Tsg101 
ablation: a severe, but transient weight loss occurring during the second week 
following activation of CreER
T2
 to initiate Tsg101 deletion.  As the CamKCreER
T2 
allele used in this study showed no detectable activity outside of the CNS, this weight 
loss is apparently a consequence of Tsg101 deletion in the brain. While I have not 
quantified the food intake of mice in this study, observations of mice during their 
acute weight-loss phase suggested that compared to their non-affected cagemates, ill 
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 Figure 5.8. Cerebral and hippocampal atrophy with expanded lateral ventricles after 
deletion of Tsg101 in forebrain neurons of adult mouse.  (A) H&E-stained coronal 
section of brain from Tsg101
flox/flox
; CamKCreER(T2)+ mouse 8 weeks after injection 
with tamoxifen. (B) Control section from Tsg101
flox/flox
; CamKCreER(T2)- mouse 8 
weeks after injection with tamoxifen. Inset shows appearance of whole brains with 
atrophy of the cerebral hemispheres evident in the Tsg101-ablated brain (top).  
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Figure 5.9. Microscopic appearance of neurodegeneration in Tsg101-ablated forebrain. 
A: View of cerebral cortex and hippocampal region of control [Tsg101
cKO/cKO
; 
CamKCreERT2(-); tamoxifen(+)] brain. B: Comparable region of Tsg101-ablated 
[Tsg101
cKO/cKO
; CamKCreERT2(+); tamoxifen(+)] brain.  Note expansion of lateral 
ventricle, atrophy of cerebral cortex. C,E,G: higher magnification images of control 
brain. D,F,H: higher magnification images of Tsg101-ablated brain. Note spongiform-
change-like appearance of vacuoles in H. 
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mice rarely sought food.  This suggests that reduced caloric intake contributes to the 
weight loss of these mice, perhaps partly due to a reduction in foraging behavior, 
drive, or efficiency.   Since widespread neurodegeneration was not observable at the 
time of weight loss, it would be interesting to know whether the apparent reduction in 
food intake is caused by a specific dysfunction in a neural pathway involved in 
feeding behavior, such as an impairment in agouti-related protein (AGRP) signaling in 
the hypothalamic orexigenic signaling pathway.   
 As discussed in chapter 1, AGRP is believed to promote feeding behavior by 
inhibiting signaling through the melanocortin-4 receptor (MC4R), in an analogous 
mechanism to the inhibition of MC1R signaling by ASP (Ollmann et al., 1997).  If 
ESCRT processing of MC4R is required for AGRP signaling by hypothalamic 
neurons (as I have proposed that ESCRT processing of MC1R is required for ASP 
signaling in melanocytes), then Tsg101 deletion in hypothalamic neurons could impair 
this orexigenic signaling pathway and cause a reduction in feeding behavior.  This 
speculative proposal is, of course, only one among many possible interpretations of 
the data presented here; there are many imaginable nonspecific pathways by which a 
general neuronal housekeeping gene impairment could lead to a disability affecting 
food intake.  However, my data are consistent with the observed consequences of an 
acute impairment in central AGRP signaling: significantly, adult mice subjected to 
ablation of AGRP-expressing hypothalamic neurons stop feeding and starve (Gropp et 
al., 2005; Luquet et al, 2005).  The rate of weight loss in AGRP-neuron-ablated mice 
averages 20% of body weight (~4g) per week, similar in severity what I observed in 
this study.  Mice in both of the AGRP neuron ablation studies cited above were 
euthanized when their weight loss reached 20% of starting body weight, so it is not 
known whether the anorexic effect of AGRP neuron ablation is transient; however, the 
orexigenic signaling network is capable of compensating for perturbation of AGRP 
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signaling, as partial depletion of AGRP neurons causes a moderate initial decrease in 
feeding that is corrected back to near-normal levels (Bewick et al., 2005).  
Hypothalamic neurogenesis has been reported to promote a similar compensatory 
response to progressive AGRP neuron degeneration (Pierce and Xu, 2010), suggesting 
that regeneration of Tsg101
+/+
 hypothalamic neurons from non-recombined precursors 
might contribute to the recovery of mice in my study.   
 The weight-loss phenotype, while potentially informative about the role of 
ESCRT in orexigenic signaling, presents an obstacle to the examination of 
neurodegeneration in Tsg101-depleted brains due to the high mortality of the 
informative mice in this study.  As the heaviest mice seem to be the best equipped to 
survive the period of transient weight loss, future cohorts of mice injected for this 
study will be composed entirely of animals with body weights over 25 grams. The 
realization that mortality seen in this study is related to weight loss should allow 
effective targeting of palliative care to maintain the welfare of future cohorts of 
injected animals.  If the weight loss is determined to be caused by a transient anorexia 
in treated mice, hand-feeding of the affected animals during the second week post-
treatment should provide a means of maintaining their body weight at healthy levels 
until normal feeding activity returns after day 15. 
 
Spongiform neurodegeneration as a consequence of ESCRT depletion: potential 
implications for other neurodegeneration models and human disease. 
 The preliminary data presented here (representing a single brain collected at 
the 8 week mark after Tsg101 ablation) suggest that neuronal Tsg101 depletion may 
cause a profound neurodegenerative response.  While the detailed pathological 
characteristics of this neurodegeneration are obscured in some regions of the brain 
(i.e., the hippocampus) by severe tissue atrophy, the appearance of other regions of the 
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affected brain is suggestive of spongiform neurodegeneration.  While great caution 
must be taken in interpreting such a limited data set, this provides preliminary support 
for the hypothesis that ESCRT dysfunction is a cause of spongiform change.  
 If additional data confirm this preliminary result, it will be of great interest to 
determine to what extent ESCRT dysfunction explains spongiform neurodegeneration 
in other mouse models of spongiform change and in human disease.  In the case of 
several mouse models of spongiform change, links to ESCRT biology are already 
known to exist.  Mgrn1 mutant animals provide a clear link to ESCRT dysfunction, as 
MGRN1 has been demonstrated to ubiquitinate TSG101 in a way that is important for 
lysosomal cargo sorting (Kim et al, 2007, Jiao et al, 2009a).  Partial impairment of 
TSG101 function in Mgrn1 mutant mice might be plausibly supposed to underlie the 
relatively slow development of spongiform change seen in these animals, in contrast to 
the severe pathology reported here in a case of TSG101 deletion. As ATRN and 
MGRN1 appear to be partners in at least a subset of their activities, the spongiform 
change seen in Atrn mutants could be explained as a similar consequence of loss of a 
subset of MGRN1-related ESCRT trafficking events.  As shown in Figure 5.2, 
cultured neurons with defective function of the ESCRT-III proteins SNF7-2 and 
CHMP2B accumulate abnormal membrane, so it would be interesting to determine 
whether the histopathological consequence of similar impairments in brain tissue 
could be spongiform change. Finally, as the ESCRT protein CHMP3/VPS24 has been 
shown to have PI(3,5)P2 dependent activity (Whitley et al., 2003), the spongiform 
vacuolation in the PI(3,5)P2 regulatory mutants Fig4 and Vac14 (see Figure 5.3) could 
be explained as a consequence of an inhibition of ESCRT activity by PI(3,5)P2 
depletion. 
 Of the human spongiform neuroencephalopathies, retrovirus-associated 
spongiform change (discussed in Chapter One) is an attractive subject for explanation 
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as an effect of ESCRT dysfunction.  It is well understood that human 
immunodeficiency virus (HIV) “hijacks” ESCRT proteins through an interaction 
between TSG101 and the GAG protein of the viral capsids (Garrus et al., 2001; 
Pornillos et al., 2003; reviewed by Hurley and Emr 2009; Bieniasz 2010).  This 
interaction subverts the ESCRT machinery by directing the ESCRT-mediated sorting 
of HIV not into the MVB, but out of the host cell.  It can be imagined that the 
“hijacking” of TSG101 by HIV could cause a functional depletion of ESCRT at the 
MVB, resulting in ESCRT dysfunction as a consequence of HIV infection.  
Significantly, HIV infection in cells of the CNS causes spongiform change. Taken 
together, these observations suggest that HIV-associated spongiform 
neurodegeneration could be a consequence of ESCRT loss-of-function due 
sequestration of TSG101 by HIV GAG (Teresa Gunn, personal communication). 
 The canonical example of spongiform encephalopathy in humans is prion 
disease. As discussed in Chapter One, neither the physiological role of PrP
C 
nor the 
pathological mechanisms set in motion by PrP
D 
are well understood, making it 
difficult to confidently identify a likely point of intersection between prion biology 
and ESCRT function.  Interestingly, however, there are parallels between prion 
biology and retroviral budding that provide food for thought.  Both PrP
D 
and budding 
retroviruses have been proposed to escape the cell using exosomes, which are 
essentially ESCRT-derived MVB-like organelles which fuse with the plasma 
membrane (rather than with the lysosome) in order to eject their contents to the 
outside of the cell (Nguyen et al., 2003; Gould, Booth, and Hildreth, 2003; Fevrier et 
al., 2004; Fevrier et al., 2005; Fang et al., 2007). Notably, co-infection of PrP
D 
and a 
murine retrovirus strongly increased the release of scrapie infectivity in cell culture, 
suggesting that retroviruses may serve as cofactors in the spread of PrP
D
 (LeBlanc et 
al, 2006).  While the dominant “protein only” hypothesis of prion pathogenesis 
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considers PrP pathology to occur strictly as a consequence of PrP protein misfolding, 
some voices have long emphasized evidence that viral cofactors could be important 
for the spread of PrP
D
: with certain protocols, the majority of scrapie infectivity 
sediments at 120S and can be filtered out at 25nm, consistent with the size and density 
of a viral particle rather than an isolated PrP
D 
oligomer (Sklaviadis, Manuelidis, and 
Manuelidis, 1989; Manuelidis et al., 1995). Furthermore, intracellular virus-like 
particles of approximately 25 nm in diameter are produced in cultured cells infected 
with scrapie and are a consistent finding in ultrastructural studies of prion-infected 
brains (Manuelidis et al., 2007; Liberski et al., 2008).  Considering these observations, 
the hypothesis of a viral cofactor in prion disease is attractive.  Defenders of the 
“protein only” hypothesis can rightly insist, however, that prion infection can occur in 
the absence of any viral cofactor, as scrapie infectivity can survive irradiation, heat 
treatment, and chemical denaturation that would destroy viral cofactors.  If viruses 
subsequently come to serve as co-factors for prion spread, where do they come from?  
 One intriguing possibility is that prion infection could promote expression of 
some of the endogenous retroviruses (ERV) that reside in thousands of copies 
throughout mammalian genomes. Several groups have produced data consistent with 
this hypothesis.  ERV RNA sequences have been shown to co-purify with scrapie 
infectivity (Akowitz, Manuelidis, and Manuelidis, 1993; Akowitz, Sklaviadis, and 
Manuelidis, 1994), prion infection up-regulates expression of some ERV in infected 
murine neuronal cells (Stengel et al, 2006), and cerebrospinal fluid from human 
Creutzfeldt-Jakob disease patients shows increased prevalence of some families of 
human ERV (Jeong et al, 2010). These data suggest that PrP
D  
may cause the irruption 
of endogenous retroviruses from the host genome.  To the extent that these 
endogenous retroviruses behave like HIV and “hijack” ESCRT function, loss of 
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ESCRT function could ensue and cause spongiform neurodegeneration in prion-
infected hosts. 
 Why PrP
D 
might cause irruption of endogenous retroviruses is an interesting 
question.  ERV make up a major portion of mammalian genomes; in the case of the 
mouse genome, almost 10% of the total sequence is ERV-derived (Mouse Genome 
Sequencing Consortium, 2002). This heavy load of selfish DNA elements presents a 
challenge for the host genome, which must find ways to edit, suppress or co-opt ERV 
elements to maintain its own function within acceptable limits.  One possibility is that 
PrP
C 
is a member of an ERV control mechanism, and that conversion of PrP
C 
 to PrP
D  
ablates or subverts this activity.  Remarkably, PrP
C 
has been reported to mimic several 
distinct properties of the HIV nucleocapsid protein NCP7.  A succession of papers 
from the Darlix lab report that in vitro, PrP
C 
facilitates the dimerization of retroviral 
RNA, inhibits self-primed reverse transcription of the viral genome, mediates initial 
tRNA annealing, and chaperones ssDNA strand transfers during reverse transcriptase 
activity (Gabus et al., 2001a; Gabus et al., 2001b; Derrington et al., 2002; Moscardini 
et al., 2002; Leblanc, Bass, and Darlix, 2004).  One view to emerge from these 
observations is that PrP
C 
can be described as a host-encoded retrovirus nucleocapsid 
mimic that may be deployed by the host cell as a defense measure, mimicking 
retroviral protein structures to subvert replication of endogenous and/or exogenous 
retroviruses.  While this is not a majority view within the field, a very interesting study 
by Lotsher et al. (2007) provides some independent support for this hypothesis.  
Immune stimulation was found to cause massive up-regulation of ERV transcription in 
mouse spleen, which in turn induced up-regulation of PrP
C
, leading to suppression of 
ERV expression. Significantly, Prnp 
-/- 
mice failed to suppress ERV.  These results 
suggest that PrP
D 
conversion may disable an innate mechanism for suppression of 
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endogenous retrovirus activity, leading to unrestrained irruption of viral capsids from 
host-encoded proviral sequence. 
 These considerations suggest a view of PrP
D 
and retroviruses, not as competing 
explanations for scrapie-like diseases, but as coevolved pathogens mutually 
reinforcing each other’s replication efficiency. The abnormal PrP
D 
form  promotes the 
production of retroviral (including ERV) gene products by disabling the host 
genome’s PrP
C
-dependent retrovirus defense pathway. In return, the budding of the 
resulting ERV viral capsids  promotes the escape of converted PrP
D 
 from the cell, and 
perhaps also promotes the uptake of PrP
D
–containing viral capsids and/or exosomes 
by new host cells. This arrangement is mutually beneficial from the point of view of 
both the PrP
D 
conformer and the ERV viral genome, and the resulting mutualism 
would be favored and refined by natural selection.  This proposed cooperative 
relationship between an exogenous protein-only pathogen and an endogenous selfish 
element could provide a unifying explanation for observations that have seemed 
difficult to synthesize; namely, the clear ability of mere PrP
D 
to initiate disease, and 
the several lines of evidence suggesting that additional cofactors are involved in the 
efficient propagation of pathology and infectivity.  In addition, the hypothesis of linear 
causal relationship leading from prion conversion to ERV irruption and budding, 
ESCRT dysfunction, and spongiform neurodegeneration suggests the exciting 
possibility that antiretroviral therapeutic strategies could be effective in the prevention 
and treatment of spongiform neurodegeneration in prion diseases, for which at present 
no effective treatment exists.  This possibility warrants further investigation of the 
relationships connecting prion propagation, ERV activation and budding, ESCRT 
dysfunction, and spongiform change.  
 Aside from the potential medical importance of understanding the connections 
between prions and ERV biology, the elucidation of their relationship is a matter of 
  142 
considerable intrinsic and theoretical interest.  If the proposed mutualism is found to 
be a real aspect of prion and ERV biology, it will provide yet another example of the 
immense resourcefulness and subversive creativity exhibited by selfish elements 
(nucleic acid or otherwise) over evolutionary time.  This author finds it fascinating to 
consider that PrP
C
, as a host-encoded mimic of viral nucleocapsid protein, may have 
been developed in the ancient intragenomic conflict against ERVs as a subversive 
countermeasure to viral function, only to be subverted in turn by an evolutionary 
partnership between budding ERVs and a rogue, self-perpetuating folding 
conformation of the PrP protein itself.  As an example of the endless creativity of 
living systems, this story of evolutionary subversion and counter-subversion 
underscores the fact that life is a masterful improvisationalist, appropriating and 
reinventing existing molecular pathways in unpredictable but fascinating ways to 
accomplish novel and interesting functions.  This work has followed a single thread of 
mechanistic and evolutionary connections along a winding path, starting at the point of 
MC1R downregulation in the hair follicle and arriving, eventually, at a potentially new 
vantage point from which to understand spongiform neurodegeneration.  But living 
things, in the richness of their history, blaze many such paths.  Where these paths lead 
is often unpredictable.  Given the nature of life, perhaps the discovery of an 
unexpected view along the way should never come as a surprise.  
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